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Abstract 
CD4+ T cell interactions with dendritic cells (DC) are pivotal in adaptive immune 
responses and play an important role in both protective immunity (e.g. infection) 
and autoimmune diseases (e.g. rheumatoid arthritis). As such, there is increasing 
interest in discovering molecules that would promote/disrupt this interaction. 
Taking advantage of transcriptomic data generated in our lab using a murine 
model of inflammatory arthritis, we aimed to identify molecules that can control 
these interactions. We hypothesised that blockade of some of these molecules will 
disrupt these interactions, affecting T cell activation and/or migration of immune 
cells that promote pathology. This will not only further our basic understanding 
of disease processes but may also highlight potential therapeutic targets for 
human disease. 
The F11 receptor (F11R) gene, which encodes the junctional adhesion molecule-A 
(JAM-A), was identified in a gene list previously generated in the laboratory. F11R 
was upregulated in non-migratory leukocytes from inflamed joints in comparison 
to migratory immune cells. To investigate the role of JAM-A on CD4+ T cell 
activation, we employed in vitro and in vivo assays with cells from transgenic T 
cell receptor (TCR) mice (OTII). Treatment with an antagonistic anti-JAM-A 
monoclonal antibody (mAb) in vitro attenuated CD4+ T cell activation and 
proliferation and decreased T cell differentiation towards the Th1 subset in 
comparison with cells treated with its isotype control. In vivo, anti-JAM-A mAb 
treatment impaired CD4+ T cell proliferation in comparison with cells from mice 
treated with its isotype control. However, prophylactic treatment with anti-JAM-
A mAb did not impact clinical disease in an acute, breach of self-tolerance model 
of arthritis. 
These findings are the first to describe a role for JAM-A during CD4+ T cell-DC 
interactions, but do not support JAM-A as a therapeutic target for rheumatoid 
arthritis (RA). Future work to evaluate the effects of treatment with JAM-A 
antagonists in late models of RA, in which autoimmune components may play a 
bigger role in clinical arthritis, or in models of other autoimmune diseases will 
further our understanding on JAM-A contribution to human disease.  
 
 
3 
Acknowledgments 
Firstly, I would like to thank my parents for all the love and support since my 
childhood in a small wood house built by my dad’s hands in the middle of the 
Brazilian Atlantic Forest. 
Secondly, I have no words to thank Paul. You believed in my potential more than 
anyone. Your trust motivated me to work harder day by day. Thanks to you, I’m 
making an old dream come true of graduating in one of the best universities in the 
world in this exciting field that is immunology. 
Third, I would like to dedicate some words to my other supervisors. Jim, for his 
amazing support during the whole PhD, and Bob, for… everything. Besides the 
countless outstanding talks about the theory, Bob was the one who taught me the 
most inside the lab. Because of you, I know I’ve been trained well. Your daily 
support and incredible guidance made everything easier. 
I would also like to show my appreciation to all other members of the LIVE group, 
from the PIs (Megan, Vicky, Pasquale) to postdocs and PhD students. Thanks 
Hannah and Gavin for the support in the lab and Hannah and Larissa for helping 
to review this work. Thanks to lab technicians in L5 and L4, to members of the 
3I’s flow cytometry facility for the constant assistance, especially Alana and Diane, 
and to members of the CRF staff (a special thanks to Tony, for his outstanding 
support). 
Together, you all made me feel like home and directly or indirectly contributed 
for everything that was produced in this thesis. 
Thanks to the CAPES Foundation (Ministry of Education, Brazil) for funding this 
PhD. 
  
 
 
4 
Author’s Declaration 
I declare that, except where reference is made to the contribution of others, this 
thesis is the result of my own work and has not been submitted for any other 
degree at the University of Glasgow or any other institution. 
Signature:  
Name: Caio Santos Bonilha 
  
 
 
5 
Table of Contents 
Abstract ........................................................................ 2 
Acknowledgments ............................................................ 3 
Author’s Declaration ........................................................ 4 
List of Tables .................................................................. 8 
List of Figures ................................................................. 9 
Abbreviations ................................................................ 11 
Chapter 1 Introduction ................................................. 15 
1.1 The Immune System ................................................................... 15 
1.2 The Adaptive Immune System ...................................................... 15 
1.3 Dendritic Cells (DC) ................................................................... 19 
1.3.1 DC Activation and Maturation ......................................................... 21 
1.3.2 DC Migration to Lymphoid Tissues .................................................... 21 
1.4 CD4+ T Cell-Antigen Presenting Cell (APC) Interactions in Lymphoid Tissues
 23 
1.4.1 CD4+ T Cell-DC Interactions and T Cell Outcomes ................................. 24 
1.4.2 CD4+ T Cell-B Cell Interactions and T Follicular Helper (Tfh) Differentiation . 29 
1.5 CD4+ T Cell-APC Interactions in Peripheral Tissues ............................ 30 
1.6 Molecules Controlling CD4+ T Cell-APC Interactions ........................... 31 
1.6.1 T Cell Co-Stimulatory Interactions .................................................... 31 
1.6.2 T Cell Co-Inhibitory Interactions ...................................................... 34 
1.7 The Role of CD4+ T Cells-APC Interactions in Pathological Conditions ..... 37 
1.7.1 Rheumatoid Arthritis (RA) .............................................................. 37 
1.8 Therapeutic Targeting of T Cell Co-Signalling Pathways ...................... 39 
1.8.1 Agonists of T Cell Co-Stimulatory Molecules ........................................ 39 
1.8.2 Antagonists of T Cell Co-Inhibitory Molecules ....................................... 41 
1.8.3 Antagonists of T Cell Co-Stimulatory Molecules .................................... 42 
1.8.4 Agonists of T Cell Co-Inhibitory Molecules ........................................... 48 
1.9 Aims ...................................................................................... 49 
Chapter 2 Materials and Methods ..................................... 51 
2.1 Animals .................................................................................. 51 
2.2 Cell Isolation and Culture ............................................................ 51 
2.2.1 T Cell Stimulation ....................................................................... 51 
2.2.2 Isolation of CD4+ T cells ................................................................ 52 
2.2.3 Generation of Bone Marrow-Derived Dendritic Cells (BMDCs) .................... 52 
2.2.4 BMDC-T-Cell Co-Culture and Stimulation ............................................ 53 
2.2.5 Small Interfering RNA (siRNA) in BMDCs .............................................. 54 
2.3 Animal Procedures .................................................................... 55 
2.3.1 Adoptive Transfer of OTII Cells into WT Mice ....................................... 55 
2.3.2 Breach of Self-Tolerance Arthritis Model ............................................ 55 
2.4 Flow Cytometry ........................................................................ 58 
2.4.1 Viability Staining ......................................................................... 58 
2.4.2 Extracellular Staining ................................................................... 58 
2.4.3 Intracellular Staining .................................................................... 59 
 
 
6 
2.4.4 Data Analysis ............................................................................. 60 
2.5 Enzyme-Linked Immunosorbent Assay (ELISA) .................................. 62 
2.5.1 Cytokine Measurement ................................................................. 62 
2.5.2 Anti-Collagen II (CII) and Anti-OVA Antibodies Measurement ..................... 62 
2.6 Imaging ................................................................................... 63 
2.6.1 Widefield Microscopy ................................................................... 63 
2.6.2 Confocal Microscopy .................................................................... 65 
2.6.3 Image Analysis ........................................................................... 65 
2.7 Statistical Analysis ..................................................................... 66 
Chapter 3 Selection of Candidate Molecules ....................... 67 
3.1 Introduction ............................................................................ 67 
3.1.2 Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 (CEACAM1) ...... 71 
3.2 Results ................................................................................... 73 
3.2.1 CEACAM1 is Expressed by DCs ......................................................... 73 
3.2.2 CEACAM1 is Upregulated on Antigen-Stimulated CD4+ T cells .................... 76 
3.2.3 CEACAM1 is Highly Expressed by BMDCs .............................................. 79 
3.2.4 Treatment with Anti-CEACAM1 Monoclonal Antibody (mAb) CC1 During Antigen 
Presentation has No Effect on CD4+ T Cells Priming ........................................... 80 
3.2.5 siRNA Targeting CEACAM1 Gene Has Minimal Impact on CEACAM1 Expression on 
BMDCs 84 
3.3 Discussion ............................................................................... 85 
Chapter 4 JAM-A Contributes to CD4+ T cell Effector Functions 
During Priming in vitro ..................................................... 90 
4.1 Introduction ............................................................................ 90 
4.1.1 Junctional Adhesion Molecule-A (JAM-A) ............................................ 90 
4.2 Results ................................................................................... 93 
4.2.1 JAM-A is Expressed by DCs ............................................................. 93 
4.2.2 Naïve CD4+ T Cells Express a Potential Ligand for JAM-A ......................... 97 
4.2.3 Antigen-Primed CD4+ T cells Express Low Levels of JAM-A ....................... 97 
4.2.4 JAM-A is Expressed by BMDCs ........................................................ 104 
4.2.5 JAM-A is Present on the Site of Interaction During CD4+ T Cell Priming ...... 105 
4.2.6 Anti-JAM-A mAb Treatment During Antigen Presentation in vitro Attenuates 
CD4+ T Cell Activation and Proliferation ...................................................... 107 
4.2.7 Anti-JAM-A mAb Treatment During Antigen Presentation in vitro Impacts T-bet 
expression and IL-17 secretion by CD4+ T Cells .............................................. 111 
4.2.8 Anti-JAM-A mAb Treatment During Antigen Presentation in vitro Impacts DC-T 
cell Cluster Formation ............................................................................ 118 
4.2.9 Anti-JAM-A mAb Treatment During Antigen Presentation in vitro Does Not 
Affect DC-T Cell Area of Interaction ........................................................... 121 
4.3 Discussion .............................................................................. 123 
Chapter 5 JAM-A Contributes to CD4+ T cell Effector Functions 
During Priming in vivo ................................................... 129 
5.1 Introduction ........................................................................... 129 
5.2 Results .................................................................................. 130 
5.2.1 JAM-A is Expressed on T Cell and Medullary Areas of Mouse Lymph Nodes (LN)
 130 
 
 
7 
5.2.2 siRNA Targeting F11R Gene Has Limited Impact on JAM-A Expression on BMDCs
 132 
5.2.3 The impact of anti-JAM-A mAb Treatment in vivo in CD4+ T Cell Activation and 
Proliferation ........................................................................................ 133 
5.2.4 Anti-JAM-A mAb Treatment in vivo Does Not Affect CD4+ T Cell Differentiation
 144 
5.3 Discussion .............................................................................. 147 
Chapter 6 JAM-A as a Therapeutic Target for Rheumatoid 
Arthritis 150 
6.1 Introduction ........................................................................... 150 
6.2 Results .................................................................................. 152 
6.2.1 JAM-A is Upregulated on Non-Migratory Immune Cells from Inflamed Joints 152 
6.2.2 Anti-JAM-A mAb Treatment Does Not Affect Arthritis in a Breach of Self-
Tolerance Murine Model of Arthritis ............................................................ 158 
6.3 Discussion .............................................................................. 163 
Chapter 7 General Discussion and Future Directions ........... 168 
7.1 Summary of Key Findings ........................................................... 168 
7.2 Detection of Molecules with Potential for Controlling T cell-DC Interactions
 170 
7.3 JAM-A Role on CD4+ T Cell Priming ............................................... 171 
7.4 JAM-A-Targeted Therapy in Rheumatoid Arthritis ............................. 175 
7.5 Final Conclusions ..................................................................... 177 
 
References ................................................................. 178 
  
 
 
8 
List of Tables 
Table 2-1. Antibodies and other reagents used for flow cytometry ......................... 61 
Table 3-1. Expression profiles of upregulated genes from joint non-migratory immune 
cells that are involved in leukocyte migration pathways ..................................... 70 
  
 
 
9 
List of Figures 
Figure 1-1. Dendritic cell functions in the adaptive immune system upon encounter with 
a pathogen ............................................................................................ 23 
Figure 1-2. Priming vs tolerance on CD4+ T cells ............................................... 25 
Figure 1-3. CD4+ T cell subsets based on T cell differentiation and its effector functions
 ......................................................................................................... 27 
Figure 1-4. CD4+ T cell co-stimulation pathways ............................................... 32 
Figure 1-5. CD4+ T cell co-inhibition pathways ................................................. 36 
Figure 2-1. Bone marrow-derived dendritic cells (BMDCs) purity analysis by flow 
cytometry ............................................................................................. 53 
Figure 2-2. Schematic representation of BMDCs culture and BMDC-T cell co-culture set-
up ...................................................................................................... 54 
Figure 2-3. Schematic representation of the breach of self-tolerance model of arthritis
 ......................................................................................................... 56 
Figure 3-1. Schematic representation of experiments previously performed in the 
laboratory that generated a joint-specific differentially regulated gene list ............. 68 
Figure 3-2. Identification of a joint-specific differentially regulated gene related to 
leukocyte migration ................................................................................. 69 
Figure 3-3. CEACAM1 expression on murine CD4+ T cells and DCs ........................... 75 
Figure 3-4. CEACAM1 and TIM-3 expression on CD4+ T cells upon priming ................. 78 
Figure 3-5. CEACAM1 expression on BMDCs ...................................................... 80 
Figure 3-6. Effects of anti-CEACAM1 mAb CC1 on CD4+ T cell activation and proliferation
 ......................................................................................................... 83 
Figure 3-7. Assessment of the capacity of purified anti-CEACAM1 mAb CC1 to block 
fluorophore conjugated anti-CEACAM1 ligation to CEACAM1 ................................. 84 
Figure 3-8. CEACAM1 siRNA effects on BMDC CEACAM1 expression .......................... 85 
Figure 4-1. JAM-A expression on murine CD4+ T cells and DCs ............................... 95 
Figure 4-2. JAM-A expression on CD4+ T cells from different lymphoid organs ........... 96 
Figure 4-3. Expression of CD11a on murine CD4+ T cells ...................................... 97 
Figure 4-4. JAM-A expression on CD4+ T cells upon agonistic antibodies stimulation .... 98 
Figure 4-5. Expression of JAM-A and its potential ligands on activated CD4+ T cells ... 101 
Figure 4-6. JAM-A expression on naïve or antigen-primed OTII CD4+ T cells and naïve 
wild-type (WT) CD4+ T cells ..................................................................... 103 
Figure 4-7. JAM-A expression on BMDCs ....................................................... 104 
Figure 4-8. JAM-A localisation on BMDC surface during CD4+ T cells priming ........... 106 
 
 
10 
Figure 4-9. Optimisation of cell ratios and antigen concentration on CD4+ T cell 
activation and proliferation in BMDC-T cell co-cultures .................................... 108 
Figure 4-10. JAM-A blockade in vitro attenuates CD4+ T cell activation and proliferation
 ....................................................................................................... 110 
Figure 4-11. JAM-A blockade in vitro increases IL-17 secretion by CD4+ T cells ........ 112 
Figure 4-12. JAM-A blockade in vitro decreases T-bet expression in CD4+ T cells ...... 115 
Figure 4-13. The impact of JAM-A blockade in vitro in CD4+ T cell IFN-γ production .. 117 
Figure 4-14. JAM-A blockade in vitro affects BMDC-T cell cluster formation ............ 120 
Figure 4-15. JAM-A blockade in vitro does not affect BMDC-T cell interactions ........ 123 
Figure 5-1. JAM-A localization in a murine lymph node (LN) ............................... 131 
Figure 5-2. F11R siRNA minimally affects bone marrow-derived dendritic cells (BMDC) 
JAM-A expression .................................................................................. 133 
Figure 5-3. Determination of a suboptimal dose of antigen in the adoptive transfer 
model ................................................................................................ 135 
Figure 5-4. JAM-A blockade in vivo impact in leukocyte accumulation in the LN ....... 138 
Figure 5-5. The impact of JAM-A blockade in vivo in CD4+ T cell proliferation ......... 140 
Figure 5-6. JAM-A blockade in vivo does not affect CD4+ T cell activation .............. 143 
Figure 5-7. JAM-A blockade in vivo does not affect CD4+ T cell differentiation ........ 146 
Figure 6-1. Proposed model for a functional role for JAM-A in the breach of self-
tolerance in RA .................................................................................... 151 
Figure 6-2. JAM-A expression on immune cells from inflamed joints and popliteal lymph 
nodes ................................................................................................ 154 
Figure 6-3. JAM-A expression on immune cell subsets from inflamed joints and popliteal 
lymph nodes ........................................................................................ 157 
Figure 6-4. JAM-A blockade in a murine model of early arthritis does not affect clinical 
disease .............................................................................................. 159 
Figure 6-5. JAM-A blockade in a murine model of early arthritis does not affect the 
activation of peripheral blood CD4+ T cells ................................................... 160 
Figure 6-6. JAM-A blockade in a murine model of early arthritis does not affect the 
secretion of anti-OVA antibodies ............................................................... 162 
Figure 6-7. JAM-A blockade in a murine model of early arthritis does not affect the 
secretion of anti-collagen type II antibodies .................................................. 163 
Figure 7-1. Proposed model for effects of JAM-A blockade in CD4+ T cell priming ..... 173 
 
 
 
 
 
 
 
11 
Abbreviations 
Ahr  Aryl hydrocarbon receptor 
APC  Antigen presenting cells 
APOE  Apolipoprotein E 
Batf3  Basic leucine zipper transcription factor ATF-like 3 
BCL6  B-cell lymphoma 6 protein 
BCR  B cell receptors 
BMDCs  Bone marrow-derived dendritic cells 
CCL  C-C motif chemokine ligand 
CCR  C-C motif chemokine receptor 
CD  Cluster of differentiation 
CD62L  L-selectin 
cDC  Conventional dendritic cell 
cDNA  Complementary Deoxyribonucleic Acid 
CFA  Complete Freund’s Adjuvant 
CFSE  Carboxyfluorescein succinimidyl ester 
CIA  Collagen-induced arthritis 
CII  Collagen II 
Con A  Concanavalin A 
CRF  Central Research Facility 
CTLA-4  Cytotoxic T-lymphocyte associated protein 4 
CXCR  C-X-C-chemokine receptor 
DC  Dendritic cell 
DMARD  Disease-modifying antirheumatic drugs 
DR3  Death receptor 3 
DSS  Dextran sulphate sodium 
Eα  Eα52–68 peptide 
F11R  F11 receptor 
FBS  Fetal bovine serum 
FcεRII  IgE receptors 
FDA  Food and Drug Administration 
Flt3L  Fms-like tyrosine kinase ligand 
FMO  Fluorescence minus one 
FOXO1  Forkhead box O1 
FoxP3  Forkhead box P3 
GAL9  Galectin-9 
 
 
12 
GATA3  GATA binding protein 3 
GC  Germinal centres 
GITR  Glucocorticoid-Induced TNF receptor-related protein 
GITRL  GITR ligand 
GM-CSF Granulocyte-macrophage colony-stimulating factor 
HAO  Heat aggregated OVA 
HEV  High endothelial venules 
HLA  Human leucocyte antigens 
HRP  Horseradish peroxidase 
HVEM  Herpesvirus entry mediator 
ICAM1  Intercellular adhesion molecule 1 
ICOS  Inducible T cell co-stimulator 
IFN-I  Type I interferon 
IFN-γ  Interferon gamma 
IFNGR1 IFN-γ receptor 1 
Ig  Immunoglobulin 
IgSF  Immunoglobulin superfamily 
IL  Interleukin 
IL17RA  IL-17 receptor A 
IRF4  Interferon response factor 4 
IRF8  Interferon regulatory factor 8 
iTreg  Induced regulatory T 
JAK  Janus kinase 
JAM-A  Junctional adhesion molecule-A 
KO  Knockout 
LAG3  Lymphocyte Activating 3 
LAIR1  Leukocyte-associated immunoglobulin-like receptor 1 
LDLR  Low density lipoprotein receptor 
LFA  Lymphocyte function-associated antigen 
LN  Lymph nodes 
LPS  Lipopolysaccharides 
LTB4  Leukotriene B4 
LYVE1  Lymphatic vessel endothelial receptor 1 
mAb  Monoclonal antibody 
MFI  Median fluorescence intensity 
MHC  Major histocompatibility complex 
MOC  Manders’ overlap coefficient 
moDC  Monocyte derived dendritic cell 
 
 
13 
MS  Multiple sclerosis 
NHS  National Health Service 
NK   Natural killer 
NSAID  Non-steroidal anti-inflammatory drugs 
nTreg  Natural T regulatory 
OVA  Chicken ovalbumin 
PAF  Platelet-activating factor 
PBS  Phosphate-Buffered Saline 
PBS-T  0.05% Tween 20 in Phosphate-Buffered Saline 
PCC  Pearson’s correlation index 
PD1  Programmed cell death-protein 1 
pDC  Plasmacytoid DCs 
PDL  Programmed cell death-ligand 
PEG  Polyethylene glycol 
pLN  Popliteal LNs 
PMA  Phorbol myristate acetate 
pOVA  OVA peptide 323-339 
RA  Rheumatoid arthritis 
RANKL  Receptor activator of nuclear factor kappa-Β ligand 
RBC  Red blood cell 
RNA  Ribonucleic acid 
RORγt  Retinoic acid-related orphan receptor gamma t 
S1P  Sphingosine-1-phosphate 
S1PR1  S1P receptor 1 
SAP  SLAM-associated protein 
SD  Standard deviation 
SEMA  Semaphorin 
SI  Site of interaction 
siRNA  Small Interfering RNA 
SLAM  Signaling lymphocytic activation molecule 
SLC  Secondary lymphoid-tissue chemokine 
SLE  Lupus erythematosus 
SOCS1  Suppressor of cytokine signalling 1 
STAT  Transducer and activator of transcription molecules 
TCR  T cell receptor 
Tfh  T follicular helper 
TGFβ  Transforming growth factor beta 
Th  T helper 
 
 
14 
TIGIT  T cell immunoglobulin and ITIM domain 
TIM  T cell immunoglobulin and mucin domain 
TL1A  TNF-like ligand 1A 
TLR  Toll-like receptors 
TNBS  2,4,6-trinitrobenzene sulfonic acid 
TNF  Tumour necrosis factor 
TNF-α  TNF alpha 
TNFRSF TNF receptor superfamily 
tolDCs  Tolerogenic DCs 
Treg  T regulatory 
VCAM1  Vascular cell adhesion molecule-1 
WT  Wild-type mice 
αβ  Alpha beta 
γδ  Gamma delta 
  
 
 
15 
Chapter 1 Introduction 
1.1 The Immune System 
The immune system is composed of a collection of cells, chemicals and processes 
with the capacity to protect tissues and organs from foreign antigens, such as 
bacteria, viruses, fungi, parasites, toxins and tumour cells1. The immune system 
can be divided in two categories: the innate and the adaptive immune systems. 
The innate immune system is traditionally known as the first line of defence, as it 
induces nonspecific responses immediately or within hours of contact with 
antigens, aiming for pathogen clearance before they can start an active infection. 
These responses are mediated by mechanisms that include physical barriers, such 
as the skin; chemicals, such as proteins and protein fragments of the complement 
system, coagulation factors and acute-phase proteins; and the participation of 
immune cells, such as natural killer (NK) cells, macrophages, dendritic cells (DC), 
mast cells and granulocytes (neutrophils, basophils and eosinophils)2. On the other 
hand, a key feature of the adaptive immune system is the ability to learn and 
remember specific pathogens to provide long-lasting protection against possible 
recurrent infections3. This protection is dependent on the ability of lymphocytes 
to recognize specific antigens. 
1.2 The Adaptive Immune System 
Immunological memory is the main feature of the adaptive immune system, in 
which specific antigens can be memorized aiming a strong specific response in 
subsequent encounters with pathogens4. Adaptive immune responses in the first 
encounter with the antigen are called primary response, and often takes days to 
develop. Lymphocytes need to proliferate and differentiate to become specialised 
immune cells that will later secrete cytokines (proteins that mediate and regulate 
the immune system) and antibodies. Memory cells are also induced during this 
process and remain ready to respond rapidly upon a second encounter with the 
antigen in a phase called secondary immune response5. This shorter delay between 
antigen exposure and maximal immune response makes the adaptive immune 
system an efficient protective system upon a second exposure to the antigen, 
 
 
16 
often clearing the pathogen before considerable damage is caused. The main 
lineages of lymphocytes responsible for adaptive immune responses are B cells 
and T cells. Memory cells, specific subsets of B and T cells, are responsible to 
maintain memory of the adaptive immune system. Nevertheless, participation of 
DCs, a cell type characteristic of the innate immune system, is essential for 
generation of memory cells and optimal adaptive immune responses against 
pathogens6,7. 
DCs are part of a group called antigen presenting cells (APC) that is also composed 
by B cells and macrophages, cells with the capacity to internalise antigens, 
process them into peptides and expose these fragments on their cell surface in 
the context of major histocompatibility complex (MHC) class II molecules8. 
Although some authors consider B cells and macrophages as professional APCs9, it 
is consensus that DCs are professional APCs6,9. These cells are driven by their 
surface receptors and chemokines present in the environment that can induce its 
maturation and facilitate its migration from affected tissues, where they can 
uptake antigen, to specialised lymphoid organs, where most of antigen 
presentation to T cells occurs10. In addition, DCs are one of the main promoters 
of central and immune tolerance. In the thymus, DCs promote negative selection 
of autoreactive T cells and generation of natural T regulatory (Treg) cells11,12. In 
peripheral tissues and lymphoid organs, DCs can also lead to T cell tolerance, 
preventing responsiveness against foreign or self-antigens that might be 
subsequently encountered. In the centre of immune tolerance mechanisms are 
steady-state DCs, cells that express low levels of T cell co-stimulatory molecules. 
Intercellular interactions between DCs and T cells exemplify the importance of 
the synergy between the innate and the adaptive immune systems for protective 
immunity against foreign antigens. 
T cells are derived from hematopoietic stem cells in the bone marrow and need 
to migrate to the thymus to complete their maturation13,14. Thymic progenitors 
that are negative for the surface molecules CD4 and CD8 recombine T cell receptor 
(TCR) genes in an important event that enables T cells to recognise a diverse range 
of antigens and that induces expression of both CD4 and CD8 in the surface of 
these cells. The CD4+ CD8+ cells then go through appropriate thymic selection to 
control undesirable generation of auto-reactive T cells12. These cells can mature 
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into two functionally distinct sub-lineages that can be distinguished by their TCR, 
alpha beta (αβ) T cells that express TCR comprised of a α and a β chain, and 
gamma delta (γδ) T cells that have a γ and a δ chain in its TCR composition15, 
although the correlation between TCR type in thymocytes and sub-lineage fate is 
not always perfect16. The TCR α chain is formed of three segments: constant (C) 
that is common to several TCRs and extends from the cytoplasm to the exterior 
of the cell membrane, variable (V) that gets in direct contact with the 
peptide/MHCII complex and joining (J) that connects the C and V regions but also 
gets in contact with the antigen17,18. Simultaneously, the β chain has a fourth 
segment called diversity (D), that connects the V and J regions in a process called 
V(D)J recombination. Their complexity dictates the diversity of T cell clonality, 
ruled by numerous rearrangements of TCR genes that result in an extensive TCR 
repertoire randomly generated19. 
T cells enter lymph nodes (LN) via lymphatic vessels or from blood through high 
endothelial venules (HEV)20. Cells from these venules/vessels express surface 
molecules that allow T cell homing. This process is constituted by three steps: 
rolling, chemokine activation and arrest, in mechanisms dependent on T cell 
surface molecules, such as L-selectin (CD62L) and CC-chemokine receptor 7 
(CCR7). The T cell then enters the T cell area in a CCR7 dependent way, where 
they can interact with other immune cells, such as DCs, before finally leaving the 
LN and re-enter the circulation. γδ T cells are more frequently found in mucosal 
tissues in comparison with blood or lymphoid tissues. These cells are known to 
have an important role in immune responses against infections and disruption of 
the epithelial barrier. Due to the gain of an effector phenotype during its 
maturation in the thymus, γδ T cells preferentially secrete the cytokines 
interferon gamma (IFN-γ) and interleukin (IL) 1721. On the other hand, αβ T cells 
require activation followed by cell expansion to differentiate and secrete optimal 
levels of cytokines. When matured, αβ T cells conventionally become CD4+CD8- 
or CD4-CD8+ T cells. Although the TCR is antigen-specific, it can only interact with 
antigen when it is bound to MHC molecules from the surface of other cells. CD8+ 
T cells, also called cytotoxic T cells, recognize antigen bound to MHC class I (MHCI), 
a molecule found on the surface of all nucleated cells. Due to the broad range of 
cell types possible, cytotoxic T cells are important not only in the immune defence 
against microbes, but also in the immune surveillance to directly avoid 
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propagation of abnormal cells. On the other hand, the TCR in CD4+ T cells can 
only interact with antigen bound to MHC class II (MHCII), a protein found on the 
surface of APCs8. These interactions can lead to CD4+ T cell activation, 
proliferation, and generation of effector and/or memory T cells22. While memory 
T cells are a long-term survival cell that will remain ready for a secondary 
exposure to the antigen, cells that can promote effector functions during primary 
exposure to antigens and are optimal secretors of cytokines are called T helper 
(Th) cells. 
B cells that are generated in the bone marrow will later migrate to the blood and 
specialized lymphoid organs, such as LN and the spleen, where they will complete 
their maturation23. Both immature and mature B cells are known to express 
antigen-specific receptors on their surface, called B cell receptors (BCR). While 
some types of antigens (T cell independent type 2) can activate both immature 
and mature B cells, others can activate only mature B cells (T cell independent 
type 1)24,25. In the centre of the BCR is a membrane-bound monomeric form of 
immunoglobulin M (IgM), that is co-expressed with immunoglobulin (Ig) D and the 
associated proteins cluster of differentiation (CD) 79A and 79B26, molecules that 
have relevant signalling functions upon antigen stimulation. B cell responses to 
antigen can be dependent or independent of T cells27. While molecules like 
polysaccharides and lipopolysaccharides are considered T cell independent 
antigens, protein antigens generally require the assistance of T cells that respond 
to the same antigen for full B cell activation. Upon activation with a T dependent 
antigen, the B cell undergoes clonal expansion and differentiation, which will 
ultimately generate high-affinity plasma cells that are fated to produce and 
secrete large amounts of antibodies. Whereas during primary adaptive immune 
responses the overall level of antibodies secreted by plasma cells is low and can 
take weeks to reach its peak, secondary responses take less time, and more 
antibodies are released. Furthermore, this higher secretion is sustained for a 
longer period of time and these antibodies have greater affinity for its specific 
antigen when compared with the antibodies produced in the primary adaptive 
immune response5. This higher affinity is due to affinity maturation, a process 
that involves hyper-mutation of B cell gene segments that encode the antigen-
binding site of the antibodies, inducing production of antibodies with higher 
affinity, avidity and anti-pathogen activity28. Therefore, although antibodies have 
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a strong role in pathogen clearance in secondary adaptive immune responses, they 
show low effectiveness in responses in which the antigen is being recognized for 
the first time. Although the main role of B cells in immunity is to produce 
antibodies, these cells can also present antigen to CD4+ T cells, in interactions 
that can not only assist T cells differentiation to a specific subset, but also 
promote B cells survival, generation of high affinity antibodies and differentiation 
into certain B cell memory subsets29. 
The adaptive immune system is responsible for acquiring tolerance against self-
antigens in intercellular mechanisms involving MHC molecules, and to mediate 
destruction and elimination of pathogens in primary and secondary responses.  
Mechanisms of induction of CD4+ T cells activation and differentiation that will 
lead to inflammatory conditions or that control it are essential for the homeostasis 
and maintenance of tissues and organs. Therefore, the way a naïve CD4+ T cell 
interacts with a DC in the context of MHCII molecules dictates the fate of 
important pathways of the adaptive immune system. 
1.3 Dendritic Cells (DC) 
Among APCs, DCs are the most efficient cells to present antigen to CD4+ T 
lymphocytes6. DCs are cells, derived from hematopoietic stem cells in the bone 
marrow and integrate the innate and adaptive immune systems. Fms-like tyrosine 
kinase ligand (Flt3L) and Flt3L receptor signalling can induce differentiation of 
these stem cells into plasmacytoid DCs (pDC), conventional DCs (cDC) or other DC 
subsets. Meanwhile, signalling of some factors, such as interferon regulatory 
factor 8 (IRF8), basic leucine zipper transcription factor ATF-like 3 (Batf3), and 
type I interferon (IFN-I), strongly restricts the development of common lymphoid 
or myeloid progenitor lineages into pDCs30. In mice, DCs can be classified into five 
lineages: cDC type 1 (cDC1), cDC type 2 (cDC2), pDC, monocyte derived DC (moDC) 
and Langerhans cells6,31. Conventional DC subtypes can be distinguished by the 
expression of markers like CD8, present in cDC1, and CD11b, present on cDC2. 
Both cDC1 and cDC2 express high levels of MHC molecules, and therefore are the 
main subtypes involved in antigen presentation in both steady state and during 
inflammation, although the two can induce CD4+ T cell activation or tolerance. 
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cDC1 are essential for differentiation of CD4+ T cells into Th1 cells. On the other 
hand, cDC2 appears to more relevant for Th2 differentiation32. 
pDCs are distinguished from cDCs by production of IFN-I and expression of markers 
such as PDCA1 and low levels of MHCII6,32. These cells are rarely found in healthy 
skin, but in inflammatory conditions, LN and splenic pDCs upregulate CCR6 and 
CCR10 that facilitate their traffic to the inflamed skin through blood vessels33. 
The entrance of pDCs in LNs is facilitated by the expression of CD62L on its surface. 
Although pDCs do not normally migrate from the gut to mesenteric LNs, they assist 
the migration of cDCs in a toll-like receptors (TLR) and tumour necrosis factor 
(TNF)-dependent manner34. Lamina propria as well as lung pDCs have also been 
found to play a role in the induction of oral tolerance35. These cells play an 
important tolerogenic role in allergic diseases like asthma36. pDCs and cDCs are 
derived from a common DC progenitor cell, while moDCs and Langerhans cells are 
part of a monocyte/macrophage lineage32,37. MoDCs are directly involved in the 
defence against microbial pathogens and other roles seem to be dependent on the 
tissue where they are normally found. Lung moDCs secret relatively large amounts 
of pro-inflammatory cytokines, while dermal moDCs preferentially secrete IL-1038, 
suggesting a tolerogenic role in the skin. Langerhans cells are mainly found on the 
epidermis and in the epithelia of the respiratory, digestive and urogenital tracts 
and their development in vivo is dependent on granulocyte-macrophage colony-
stimulating factor (GM-CSF)37 and IL-3439. Langerhans cells act as APCs in many 
infections and are known to be an optimal driver of Th17 differentiation40,41. 
The development of techniques for generation of mouse DCs induced by GM-CSF 
in vitro, such as bone marrow-derived DCs (BMDCs)42,43, facilitated the study of T 
cell-DC interactions and the development of DC immunotherapies. In vitro 
generated tolerogenic DCs (tolDCs), for instance, hold a tolerogenic trait similar 
to steady-state DCs. TolDCs are being extensively studied for the treatment of 
autoimmune diseases due to their anti-inflammatory capacity to induce 
tolerance44,45. TolDCs are cells that exhibit resistance to maturation in the 
presence of stimulatory signals. In vitro induction of tolDCs requires IL-1046. These 
IL-10-induced cells acquire the ability to secrete IL-10, that is known to be 
essential in the generation of Treg cells. IL-10-induced tolDCs display a semi-
mature phenotype, expressing intermediate levels of CD80 and CD86, and low 
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levels of MHCII. Both BMDCs and tolDCs express different levels of surface proteins 
in comparison to endogenous equivalent subtypes of DCs found in the spleen, LN 
or tissue resident DCs31,47. However, studies using these cells allowed us to 
understand better about mechanisms of DC antigen uptake, migration and antigen 
presentation, essential DC immunomodulatory roles. 
1.3.1 DC Activation and Maturation 
Immature DCs express a number of receptors that respond to chemokines, such as 
C-C motif chemokine receptor (CCR) 1, CCR2, CCR6, and assist their migration 
from the bone marrow to inflamed tissues48. When an immature DC captures 
antigen, stimulation of DC cytokine receptors by inflammatory cytokines (e.g. IL-
1) or agonism of TLR receptors by non-bacterial (e.g. DNA/RNA from viruses) or 
bacteria-derived (e.g. lipopolysaccharides, LPS) antigens trigger DC activation49. 
DC activation induces its transition from immature to mature antigen-presenting 
DC, in processes that involve loss of endocytic/phagocytic receptors, upregulation 
of co-stimulatory molecules, change in MHCII compartments and change in 
morphology. Several surface molecules that actively participate in the crosstalk 
with CD4+ T cells are upregulated in mature DCs and give an enhanced T cell 
activation capability to these cells. These are CD80, CD83, CD86, CD40 and 
MHCII42,43. In addition, a profile of proinflammatory cytokine production, 
characteristic of mature DCs, assures delivery of signal 3 to naïve T cells during 
priming. In this context, different DC subtypes are specialized in priming T cells 
that preferentially differentiate into distinct subsets32. Changes in morphology 
increase the motility of the DC50, an essential feature of DC in the context of the 
adaptive immune system. 
1.3.2 DC Migration to Lymphoid Tissues 
DCs are the most efficient APCs for the initial activation of naïve T cells. This 
function is not only related to the direct crosstalk with the T cell but also to the 
highly efficient migratory properties of DCs in comparison to other APCs, as they 
can migrate in a high number from inflamed tissues to lymphoid tissues within 
hours51,52. DCs take up pathogens in affected sites (Figure 1-1), in a process that 
will often induce their maturation53,54 and internalize it to carry it through 
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lymphatic vessels to the LN. DC migration to lymphoid organs requires coordinated 
action of a number of chemokines. Mature DCs downregulate CCR6 and other 
chemokine receptors and upregulate CCR7. Agonism of this receptor by 
chemokines in lymphatic vessels, such as C-C motif chemokine ligand (CCL) 19 and 
secondary lymphoid-tissue chemokine (SLC), facilitates DC migration to the LN49. 
After entering the LN through afferent lymphatic vessels, the DC reaches the T 
cell area, where it will present the antigen to naïve CD4+ T cells. Costimulatory 
signals are delivered by the DCs to the CD4+ T cell, along with the MHCII-peptide 
complex, and assisted by several cytokines that will stimulate receptors on the 
surface of the T cell. This will lead to CD4+ T cell activation, clonal expansion and 
differentiation into Th cells. These effector T cells, thus, egress the LN to migrate 
to the affected site to assist in pathogen clearance and recruit more immune cells. 
These coordinated steps are fundamental not only for the immediate response 
against microbes but also for acquisition of immunological memory by memory T 
cells6. 
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Figure 1-1. Dendritic cell functions in the adaptive immune system upon encounter with a 
pathogen 
Immature dendritic cells (DC) capture potential pathogenic antigens and internalising it in a 
process that induces its maturation. Mature DC upregulates C-C chemokine receptor 7 (CCR7) that 
assists DC migration through the lymphatic vascular network to the draining lymph nodes (LN), via 
afferent lymphatic vessels. In the T cell area of the LN, the antigen is presented through major 
histocompatibility complex class II (MHCII) molecule to the T cell receptor (TCR) with specificity 
for this antigen, leading to activation of CD4+ T cells, clonal expansion and differentiation into 
effector cells that will later execute fundamental functions aiming clearance of the foreign 
peptide. 
1.4 CD4+ T Cell-Antigen Presenting Cell (APC) 
Interactions in Lymphoid Tissues 
While primary lymphoid organs are responsible for generation (bone marrow) and 
maturation (thymus) of T cells, secondary lymphoid organs, such as LNs and spleen, 
are a critical location for encounter of leukocytes and its interactions. Several cell 
types express MHCII and work as APCs to deliver antigen to CD4+ T cells, such as 
macrophages, B cells and DCs. B cells play an important role in the adaptive 
immune system not only by differentiating into plasma cells after being activated 
and secreting antibodies, but also by working as APCs29. These cells express high 
levels of MHCII as a mechanism to present antigen to CD4+ T cells and obtain 
 
 
24 
feedback from these cells for the production of antibodies with high affinity to 
the specific antigen involved in these processes. 
The TCR is an essential part of the T cell that allows recognition of cognate antigen 
in the context of MHC molecules. The TCR complex is composed of both TCR chains 
and an auxiliary protein called CD3, essential for T cell signalling. Many anti-CD3 
antibody clones can trigger TCR signalling by directly crosslinking CD3 co-
receptors55,56. Other transmembrane proteins also bind to MHC molecules and act 
as a co-receptors for T cell activation, such as CD457,58. This surface molecule is 
known to contribute to signalling functions, exert intercellular adhesion functions, 
and stabilize the interaction between the TCR and the MHCII. 
1.4.1 CD4+ T Cell-DC Interactions and T Cell Outcomes 
The activation of CD4+ T cells induces T cell clonal expansion and differentiation 
into effector and memory cells that will assist adaptive immune responses. Upon 
DC migration to the LNs, these cells interact with CD4+ T cells in the T cell area 
in a complex crosstalk involving several pathways that are described later in this 
Chapter. Mature recirculating T cells that have not yet encountered an antigen 
are known as naïve T cells. Naïve CD4+ T cells are found in high proportion in 
specialized lymphoid organs, where most of antigen presentation occurs. The way 
a naïve CD4+ T cell encounters an antigen for the first time determines its 
subsequent phenotype: activated, apoptotic or anergic (Figure 1-2). For optimal 
T cell activation, three signals are required: the antigen needs to be presented 
bound by MHCII molecules to the TCR (signal 1), co-stimulation needs to be 
delivered by intercellular interaction of surface molecules (signal 2), such as 
CD28-CD80/CD86, and cytokines receptors must be stimulated by proteins 
released by the APC or other cell types in the immunological environment (signal 
3)59. In case signal 1 is present but not signal 2, for instance, the T cell will undergo 
apoptosis or anergy. Tolerance mechanisms such as apoptosis and anergy are 
essential to keep tissues intact from potential damage caused by self-reactive T 
cells that escaped the appropriate selection in the thymus. Anergy is a 
hyporesponsive state of T cells in which they remain inactive, whereas apoptosis 
is a form of programmed cell death, that will lead to clonal deletion. On the other 
hand, when an effector state is desirable for assistance of the adaptive immune 
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system, the T cell will undergo activation. Both the TCR and CD4+ T cells co-
receptors are essential for the activation of T cells under the first contact with 
antigen presented by APCs. This process is called priming.  
 
Figure 1-2. Priming vs tolerance on CD4+ T cells 
Adapted from9. Three signals are required for optimal activation of naïve CD4+ T cells, antigen 
presentation (signal 1), co-stimulation (signal 2) and stimulation of cytokine receptors (signal 3). 
On CD4+ T cells, signal 1 is delivered by the professional antigen presenting cell (APC) through 
presentation of the antigen bound to the surface molecule major histocompatibility complex class 
II (MHCII) to the T cell receptor (TCR) and is specific. Signal 2 is a non-specific and antigen 
independent signal that is induced by the interaction of the costimulatory receptor for T cell 
activation CD28 and the molecules CD80 and CD86 (B7), expressed on the surface of dendritic cells 
(DC). If costimulatory signal is absent, the cell will undergo apoptosis (deletion) or anergy 
(unresponsiveness). The stimulation of cytokine receptors on the CD4+ T cell surface triggers 
pathways that affect T cell activation and proliferation and will dictate T cell differentiation. 
Once primed, T cells undergo physical changes, consisting of cell enlargement, an 
increase in their total ribonucleic acid (RNA) content and a differential regulation 
of the expression of hundreds of genes60,61. This change in gene expression assures 
a higher expression of surface proteins essential for effector functions of activated 
CD4+ T cells, as well as a decrease in molecules that prevent achievement of 
appropriate functions. At this stage, CD62L and CCR7 that functioned as homing 
receptors to mediate extravasation of naïve T cells migration from the thymus to 
the LNs through the afferent lymph vessel are no longer necessary20. In addition, 
the type II C-lectin CD69 is upregulated. This molecule forms a complex with the 
sphingosine-1-phosphate (S1P) receptor 1 (S1PR1), that has a role in the egress of 
T cells from the LN to inflamed tissues, leading to S1PR1 internalisation and 
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degradation and inhibiting temporarily T cell egress by local detection of its ligand 
S1P62. After reaching its peak of expression, CD69 starts to downregulate, allowing 
S1P to interact with its ligand present on the surface of lymphatic endothelial 
cells, triggering a series of other interactions that end with the CD4+ T cell leaving 
the LN through the efferent lymph vessel. CD44 is another molecule that is 
upregulated in activated CD4+ T cells and is widely used as an antigen experienced 
cell marker. CD44 assists LN egress by regulating tethering and rolling interactions 
between activated CD4+ T cells and the endothelia63 ultimately allowing these 
cells to exert their effector functions in the affected tissues. The many changes 
promoted by activation of CD4+ T cells, such as the increase in cell metabolism, 
are essential for its proliferation and differentiation. On average, a CD4+ T cell 
undergo 7 divisions, but there are reports of up to 10 divisions64. The division of 
activated CD4+ T cells usually starts 24 hours after antigen presentation65, 
reaching its peak 1-2 days later. T cell clonal expansion assists the adaptive 
immune system by increasing the “army” of T memory and Th cells. 
Following activation, and depending on the way the cell gets activated, CD4+ T 
cells can differentiate into different subsets of Th cells (Figure 1-3) that play 
supportive and immunomodulatory roles in the adaptive immune system. This 
differentiation is regulated not only by the crosstalk with the APC, but also by 
cytokines released by this or other immune cells. Th1 cells, for instance, are 
induced in an environment with abundant IL-12 produced by APCs66 and IFN-γ that 
subsequently comes from IL-12 stimulation of NK cells67,68. Th cells express 
different transcription factors that are necessary for the synthesis of distinct 
cytokines. Transcription factors are proteins that bind to specific regions of the 
DNA and lead to a regulation of the production of mRNA, leading to protein 
expression. Th1 cells, in comparison with other Th cells, intracellularly express 
high levels of a T-box transcription factor known as T-bet. T-bet is not only 
required for optimal production of IFN-γ, one of the key cytokines that drive Th1 
effector functions, but it is also required for survival of effector and memory cells 
in the sites of inflammation69. Th1 cells are mainly involved in pathogen clearance. 
IFN-γ activates macrophages70, cells that engulf and digest cellular debris, foreign 
substances, microbes and cancer cells. However, Th1 cells are also usually the 
most frequent pathogenic subset found in organ-specific autoimmune diseases70,71. 
Besides IFN-γ, TNF alpha (TNF-α), another cell signalling protein produced in high 
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levels by Th1 cells, is also a pro-inflammatory cytokine implicated in the 
pathogenesis of connective tissue autoimmune disorders, such as rheumatoid 
arthritis (RA), an autoimmune disease that mainly affect joints72. 
 
 
Figure 1-3. CD4+ T cell subsets based on T cell differentiation and its effector functions 
Adapted from73,74. Following recognition of cognate antigen and induction of CD4+ T cell activation, 
T cells can differentiate into different Th subtypes, depending on the cytokines that they may 
encounter. Interleukin (IL) 12 induces T helper (Th) 1 differentiation, that express T-bet and leads 
to secretion of interferon gamma (IFN-γ) and tumour necrosis factor alpha (TNF-α). IL-4 promotes 
Th2 differentiation. These cells express GATA binding protein 3 (GATA3) and are optimal secretors 
of IL-4, IL-5 and IL-13 and play an essential role in humoral immunity. Th9 cells are induced under 
concomitant presence of IL-4 and transforming growth factor beta (TGFβ) and are IL-9 secretors. 
These cells are important in mucosal immunity and autoimmunity and express the transcription 
factor PU.1. Th17 cells undergo differentiation in the presence of IL-6 and TGFβ, and express 
retinoic acid-related orphan receptor gamma t (RORγt) that is required for the production of IL-
17A and IL-17F. Th22 differentiation is more likely to happen in an environment rich in IL-6 and 
TNF-α. This cell subset expresses the aryl hydrocarbon receptor (Ahr), that is related to the 
production of IL-22. In the context of CD4+ T cell activation, regulatory T (Treg) cells 
differentiation can be induced in the presence of IL-2 and TGFβ. Treg cells secret optimal amounts 
of IL-10 that is assisted by the transcript factor Forkhead box P3 (FoxP3). Th1, Th17 and Th22 cells 
play important roles in inflammatory responses, while Treg cells induce its suppression. 
It is important to note that induction towards a single CD4+ T cell subset usually 
inhibits differentiation to other subsets. This can be seen in observations that 
showed that T-bet suppresses the development of Th2 cells by inhibiting the main 
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IL-4 gene and impairing the function of the main Th2 transcription factor, GATA 
binding protein 3 (GATA3)75. In addition, T-bet interacts with promoters of the 
RORC gene, responsible for encoding the retinoic acid-related orphan receptor 
gamma t (RORγt)76, the master transcript factor of Th17 cells. Th2 cells also 
express transducer and activator of transcription molecules (STAT), such as STAT5. 
STAT5 is not exclusively expressed by Th2, but its coordinated activity associated 
with GATA3 is necessary for production of IL-477, one of Th2 cells most expressed 
cytokines which is also necessary for its initial differentiation78, along with IL-279. 
IL-6 was also found to promote Th2 differentiation. The presence of IL-6 at high 
levels inhibits Th1 development through upregulation of suppressor of cytokine 
signalling 1 (SOCS1)80, a direct inhibitor of Janus kinase (JAK) activity that 
transduces cytokine-mediated signals, being a potent inhibitor of IFN-γ pathway. 
Th2 cells help the adaptive immune system in the response against multicellular 
parasites, a role sustained by IL-13 and assisted by IL-10, a cytokine that helps 
achievement of homeostasis after the pathogen is eliminated81. IL-25 is another 
cytokine that assists the induction of differentiation towards Th2 cells by 
supressing Th17 responses and consequently inhibiting the secretion of cytokines 
that drive Th17 differentiation82. In the context of allergic reactions, IL-4 
upregulates especially high-affinity immunoglobulin E (IgE) receptors (FcεRII) on 
the surface of mast cells and basophils83, facilitating degranulation of these cells 
with release of large amounts of histamine, a potent vasodilator that increases 
vascular permeability, heart rate, cardiac contraction, and glandular secretion 
and can lead to severe complications, such as anaphylaxis. IL-4 is also important 
in the differentiation of Th9 cells84. This subset was initially characterised as a 
subtype of Th2 cells. Th9 cells can be distinguished from Th2 by the expression of 
transcription factors such as PU.1, interferon response factor 4 (IRF4) and 
forkhead box O1 (FOXO1), all necessary for IL-9 protein coding85,86. IL-9 
participates in many inflammatory conditions, such as asthma in which it promotes 
hypersecretion of mucus87,88 and in RA, where it not only facilitates Th17 
differentiation but also assists neutrophil survival that play a definitive role in the 
pathogenesis of the disease89. 
Th22 cells are optimal secretors of IL-22, a cytokine that is involved in mucosal 
host defence against bacteria, and also plays a part in the development and 
pathogenesis of autoimmune diseases such as RA, systemic lupus erythematosus 
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(SLE), multiple sclerosis (MS) and psoriasis90,91. Th22 cells require IL-6 and TNF-α 
to develop92 and express the aryl hydrocarbon receptor (Ahr), that regulates IL-22 
production and Th17 differentiation. Th17 cells express RORγt which is necessary 
for the secretion of IL-17A and IL-17F. IL-17A and IL-17F bind to the IL-17 receptor 
A (IL17RA) and are involved in the development of autoimmune diseases. IL-17 is 
important in the response against bacteria and fungi and leads to indirect increase 
of other pro-inflammatory cytokines that recruit immune cells to the affected site, 
such as IL-6 and TNF-α93. 
Although regulatory CD4+ T cells (Treg) expressing forkhead box P3 (FoxP3) and 
CD25 are naturally released from the thymus (nTreg), induced regulatory T (iTreg) 
cells can also be developed upon TCR stimulation of naïve CD4+ T cells94, where 
IL-2 and transforming growth factor beta (TGFβ) are of major importance. Even 
though TGFβ is needed for both Treg and Th17 differentiation, the absence of 
proinflammatory cytokines signalling, such as IL-6, inhibits RORγt function and 
induces Treg differentiation95. In addition, the transcription factor responsible for 
the production of IL-10, FoxP3, can also inhibit Th17 differentiation by direct 
interaction with RORγt96. IL-10 plays a definitive role in supressing inflammation 
and autoimmune processes. In addition to these CD4+ T cell subsets that can 
differentiate exclusively upon antigen presentation by DCs and stimulation with 
specific cytokines, another subset requires B cell signals to differentiate. This 
subset is called T follicular helper (Tfh) cell. 
1.4.2 CD4+ T Cell-B Cell Interactions and T Follicular Helper (Tfh) 
Differentiation 
Tfh cells are frequently found in follicular areas of lymphoid tissues, playing an 
immunomodulatory role in the humoral immunity assisting formation of effective 
memory B cell and antibody responses through interaction with B cells97–99. After 
a naïve CD4+ T cell is primed in the T cell area of LNs by DCs in conditions to 
promote differentiation into pre-Tfh cells, these T cells upregulate CXC-
chemokine receptor 5 (CXCR5) and B-cell lymphoma 6 protein (BCL6)100. In 
association to downregulation of CCR7, a T cell zone homing chemokine receptor, 
upregulation of CXCR5 allows initial migration of these Tfh precursor cells toward 
the B cell zone. In the T cell-B cell border, these cells interact with cognate B 
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cells that provide co-stimulation by surface molecules ligation and activation of 
cytokines receptors, such as IL-6R, by secreting high levels of IL-6, an essential 
cytokine for Tfh differentiation101. Tfh cells express high levels of BCL6102, known 
to be essential for the production of IL-21. This cytokine is key for Tfh feedback 
to B cells during their interactions and assistance of formation of germinal centres 
(GC)100. IL-21, IL-4 and IL-10 are secreted by Tfh cells and stimulate B cell 
cytokines receptors, stimulating B cells differentiation into plasma cells that will 
later produce and secrete antigen-specific antibodies, which will assist adaptive 
immune responses against antigen of a specific pathogen. 
1.5 CD4+ T Cell-APC Interactions in Peripheral Tissues 
CD4+ T cell-APC interactions in peripheral tissues participate in the 
immunopathology of several inflammatory conditions. Macrophages are one of the 
earliest leukocytes to contact antigen in sites of injury7. These cells play 
important roles in sites of inflammation by clearing necrotic and apoptotic 
material and may also work as APCs103,104. These APCs secrete considerable levels 
of inflammatory cytokines, such as IFN-γ, assisting the recruitment of other 
immune cells to inflammatory sites. However, depending on the way they get 
activated, macrophages can also secrete IL-10, a cytokine that regulates 
inflammation and is important for maintaining integrity of epithelial barriers105. 
DCs can present antigen and activate CD4+ T cells in the synovium of RA106,107. In 
addition, during certain states, such as chronic inflammation, immune cells 
accumulate in peripheral tissues and form tertiary lymphoid organs that share 
common structural and functional features with secondary lymphoid tissues, 
including T cell areas, B cell follicles, GCs, and vascularization with HEVs7,108,109. 
These similarities may suggest that these tertiary organs could support not only 
CD4+ T cell-DC interactions in the T cell areas, but also CD4+ T cell-B cell 
interactions in T cell-B cell intermediate areas, which could promote B cell 
differentiation and support local production of specific antibodies proximal to the 
site of inflammation. 
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1.6 Molecules Controlling CD4+ T Cell-APC Interactions 
Depending on the phase of T cell-DC interactions, different molecules are 
recruited to the site of interaction and play distinct roles in the cells’ crosstalk. 
Whereas interactions within the first 8 hours of contact with antigen are usually 
short (<5 minutes), later interactions, up to 20 hours after antigen presentation 
starts, are long-term (>10 minutes)107. Behind all this are the interactions between 
surface molecules, such as adhesion molecules, that ensure a strong cell-cell 
interaction and trigger pathways that will decide the fate of naïve CD4+ T cells. 
Several molecule ligations have been described to control T cell-APC interactions. 
These pathways can be classified as co-stimulatory or co-inhibitory, depending on 
the outcome of the cells’ crosstalk upon disruption of these ligations in different 
time points, especially during priming.  
1.6.1 T Cell Co-Stimulatory Interactions 
Several molecules present on the surface of T cells and APCs have been described 
as contributing to CD4+ T cell co-stimulation (Figure 1-4). Co-stimulatory 
interactions can promote enhanced T cell activation, cell growth, differentiation 
and can be important for T cell effector functions, survival and memory. Several 
members of the immunoglobulin superfamily (IgSF) participate in that. CD80, also 
known as B7-1, and CD86, also known as B7-2, are well characterized co-signalling 
molecules from the B7-CD28 family110. When binding to CD28, a transmembrane 
protein expressed by T cells, CD80 and CD86 trigger a pathway that optimises 
priming outcomes. CD28 is also required for both natural development of Treg 
cells in the thymus, contributing to their survival and homeostasis in the 
periphery,111and in vivo differentiation of naïve CD4+ T cells into Treg cells, a 
mechanism dependent on IL-2. The inducible T cell co-stimulator (ICOS) receptor 
is another member of the B7-CD28 family expressed on activated CD4+ T cells and 
is essential for T cell survival and critical during the effector phase of the adaptive 
immune response112. This molecule is also expressed on Tregs and its ligation 
facilitates FoxP3 transcription, subsequently optimizing the production of IL-10113.  
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Figure 1-4. CD4+ T cell co-stimulation pathways 
Adapted from114,115. Co-stimulatory molecules on the surface of CD4+ T cells are engaged by ligands 
expressed by antigen presenting cells (APC) and control the outcome of these cell-cell interactions. 
Interactions between members of the immunoglobulin superfamily (IgSF) can be seen with CD28 
binding to CD80 and CD86 (B7), the inducible T cell co-stimulator (ICOS) binding by its ligand on 
the APC surface (ICOSL), CD2 binding to CD58 and CD48, the T-cell immunoglobulin and mucin 
domain 1 (TIM) 1 binding to TIM4 and the signalling lymphocytic activation molecule (SLAM) being 
engaged by SLAM-associated proteins (SAP) present on the surface of APCs, leading to optimal T 
cell activation. Members of the IgSF expressed by CD4+ T cells can also bind to other superfamilies, 
such as TIM2, that binds to Semaphorin (SEMA) 4A. SEMA4D can bind to CD72, another member of 
the C-type lectin superfamily. Lymphocyte function-associated antigen 1 (LFA1) is an integrin that 
binds to the member of the IgSF, ICAM1. Most of the CD4+ T cell co-stimulatory molecules 
described in the literature are part of the Tumour necrosis factor receptor superfamily (TNFRSF). 
Within this superfamily, CD27 binds to CD70. OX40, 4-1BB, CD30 and the glucocorticoid-Induced 
TNF receptor-Related protein (GITR) are engaged by OX40L, 4-1BBL, CD30L and GITRL, respectively. 
CD40 ligand (CD40L) interacts with the CD40 receptor expressed by APCs. The death receptor 3 
(DR3) binds to TL1A. The herpesvirus entry mediator (HVEM) and the LIGHT protein are both 
expressed by T cells and APCs and interactions can occur on both ways, although it was not 
described to occur at the same time. Furthermore, the receptor activator of nuclear factor kappa-
Β ligand (RANKL) expressed on T cells binds to the surface molecule RANK delivering co-stimulatory 
signals to the CD4+ T cell during its interaction with APCs. 
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The CD2-signaling lymphocytic activation molecule (SLAM) family of proteins is 
also part of the IgSF. CD2 is a transmembrane molecule that is widely expressed 
in different T cell subsets and binds to lymphocyte function-associated antigen 
(LFA) 3, also known as CD58, and SLAMF2, also known as CD48, to promote 
stimulatory responses116. Within this same family is the SLAM-associated protein 
(SAP), highly expressed on Th cells. SAPs were found to contribute to 
differentiation of Th17 cells through interaction with SLAM molecules on the 
surface of APCs117. Other co-stimulatory roles, such as enhanced proliferation, 
were described upon activation of pathways involving members of the T cell 
immunoglobulin and mucin domain (TIM) family. TIM-1 interacts with TIM-4 and 
regulates T cell proliferation and is associated with the regulation of Th2 
responses. This pathway enhances Th2 cells proliferation and IL-4 production118. 
TIM-2 binds to the protein Semaphorin (SEMA) 4A on the surface of DCs and is 
implicated in co-simulation of T cells and Th1 differentiation119. LFA1 is an integrin 
composed of an α (CD11a) and a β chain (CD18) and is highly expressed on the 
surface of naïve CD4+ T cells. Its interaction with intercellular adhesion molecule 
1 (ICAM1), also known as CD54, was found to support firm arrest during antigen 
recognition promoting long-lived contacts, thereby enhancing T cells activation 
and contributing to Th1 differentiation120,121. In addition, the ligation between 
SEMA4D, a protein expressed on the surface of T cells, and CD72 is also important 
for proliferation and enhances the activation of DCs122. Plexin-B1 was described 
to possibly be involved in some of the interactions with CD72 that contribute to 
proliferation of T cells, although this has not been proved yet123. 
The TNF receptor superfamily (TNFRSF) is characterised by the ability to bind to 
TNFs but also comprises a large family of T cell co-stimulatory molecules with 
different roles124, of which the CD27-CD70 pathway is the most extensively 
described. CD27 and CD70 are molecules from the type V family and this pathway 
enhances T cell activation, proliferation, induces Th1 differentiation125, inhibits 
Th17 differentiation126, promotes survival127 and contributes to effector memory 
T cell formation128. The ligation between OX40, also known as CD134, found on 
the surface of T cells, and its ligand, named OX40L or CD252, also potentiates TCR 
signalling, and is known to be important in T cell activation and survival129 and to 
contribute to Th9 differentiation130. In the same family the 4-1BB protein, also 
known as CD137, and its ligand 4-1BBL (or CD137L), a pathway that when activated, 
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promotes T cell clonal expansion and secretion of pro-inflammatory cytokines131. 
Both OX40 and 4-1BB have been shown to be important for memory T cell 
responses, to increase Treg cell expansion and to enhance its production of the 
proinflammatory cytokine IFN-γ132,133. CD30 is another member of the type V 
family expressed by CD4+ T cells and upon interaction with its ligand located on 
the surface of DCs (CD30L) promotes T cell growth and differentiation towards a 
Th17 phenotype124. Finally, the glucocorticoid-Induced TNF receptor-related 
protein (GITR) is related to CD4+ T cell proliferation of both effector and 
regulatory subtypes, when associated with its ligand present on the DCs’ surface, 
GITR ligand (GITRL)134,135. 
Within the TNFRSF, members of the type L family have also been described to 
have co-stimulatory roles. CD40 is a widely used marker to detect maturation of 
DCs. Its ligand is present on the surface of activated CD4+ T cells (CD40L), and 
this pathway induces release of pro-inflammatory cytokines, including IL-17136. 
The expression of other molecules from the same family also co-stimulate T cell 
activation and induces cytokine secretion. This is the case of the pathway 
triggered by the ligation between the death receptor 3 (DR3) and the TNF-like 
ligand 1A (TL1A) and between the Herpesvirus entry mediator (HVEM) and another 
protein called LIGHT. HVEM and LIGHT are both expressed by T cells and DCs, 
although concomitant expression on the same cell has not been observed, due to 
an unexplained mechanism that is suggested to avoid cis interactions on the 
surface of T cells114. This is exemplified by the fact that HVEM is highly expressed 
by naïve CD4+ T cells, downregulated upon activation but re-expressed later on137. 
On the other hand, LIGHT is upregulated on activated CD4+ T cells but 
downregulated on effector and memory T cells. The Receptor activator of nuclear 
factor kappa-Β ligand (RANKL) is another member of the TNFRSF that binds to the 
RANK molecule, also known as CD265. This signal , delivered by the T cell to the 
DC, assists cDC survival and ensures T cells priming, enhancing the effectiveness 
of T cell activation138. 
1.6.2 T Cell Co-Inhibitory Interactions 
In the context of immune tolerance, T cells are targets for the induction of anergy 
or apoptosis, and co-inhibitory interactions between surface molecules are 
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essential for this (Figure 1-5). Co-signalling through members of the same family 
of molecules can promote opposite outcomes on CD4+ T cells. Although CD80 and 
CD86 are highly expressed on mature DCs and less in TolDCs, these B7 molecules 
have a co-inhibitory role when binding to the cytotoxic T-lymphocyte associated 
protein 4 (CTLA-4), expressed by activated CD4+ T cells139. CD80/CD86-CTLA-4 
ligation has higher affinity in comparison to CD80/CD86-CD28 interaction140. Upon 
TCR stimulation and under recruitment of CTLA-4, T cell CTLA-4 captures DC co-
stimulatory molecules, such as CD86, that is internalised by the CD4+ T cell, 
possibly decreasing the availability of surface CD86 that could be recruited by 
CD28141,142. Within the same family is the programmed cell death-protein 1 (PD1), 
or CD279, a protein expressed on CD4+ T cells that binds to the molecules 
programmed cell death-ligand (PDL) 1 and 2 in interactions that prevent CD28-
induced changes in the T cell gene profile under TCR signalling143. This inhibition 
leads to a control in T cell activation.  
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Figure 1-5. CD4+ T cell co-inhibition pathways 
Adapted from114,115. Co-inhibitory molecules expressed by CD4+ T cells are engaged by ligands 
present on the surface of antigen presenting cells (APC) and control the outcome of these cell-cell 
interactions. Interactions between members of the immunoglobulin superfamily (IgSF) are the vast 
majority of co-signalling molecules found to have inhibition effects on CD4+ T cells. The Cytotoxic 
T-Lymphocyte Associated Protein 4 (CTLA4) is a well characterised co-inhibition receptor that 
binds to CD80 and CD86. Programmed cell death protein 1 (PD1) also has inhibitory effects when 
engaged by the programmed death-ligand 1 (PDL1) or PDL2. The T cell immunoglobulin and ITIM 
domain (TIGIT) expressed on CD4+ T cells can bind to CD155, CD112 and CD113. Besides the 
interactions between molecules of the same superfamily, other co-inhibitory pathways were 
described of proteins from the IgSF binding to proteins from different superfamilies. This is case 
of the T cell immunoglobulin and mucin domain-containing protein 3 (TIM3) that interacts with the 
Galectin 9 (GAL9), CD160 that binds to the herpesvirus entry mediator (HVEM) and the Leukocyte 
Associated Immunoglobulin Like Receptor 1 (LAIR1) that is engaged by molecules of Collagen, 
present on the APCs’ membrane surface. 
The T cell immunoglobulin and ITIM domain (TIGIT) coreceptor is also part of the 
IgSF and binds to CD155 and different members of the Nectin family, CD112 and 
CD113, to control T cell activation and proliferation144–146. Although TIM-1 shows 
function of a co-stimulatory receptor, a ligation between two other members of 
the TIM family promotes a different outcome. TIM-3, expressed on the surface of 
T cells, binds to galectin-9 (GAL9) to promote inhibitory effects147. Similarly, 
HVEM that have co-stimulatory functions when binding to LIGHT modulates 
immune responses by controlling T cell proliferation when binding to CD160 
expressed on DCs137. Leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) 
is a protein found on the surface of T cells that binds to collagen from the surface 
of other immune cells such as DCs and also negatively regulate T cell 
activation148,149. Subtypes of collagen molecules are relevant in the context of 
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several autoimmune disorders, such as collagen II (CII) that is one of the 
autoantigens in RA and SLE150,151. Interestingly, autoantibodies against collagen in 
these pathologies could potentially interfere in the LAIR1-Collagen pathway, 
leading to an augmented auto-reactivity by inhibition of this pathway148. This 
rationale highlights the importance of considering the different mechanisms 
involved in these diseases when developing drugs targeting T cell co-stimulatory 
or co-inhibitory molecules for therapeutic use in distinct medical conditions. 
1.7 The Role of CD4+ T Cells-APC Interactions in 
Pathological Conditions 
The interactions between CD4+ T cells and APCs participate in the 
immunopathogenesis of a number of inflammatory conditions and cancer, through 
modulation of effector and memory T cell responses. In normal conditions, upon 
maturation, DCs migrate to LNs and present tumour antigens to antigen specific 
CD4+ (via MHCII) and CD8+ (via MHCI) T cells152.  Primed CD4+ T cell are required 
for generation and maintenance of effector and memory CD8+ T cells, T cells 
subtypes that have a major contribution to anti-tumour mechanisms153. Treg cells 
directly and effectively supress tumour responses97. In addition, Tfh cells are 
essential for a more efficient tumour eradication, as these increase CD8+ T cells 
expansion and activity154,155. However, abnormal cells that escape immune 
surveillance to recognise and destroy them can lead to tumour formation. This is 
evidenced by DCs infiltrated in tumours of cancer patients that have phenotypes 
with low levels of co-stimulatory molecules and MHCII, suggesting impaired 
tumour-specific CD4+ T cell priming functions156,157. 
1.7.1 Rheumatoid Arthritis (RA) 
The interactions between CD4+ T cells and DCs play a dominant role in RA. CD4+ 
In autoimmune diseases such as RA, a breach of self-tolerance led by failure in 
immune regulatory mechanisms results in activation of immune responses that 
leads to the production and secretion of several autoantibodies158. T cell priming 
following a primary recognition of specific antigen-MHCII complexes induces T cell 
activation, proliferation and differentiation into Th cells and underlies the breach 
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of self-tolerance required for the initiation of RA107. In addition, a second or next 
recognition of cognate antigen by antigen experienced CD4+ T cells can lead to 
re-activation and re-expansion of resting memory cells, playing a fundamental 
part in propagation of RA pathogenesis106. Antibodies against cartilage 
components (e.g. collagen), nuclear proteins, stress proteins, citrullinated 
proteins and the Fc portion of IgG antibodies (rheumatoid factor) can be found in 
the serum of RA patients159–161. These autoantibodies mediate adaptive immune 
responses against articular cartilage and bone, leading to deposition of immune 
complexes that can increase tissue damage and persistent synovial 
inflammation159,162. CXCR5+ Tfh cells that originate from the interactions of B cells 
with antigen experienced CD4+ T cells are required for the production of 
antibodies against type II collage (CII) and for the development of RA163–165. 
Patients with specific polymorphisms in MHCII genes, which encode human 
leucocyte antigens (HLA) that mediate antigen presentation to CD4+ T cells, have 
differential risks for developing RA166, and associations between these and 
autoantibodies are reported. MHCII-expressing DCs are essential on discriminating 
self-antigen from foreign antigens and found in high numbers in joints tissues and 
synovial fluids of RA patients167. As such, these polymorphisms associated with 
other genes that encode molecules involved in T-cell signalling may contribute to 
the development of a more autoimmune phenotype107. 
A number of animal models of RA are used to study possible therapeutic 
intervention in this disease, such as the collagen-induced arthritis (CIA) model or 
the K/BxN model168. The CIA model is induced by immunisation of mice with 
collagen injections and an adjuvant (e.g. CFA), therefore directly stimulating 
adaptive immune responses against collagen. On the other hand, the K/BxN model 
is induced upon transferring serum from arthritic mice that contain autoantibodies 
that will induce joint inflammation169. In addition to these models, there is the 
breach of self-tolerance model of RA170, utilised in this thesis. In this model, joint 
inflammation is mediated by antigen specific Th1 cells, that ultimately leads to 
adaptive immune responses against self-antigens like collagen. The breach of self-
tolerance model allows clear distinction in the effects of the used treatment in 
adaptive immune responses mediated by antigen-experienced T cells, that can be 
measured by the analysis adoptively transferred Th1 cells and anti-OVA antibodies, 
and adaptive immune responses by recently primed T cells, that can be measured 
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by analysing endogenous T cells and production of autoantibodies. However, it is 
important to note that none of these animal models reliably simulate human 
disease, as RA in humans is a complex autoimmune disease in which several 
immune components may play a major role, such as the undiscovered antigen that 
initiates RA171. 
1.8 Therapeutic Targeting of T Cell Co-Signalling 
Pathways 
The expression of T cell co-signalling molecules has been studied in many 
pathological tissues and their manipulation in preclinical and clinical trials has 
established their use for medical conditions. In general terms, blockade of co-
stimulatory interactions can be targeted for inflammatory conditions and blockade 
of co-inhibitory interactions has been used for the treatment of cancer. In addition, 
while some reagents may block these interactions, others may promote them. It 
is also important to consider the affinity of these reagents, since the target 
molecules may compete with other ligands that perhaps have not yet been 
described. Furthermore, each disease has its peculiarities, and the blockade of 
these molecules can have distinct outcomes not only on T cell-DC interactions, 
but on the interactions between other immune cell types. Therefore, studies to 
analyse clinical effects and involved mechanisms in different disease models are 
essential for the development of prospective successful drugs. 
1.8.1 Agonists of T Cell Co-Stimulatory Molecules 
Agonists of co-stimulatory molecules from the IgSF and TNFRSF have been used in 
several preclinical cancer models. A bioinformatic tool called High-Throughput 
Systematic Evolution of Ligands by EXponential Enrichment (HT-SELEX) was used 
to engineer an ICOS agonistic aptamer that although not able to independently 
induce a potent antitumor response, was able to potentiate CTLA-4 blockade 
efficacy to inhibit tumour growth172. In the TNFRSF, anti-CD27 agonistic antibodies 
enhanced survival of mice in a B cell lymphoma model173 and improved tumour 
control in melanoma models174, with mechanisms that seem to involve CD8+ T 
cells more than CD4+ T cells. In addition, multiple lymphoma models have shown 
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that treatment with agonistic anti-CD27 antibody concomitantly with an anti-CD20 
antibody treatment induced cure of all treated mice beyond 100 days175. The 
authors have also demonstrated the essential role of T cells on the therapeutic 
effect by showing that deletion of either CD4+ or CD8+ T cells alone had minimal 
impact, but deletion of both T cells types considerably reduced the therapeutic 
effect of the combined treatment. A phase 2 clinical trial has been recently 
completed using Varlilumab, an anti-CD27 agonistic antibody, in combination with 
Nivolumab, a PD1 blocker, on the treatment of colorectal and ovarian cancer176. 
This study showed that Varlilumab induced tumoral changes that led to better 
outcomes, with patients safely tolerating the drugs. 
The potential for OX40 agonistic targeting has been analysed in some preclinical 
and clinical studies177. However, the results between in vitro and in vivo studies 
are conflicting and the mechanisms are yet not well understood. A few clinical 
trials are still underway, while others have been terminated early178 or finished 
with good results of remission179. The most promising study showed an increase in 
survival of patients treated with an agonistic target of OX40180. The amelioration 
in clinical condition was mediated by antigen processing related to MHCI, and 
differences in the expression of genes associated with MHCI were correlated to 
clinical responsiveness. 4-1BB is a T cell co-stimulatory molecule, also from the 
TNFRSF, that is targeted for agonistic drugs. They are also being studied in clinical 
trials due to their capacity to stimulate the 4-1BB pathway and activate T cells 
that will help on cancer cells clearance. Utomilumab and Urelumab are 4-1BB 
agonists that are being tested in combination with other drugs for treatment of 
leukaemia, multiple myeloma, solid tumours and B cell non-Hodgkin’s 
lymphoma181. Brentuximab is a well-established drug approved by the U.S. Food 
and Drug Administration (FDA) and used within the UK’s National Health Service 
(NHS) that targets CD30 and is used for the treatment of relapsed or refractory 
Hodgkin lymphoma and systemic anaplastic large cell lymphoma182,183. 
Agonistic targeting of other T cell co-stimulatory molecules from the TNFRSF is 
also being tested in preclinical and clinical phases, such as GITR and CD40L. GITR 
agonist antibodies were also found to have potential anti-tumour effects in mouse 
models of cancer by enhancing both CD4+ and CD8+ T cell effector functions and 
Treg cell apoptosis184,185. Furthermore, the combination of GITR agonist with 
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blockade of CTLA-4 was found to reduce the immune suppression induced by Treg 
cells and restore the cytokine secretion of effector T cells in human liver tumour 
ex vivo186. Currently, a drug targeting GITR in the treatment of advanced or 
metastatic malignancies is in course (ID NCT03126110) to try to establish efficacy, 
safety and tolerability of this drug in combination with others. Besides GITR, 
CD40L is also a target of agonistic drugs on the treatment of cancer. The use of 
recombinant CD40L molecules and agonistic antibodies against CD40 in early 
clinical trials show promising results regarding anti-tumour effect and biological 
safety187. 
1.8.2 Antagonists of T Cell Co-Inhibitory Molecules 
CTLA-4 alone has also been a target for treatment of diseases where induction of 
Th cell activity and inhibition of Treg immunosuppressive functions are desirable. 
Ipilimumab is a commercially available monoclonal antibody that blocks CTLA-4 
binding with CD80/CD86 and prolongs survival in patients with metastatic 
melanoma, with ongoing clinical trials in many other types of cancer188–190. 
However, this drug was found to show limited effects in tumour cells with genomic 
defects in the IFN-γ pathway genes. Mice deficient in IFN-γ receptor 1 (IFNGR1) 
showed high mortality despite treatment with this CTLA-4 blocker191, IFN-g 
therefore being a potential marker for predicting responder vs non-responder 
patients. 
PD1-PDL1/PDL2 is another pathway of members from the IgSF. Atezolizumab is a 
monoclonal antibody anti-PD1L that has been approved by FDA for medical use on 
the treatment of small cell lung cancer, non-small cell lung cancer, triple-
negative breast cancer and urothelial carcinoma192. Like any cancer treatment, 
the importance of detecting non-responders can increase the chances of survival 
and reduce patient suffering. A study with 51 patients with non-small cell lung 
carcinoma, who were treated with Atezolizumab, Nivolumab and Pembrolizumab, 
all drugs targeting the PD1-PDL1 pathway, showed that the therapeutic effects 
expected by these treatments were compromised in patients with dysfunctional 
systemic CD4 immunity193. In addition, a study of 171 patients with the same kind 
of cancer showed that the percentage of Tregs in the peripheral blood of patients 
prior to anti-PD1 therapy was higher in non-responders, while long-term 
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responders had higher numbers of CD4+ T cells expressing low levels of CD62L 
prior to the therapy194. 
In mice, blockade of the pathway TIGIT-CD155, also members of the IgSF, with 
anti-TIGIT monoclonal antibody was found to inhibit tumour growth and prevent 
T cell exhaustion, enhancing anti-tumour effects195. Treatment with anti-TIGIT 
antibody in combination with Nivolumab, a PD1 blocker, or with an antibody 
targeting the anti-Lymphocyte Activating 3 (LAG3), a protein expressed by T cells 
that plays a role on maintenance of CD8+ T cells tolerogenic state196, are being 
studied in clinical trials for solid tumours (ID NCT02913313) and multiple myeloma 
(ID NCT04150965), respectively179. In addition, TIM-3 blockade was used in a 
number of preclinical studies and showed enhancement of anti-tumour immunity, 
suggesting it may be an effective target for cancer treatment197. 
1.8.3 Antagonists of T Cell Co-Stimulatory Molecules 
CTLA4-Ig, a protein synthetized by fusion of extracellular domain of human CTLA4 
and a modified human IgG1 heavy chain, binds to CD80/CD86 blocking a possible 
ligation with T cell CD28198. Abatacept, the first FDA-approved co-stimulation 
blocker and a CTLA4-Ig fusion protein, is widely used in the treatment of 
autoimmune diseases like RA, juvenile idiopathic arthritis, adult psoriatic arthritis 
and SLE199. Abatacept’s mechanism of action includes a limit on the breach of self-
tolerance that was demonstrated in a murine model of RA by decreasing 
maturation and expansion of Tfh cells and reducing the production of 
inflammatory mediators, such as IFN-γ, IL-17 and CCL3200. Similar effects could 
also be seen in a mice model of collagen-induced arthritis (CIA), in which lower 
levels of collagen-specific IgG1 and IgG2c antibodies were found in comparison 
with the control group201. A reduction in autoantibodies such as rheumatoid factor 
could also be seen in the serum of patients treated with abatacept202. Although 
this drug is already in use for treating RA patients, other aspects of the mechanism 
of action remain unclear, such as the duration of the effect on T cells in vivo and 
the influence of the drug on the migration of immune cells, such as DCs. Abatacept 
was also found to reduce the progression and severity of a murine model of heart 
failure by inhibiting the activation and infiltration of T cells and macrophages203. 
In addition, the use of IL-10-deficient mice in this same study allowed researchers 
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to identify an important role of IL-10 in the therapeutic effects of abatacept in 
this model of cardiovascular disease. IL-10 deficient mice were unable to acquire 
protection against the development of the disease, but abatacept’s protective 
effects were restored upon adoptive transfer of IL-10-sufficient B cells. Clinical 
trials using abatacept for other immune conditions, such as graft-versus-host 
disease, the major cause of mortality after allogeneic transplant of hematopoietic 
stem cells204,205, are also underway (ID NCT01743131). 
Other pathways of molecules from the IgSF play important roles in a number of 
pathologies, and a few disease models have been tested aiming to evaluate the 
clinical effects and mechanisms of blockade of these routes. The ICOS-ICOSL 
pathway was addressed using ICOSL knockout (KO) mice in a murine model of 
antigen-induced asthma. Mice lacking ICOSL showed less lung eosinophilic 
infiltration; reduced mucus production and airway hyperresponsiveness upon 
challenge in comparison with wild-type mice (WT)206. This therapeutic effect 
seems to be related to a decrease in antigen specific antibodies, such as IgG1, 
IgG2a and IgE. Additionally, CD4+ T cells from the ICOSL KO mice produced less 
IL-4, IL-5, IL-10, IL-13, but more IL-17 than the WT controls, suggesting a higher 
differentiation into Th17 cells. Recently, antagonistic anti-ICOSL antibodies were 
used in a different model of allergic airway disease showing an amelioration in 
the clinical condition of the treated mice in comparison to the control group207. 
Here, the treatment decreased the differentiation of Tfh cells, cells that are 
essential in the regulation of allergic airway diseases like asthma207,208. The 
mechanisms of amelioration of the disease were also possibly related to a 
reduction in the concentration of antigen specific IgE in the serum and pulmonary 
IL-13. Antigen receptor domains with the ability to block ICOS-ICOSL ligation were 
used in a murine model of CIA, delayed the disease onset and reduced the disease 
progression and severity209. On the other hand, a model of Th1-driven crescentic 
glomerulonephritis showed that ICOSL blockade increased glomerular 
accumulation of CD4+ T cells and macrophages, leading to augmented renal 
injury210. Apolipoprotein E (APOE) KO mice fed with a high-fat diet in a mouse 
model of atherosclerosis and treated with anti-ICOS antibody showed augmented 
disease, with an increase by 40% in aortic lesions211. In this case, a reduction on 
the number of Tregs was found in the iliac LNs, which may have contributed to 
the increase in pathology. 
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Immunotherapies aiming for disruption of the CD2-CD48/CD58 pathway were used 
in models of colitis, allergy and arthritis, among others. Prophylactic treatment 
with anti-CD2 blocking antibody attenuated and delayed the onset of adoptive 
transfer colitis in mice, with a reduction in T cell proliferation and IL-2 secretion212. 
In a model of allergic eosinophilic airway inflammation, anti-CD48 administration 
attenuated eosinophilic inflammation by decreasing Th2 responses and secretion 
of IL-4, IL-5, IL-13 and TNF-α213. Anti-CD48 was also used in a model of 
autoimmune encephalomyelitis where it decreased disease severity by reducing 
lymphocyte accumulation and the production of IFN-γ, TNF-α and IL-17 by splenic 
CD4+ T cells214. 
The TIM1-TIM4 pathway has also been tested in a few disease models. In a model 
of atherosclerosis, low density lipoprotein receptor (LDLR) KO mice treated with 
anti-TIM1 or anti-TIM4 had increased atherosclerotic lesions when compared to 
the control group215. While the effects on this disease of TIM1 blockade is believed 
to be due to an accumulation of CD4+ T cells in the lesions, TIM4 blockade reduced 
the number of circulating Tregs and increased Th1 and Th2 responses. In the 
context of autoimmune diseases, treatment with anti-TIM4 antibody just before 
or after the disease onset suppressed the development and progression of arthritis 
in a CIA model by reduction of proinflammatory cytokines, such as IL-6, TNF-α and 
IL-1β, although serum levels of anti-CII antibodies were not different in 
comparison with the control group216. 
SEMA4D has been targeted for a number of inflammatory diseases. SEMA4D KO 
mice showed reduced lung inflammation in an airway allergic inflammation 
model217. This reduction was associated with a decrease in the levels of IL-5, IL-
6, IL-13, IL-17 and TGFβ. Additionally, T cells from the SEMA4D KO mice re-
stimulated in vitro showed decreased proliferation, and the proportion of Treg 
cells found in the spleen was higher in comparison to the WT control group. 
Administration of anti-SEMA4D antibody inhibited neuroinflammation during the 
development of experimental autoimmune encephalomyelitis218. Mice lacking 
SEMA4D and LDLR simultaneously accumulated less platelets during the induction 
of thrombus formation in comparison to LDLR KO mice, although they still 
developed the induced dyslipidaemia219. Finally, treatment with anti-SEMA4D 
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antibody ameliorated severity of arthritis in CIA mice, reducing the level of serum 
TNF-α, IL-6 and anti-collagen antibodies220. 
The pathway involving ICAM1, also a member of the IgSF, and the integrin LFA1 
have been studied in several inflammation models. Simultaneous treatment with 
peptides that bind to ICAM1 and LFA1 in the first week after disease induction had 
a beneficial effect in a mouse model of emphysema, preventing lung tissue 
destruction, reducing leukocyte infiltration and inhibiting the decrease in the 
ratio of CD4:CD8 T cells that is characteristic in human emphysema221. Blockade 
with anti-ICAM1 or anti-LFA1 antibodies inhibited experimental allergic 
conjunctivitis222. For both treatments, there were a decrease in clinical scores 
and leukocyte infiltration in the conjunctiva. In a model of adoptive transfer of 
Crohn’s disease, ICAM1 blockade associated with blockade of vascular cell 
adhesion molecule-1 (VCAM1), a protein upregulated in endothelial cells during 
inflammation, achieved a 70% resolution of the acute inflammation on the gut223. 
Interestingly, this effect was not seen in treatments with ICAM1 or VCAM1 alone. 
In a model of arthritis, where the transfer of serum from arthritic transgenic 
(K/BxN) mice to WT mice to induces inflammation driven by autoantibodies, 
treatment with anti-ICAM1 antibody was able to delay the disease onset and 
permitted a faster resolution of the disease224. 
CD27 and CD70 are molecules from the TNFRSF that represent an important 
pathway in many diseases when binding to each other. Mice lacking APOE and 
CD70 showed larger atherosclerotic plaques with lower cellularity and a more 
advanced phenotype in comparison to APOE KO mice225. Treatment with anti-CD70 
blocking antibody inhibited the induction of allergic lung inflammation in mice by 
reducing eosinophil infiltration in lung tissue and decreasing the secretion of IL-4, 
IL-5 and IL-13, cytokines that are characteristic of Th2 cells226. An experimental 
model of inflammatory bowel disease was also used to evaluate the clinical effects 
of treatment with a different anti-CD70 blocking antibody. The treatment 
suppressed the induction of 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced 
colitis in mice but was not able to inhibit non-T cell mediated colitis227. Anti-CD70 
treatment both before and after the disease onset was also used in a CIA mouse 
model that ameliorated arthritis with a reduction in inflammation and a decrease 
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in bone and cartilage destruction228. The treatment significantly decreased the 
concentration of anti-CII found in the serum. 
Blockade of the OX40-OX40L pathway was also addressed in many inflammatory 
conditions. In a model of allergic conjunctivitis, mice treated with an anti-OX40L 
blocking antibody, during the induction phase of the disease, showed decreased 
eosinophil infiltration, with splenocytes re-stimulated in vitro with Concanavalin 
A (Con A) produced less IL-2 and IL-5 but significantly more IFN-γ, characteristic 
of a Th1 phenotypic differentiation229. Blockade of the OX40-OX40L interaction 
with an OX40-Ig fusion protein ameliorated dextran sulphate sodium (DSS)-induced 
colitis, with a significant increase in the production of IL-10 and IL-5 by immune 
cells from the mesenteric LNs230. Similarly, IL-10 mRNA levels were increased in 
colonic tissue, and T-bet expression was significantly decreased. This therapeutic 
effect was partially inhibited with blockade of IL-10. In the context of 
cardiovascular diseases, blockade of this pathway also seems beneficial. Anti-
OX40L treatment showed a reduction on the number of T cells within cells that 
formed atherosclerotic plaques, plaque size and cytokines related to Th2 
responses in LDLR KO mice231. Similarly, treatment with an antagonistic anti-
OX40L antibody in APOE KO mice reduced aortic atherosclerotic plaque 
formation232. In a CIA model, an antagonistic anti-OX40 conjugated to a 
polyethylene glycol molecule and an OX40L-Ig fusion protein reduced arthritic 
inflammation and restored tissue integrity by an inhibition in the production of 
inflammatory cytokines by macrophages expressing OX40L233. Blockade of OX40 
also prevented the development of arthritis in K/BxN mice by reduction of IL-17-
secreting Tfh cells234. 
Although only few studies are available in the literature, targeting the 4-1BB-4-
1BBL pathway may represent a promising therapeutic strategy for treatment of 
inflammatory diseases. Two models of hyperlipidaemia were tested in a study that 
showed that mice lacking APOE or 4-1BB were found to have smaller 
atherosclerotic plaques compared to the APOE control mice235. This same effect 
was found on mice lacking LDLR and 4-1BB simultaneously. These effects were 
attributed to a decrease in IFN-γ, TNF-α and CCL2 expression. Treatment with 
anti-4-1BB antibody in a CIA model inhibited the establishment of arthritis in mice 
and reduced the concentration of serum anti-CII236. This amelioration is believed 
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to be driven by an increase of IFN-γ-producing-CD11c+ CD8+ T cells, that depleted 
CD4+ T cells. 
Anti-CD30L treatment of LDLR KO mice resulted in a reduction in atherosclerotic 
lesions, with a decrease in proliferation of splenocytes and T cells, indicating that 
the therapeutic effect may be driven by T cells237. Blockade of this pathway was 
also tested in a model of enteritis using CD30 KO mice that showed reduced 
inflammation with a decrease in Th1 and Th17 responses measured by secreted 
IFN-γ and IL-17, respectively238. Mice lacking CD30L were also used in another 
model of inflammatory bowel disease, in which these animals resisted induction 
of acute and chronic DSS-induced colitis239. Here, levels of IFN-γ and IL-17 were 
also lower, and T cells from the lamina propria produced higher levels of IL-2. This 
study also used an antagonistic CD30-Ig fusion protein that ameliorated both acute 
and chronic models of colitis, associated with an inhibition of Th17 differentiation. 
The GITR-GITRL interaction is another pathway from the TNFRSF that was found 
to have beneficial effects in models of colitis and arthritis. Blockade of this 
pathway with the use of GITR KO mice or with the treatment of WT mice with 
soluble GITR protein was able to protect mice against TNBS-induced colitis240. 
CD4+ T cells from the lamina propria of the GITR KO mice with colitis were found 
to secrete less IFN-γ, TNF-α and IL-2 and more IL-10 and TGFβ than the WT mice 
that were subjected to the same inflammation model. GITR-Ig fusion protein was 
found to ameliorate CIA pathology in mice. This effect was believed to be due to 
a supressed Tfh response. The treatment reduced not only the levels of anti-CII 
IgG1 and IgG2a antibodies but also the number of CII specific IgG-secreting cells 
in the bone marrow241. 
The pathway DR3-TL1A is also a focus of study for treatment of inflammatory 
diseases. In a study that analysed the role of this molecular route using two 
different murine models of arthritis, DR3 KO mice had decreased development 
both bone pathology in antigen-induced arthritis and subchondral bone erosions 
in a CIA model. In the same study, the CIA model was also used in WT mice treated 
with anti-TL1A antibody and these also showed amelioration in the arthritis 
immunopathology in comparison with the control group242. In the context of 
inflammatory bowel diseases, blockade of TL1A with monoclonal antibody 
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inhibited DSS-induced colitis in mice by downregulating Th1 and Th17 
differentiation243. This finding was corroborated by another study that showed 
that DR3 deficient mice had protection against development of intestinal 
inflammation in mice upregulating TL1A in T cells and DCs that spontaneously 
develop IL-13 dependent inflammatory small bowel pathology244. In this same 
study, they also administered anti-TL1A and anti-DR3 blocking antibodies in mice 
with TNBS-induced colitis, with significant amelioration of the disease. Anti-TL1A 
treatment also seems to be relevant in the context of allergies. In an antigen-
induced model of asthma, treatment with antibody against TL1A significantly 
reduced the levels of Th2 cytokines, such as IL-4, IL-5 and IL-13, inducing an 
amelioration in airway inflammation245. 
The CD40L-CD40 pathway has been extensively studied and treatments blockade 
of this pathway ligation are already being tested in clinical trials, for different 
diseases. Dapirolizumab pegol is a Polyethylene glycol (PEG)ylated Fab fragment 
that is being tested for SLE in a Phase 3 clinical trial (ID NCT04294667) but has 
also potential for use in other autoimmune diseases. VIB4920 is a CD40L binding 
protein that significantly reduced disease activity in RA patients, with a decrease 
in autoantibodies such as RF in a Phase 1 clinical trial, whereas results from a 
Phase 2 trial in RA patients are being currently analysed (ID NCT04163991). 
Letolizumab is an anti-CD40L antagonistic antibody that is being tested in a phase 
2 clinical trial for primary immune thrombocytopenia, with results currently being 
analysed (ID NCT02273960). Drugs targeting CD40 are also being tested in patients 
with a number of autoimmune diseases, such as RA, SLE, Sjogren’s syndrome, 
myasthenia gravis, psoriasis, focal segmental glomerulosclerosis, immune 
thrombocytopenia, lupus nephritis, Chron’s disease and primary biliary cirrhosis246. 
1.8.4 Agonists of T Cell Co-Inhibitory Molecules 
Disruption of the TIGIT-CD155/CD112/CD113 T cell co-inhibitory pathway with 
TIGIT agonists has been studied. An anti-TIGIT antagonistic antibody was used in 
a model of cardiovascular disease in mice. The treatment was able to decrease T 
cell activation and expansion, but this effect was not enough to see an effect on 
atherosclerotic lesion development in LDLR KO mice247. Additionally, a higher 
percentage of DCs was also seen in the spleen. These cells had increased 
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activation and a lower production of IL-10. Nevertheless, although more studies 
should evaluate the potential of agonistic targeting of T cell co-inhibitory 
pathways in pre-clinical models, it seems that antagonism of co-stimulatory 
pathways have better results on manipulating immune responses that promotes 
amelioration of clinical disease in models of inflammation. 
1.9 Aims 
Several molecules expressed by CD4+ T cells have been described to have 
stimulatory or inhibitory effects over their encounter with APCs during antigen 
presentation. Due to the important role that CD4+ T cells have in the pathogenesis 
of many diseases, the manipulation of a number of these molecules have been 
tested in preclinical trials with promising results. As a matter of fact, drugs that 
target many of these molecules have passed all clinical trials and have been 
successfully established for the treatment of a number of immunological disorders, 
such as autoimmune diseases and cancer. For this thesis, transcriptomic data, 
previously generated in our laboratory, in which a murine model of RA was used 
to obtain a list of upregulated genes from immune cells that were retained in the 
joints in comparison to immune cells that migrated to the popliteal LNs (pLN) was 
used to identify potential candidates to test my hypothesis that blockade of some 
of these molecules can disrupt CD4+ T cell-DC interactions. Due to the fact that 
this model is antigen-induced and that antigen presentation has been shown to 
occur in the synovium of RA joints, we believe that these upregulated genes may 
translate to an upregulation in surface molecules that can be important for the 
immune synapses between T cells and APCs in the synovium. Therefore, the 
following aims will be addressed: 
1. To screen candidate molecules from the gene list, based on a literature 
review and availability of reagents, to evaluate if blockade of the candidate 
molecules with their potential ligands during antigen presentation is able 
to manipulate CD4+ T cell activation, proliferation or differentiation in 
vitro, with selection of the most promising candidate for the next aims. 
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2. To assess if blockade of the most promising candidate molecule with its 
potential ligands during antigen presentation is able to manipulate CD4+ T 
cells activation, proliferation or differentiation in vivo. 
3. To monitor the progress of inflammation in a model of acute murine 
antigen-induced arthritis during treatment with an antagonist of the most 
promising candidate molecule and the study of potential involved 
mechanisms. 
Addressing these aims should allow us to identify a new molecule that can control 
the interactions between CD4+ T cells and DCs and further our understanding on 
these cells’ crosstalk in vitro and in vivo. In addition, the results of the study on 
the chosen murine model of inflammation can direct follow up studies on the 
treatment of RA targeting this new molecule, with or without combined use with 
other drugs. The elucidation of the mechanisms of the potential effects caused by 
this prospective treatment may contribute to a better understanding of the 
immunological mechanisms involved on this disease. Furthermore, the discovery 
of a novel molecule controlling CD4+ T cell-DC interactions can contribute to the 
development of drugs aiming the new pathway for prophylaxis or treatment of 
different types of inflammatory disease, as well as cancer. 
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Chapter 2 Materials and Methods 
2.1 Animals 
Six to 12-week-old male and female C57BL/6J mice (substrain C57BL/6JOlaHsd 
expressing MHC H-2b haplotype) were purchased from Envigo (formerly Harlan) UK 
and are considered as WT mice in this thesis. OTII transgenic mice248 containing 
CD4+ T cells expressing TCR that recognizes the peptide 323-339 from chicken 
ovalbumin (OVA) bound to MHCII molecule I-Ab and with all immune cells 
expressing CD45.1 and Kaede mice249 expressing a photoconvertible protein in all 
cell types were bred at the University of Glasgow, Central Research Facility (CRF). 
All mice were housed at the CRF and all protocols were conducted under licenses 
issued by the U.K. Home Office under the Animals (Scientific Procedures) Act of 
1986 and approved by the University of Glasgow Ethical Review Committee. 
2.2 Cell Isolation and Culture 
2.2.1 T Cell Stimulation 
Spleens were homogenised using a 70 µm EASYstrainer (Greiner-Bio-One) inserted 
into a 50 mL centrifuge tube (Corning), with help of the flat end of a plunger from 
a 2 mL syringe (Fisher Scientific). The strainer was washed with Phosphate-
Buffered Saline (PBS) (Gibco) and tubes were centrifuged at 400 g for 5 minutes 
at 4oC. The cell suspension obtained from the spleens was then treated with 1 mL 
of Red Blood Cell (RBC) Lysis Buffer (eBioscience) per mouse, incubated at room 
temperature for 3 minutes, washed with PBS and centrifuged once again. 1x106 
cells were then stimulated with 1 µg/mL anti-CD3 monoclonal antibody (mAb) 
17A2 (BioLegend) and 3 µg/mL anti-CD28 mAb 37.51 (BioLegend) in complete 
medium (RPMI 1640 (Gibco), 10% foetal bovine serum (FBS) (gibco), 100 IU/ml 
Penicillin and 100 ug/ml streptomycin, 2 mM L-glutamine) for 72 hours as 
previously described250. Cells were then harvested and stained as described in 
section 2.4 for flow cytometry analysis. 
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2.2.2 Isolation of CD4+ T cells 
Cells were obtained from peripheral LNs (popliteal, superficial cervical, inguinal, 
brachial, and axillary), mesenteric LNs and spleens of euthanized OTII transgenic 
mice and homogenised as described in section 2.2.1. Cells from all tubes were 
then pooled, counted by trypan blue (Sigma Aldrich) exclusion using a 
haemocytometer and resuspended in MACS buffer (PBS and 2% FBS) at the required 
concentration. CD4+ T cells were isolated with a negative antibody selection kit 
(CD4+ T Cell Isolation Kit Mouse, Miltenyi Biotec) according to the manufacturer’s 
instructions and as previously described250. 
2.2.3 Generation of Bone Marrow-Derived Dendritic Cells (BMDCs) 
BMDCs were generated as previously described251. Bone marrow of C57BL/6 mice 
was extracted by flushing RPMI 1640 Medium through the interior of femurs and 
tibias with a 25G needle and a 5 mL syringe. Cells were centrifuged at 400 g for 5 
min at 4oC and resuspended with 2 mL RBC lysis buffer per mouse, incubated at 
room temperature for 3 minutes, washed with RPMI and centrifuged again. Viable 
cells were counted by trypan blue exclusion and haemocytometer and 
resuspended with complete medium supplemented with 5% GM-CSF (made in 
house from X63 GM-CSF cell line) at the appropriate cell concentration. 2x106 cells 
per well were seeded to 6-well non-treated tissue culture plates (Corning) and 
incubated at 37°C and 5% CO2. At day 2, cells received additional complete 
medium, and at day 3 and 6, the entire medium was removed before fresh 
complete medium was added. At day 6, mature BMDCs were obtained by overnight 
stimulation with 100 ng/mL Lipopolysaccharide from Escherichia coli O111:B4 (LPS) 
(Sigma-Aldrich) at 37°C and 5% CO2. BMDCs were harvested on day 7. BMDCs purity 
was constantly assessed by flow cytometry (Figure 2-1) across the experiments 
and cells were usually 50-70% double positive for CD11c and MHCII. 
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Figure 2-1. Bone marrow-derived dendritic cells (BMDCs) purity analysis by flow cytometry 
BMDCs with or without LPS stimulation were harvested on day 7 and analysed for purity by flow 
cytometry. Events were gated to exclude debris, doublets and dead cells with the use of a Fixable 
Viability Dye (eBioscience). BMDCs were then identified as CD11c+ MHCII+. 
2.2.4 BMDC-T-Cell Co-Culture and Stimulation 
BMDCs were pulsed with different concentrations of OVA peptide 323-339 (pOVA) 
(Sigma-Aldrich) prior to the co-culture set-up as previously described251. For 
proliferation assays, isolated CD4+ T cells were labelled with 1 µM 
Carboxyfluorescein succinimidyl ester (CFSE) (CFSE Cell Proliferation Kit, 
Invitrogen) in warm PBS for 20 min at 37oC 5% CO2. T cells were then re-incubated 
for further 10 min in complete medium and washed twice. For flow cytometry 
analysis or detection of cytokines from the supernatant, pOVA-pulsed BMDCs and 
CD4+ T cells were cultured at 1:10 BMDC:T cell ratio or at different ratios when 
indicated in 96-well culture plates (Corning) for different time points (Figure 2-2), 
according to the objective of the experiment, in a final volume of 200 µL complete 
medium at 37oC 5% CO2. For CEACAM1 targeting, treatments consisted of anti-
CEACAM1 mAb CC1 (BioLegend) or Purified Mouse IgG1κ mAb MG1-45 Isotype 
Control (BioLegend), both at 20 µg/mL. For JAM-A targeting, treatments consisted 
of anti-JAM-A antibody clone BV11 (Sigma Aldrich) or Ultra-LEAF Purified Rat 
IgG2bk Isotype Control (BioLegend), both at 20 µg/mL. 
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Figure 2-2. Schematic representation of BMDCs culture and BMDC-T cell co-culture set-up 
Bone marrow cells were cultured in Granulocyte-macrophage colony-stimulating factor (GM-CSF)-
enriched complete RPMI. Fresh medium is added 2 and 3 days after the initial culture. Three days 
later, the medium is again replaced with Lipopolysaccharides (LPS) and OVA peptide (pOVA). In 
the following day, BMDCs are harvested and CD4+ T cells from OTII transgenic mice are isolated. 
Cells are placed together in appropriate plates or slides for different time points. Cells were 
analysed one, two or three days after the co-culture set-up by fluorescence microscopy, widefield 
microscopy or flow cytometry, respectively. 
2.2.5 Small Interfering RNA (siRNA) in BMDCs 
On day 7 of BMDCs culture, immature cells were washed with RPMI, seeded in 6-
well non-treated tissue culture plates in serum/antibiotics-free RPMI 1640 Medium 
(Gibco), to avoid cell death and decrease in transfection efficiency, and incubated 
for 1 hour at 37oC, 5% CO2. Cells were seeded in a total volume of 2 mL but in 
different cell concentrations to find the most appropriate confluency for the 
transfection. Lipofectamine 2000 (Invitrogen) and MISSION esiRNA targeting EGFP, 
CEACAM1 or F11R (Sigma Aldrich) were separately diluted in serum/antibiotics-
free RPMI, both at 1:25 or in different concentrations when indicated, and 
incubated for 15 min at room temperature. Lipofectamine 2000 and the 
correspondent siRNA were mixed in serum/antibiotics-free RPMI and incubated for 
another 20 min to allow complexes to form. The volume used for the transfection 
was 400 µL, that was directly transferred to wells containing BMDCs. Cells were 
then incubated for 6 hours at 37oC and 5% CO2. Following the transfection, cells 
were fed with 800 µL concentrated complete medium to achieve concentrations 
of 10% FBS, 1% Penicillin and streptomycin and 1% L-glutamine and re-incubated 
at 37oC, 5% CO2. Prior to harvest, cells were stimulated with 100 ng/mL LPS. Cells 
were harvested 3 days after the transfection and stained to be analysed by flow 
cytometry.  
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2.3 Animal Procedures 
2.3.1 Adoptive Transfer of OTII Cells into WT Mice 
Adoptive transfer was performed as previously described10. Cell suspensions 
obtained from spleens and LNs of OTII transgenic mice were stained with CFSE as 
described in section 2.2.3. Cells were resuspended in PBS and a small aliquot was 
used to estimate the proportion of cells expressing CD4 and the α and β chains of 
the transgenic TCR, Vα2 and Vβ5 by flow cytometry. 1x106 CD4+ OT-II T cells were 
transferred intravenously into WT recipients. One day later, different 
concentrations of Tissue Culture Grade OVA (Code OAC – Worthington 
Biochemicals) and 8 µg LPS were dissolved in 50 µL PBS and injected into each 
hind footpad, and 100 µg anti-JAM-A antibody or Rat IgG2b Isotype Control, when 
indicated, was injected intraperitoneally (200 µL per injection). In the following 
day, mice were euthanized and the pLNs harvested for flow cytometry analysis. 
2.3.2 Breach of Self-Tolerance Arthritis Model 
The breach of self-tolerance arthritis model, described by Maffia et. Al.170, was 
the chosen inflammatory disease model for this thesis, as the experiment that 
generated the gene list containing the potential candidates tested in this present 
work used this model. This model of arthritis was conducted in Kaede mice (Figure 
2-3A) for the detection of expression of the marker of interest on migratory 
immune cells and in WT mice (Figure 2-3B). It was also used as a model to evaluate 
the effects of disrupting specific molecules and pathways on the development of 
arthritis in mice. 
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Figure 2-3. Schematic representation of the breach of self-tolerance model of arthritis 
The breach of self-tolerance model of arthritis170 was induced in Kaede and wild-type (WT) mice. 
Isolated OTII CD4+ T cells were incubated with antigen presenting cells (APC) to induce Th1 
polarization (OVA peptide, IL12 and anti-IL4 antibody). After 3 days, Th1 cells were transferred 
intravenously into Kaede (A) or WT (B) mice. In both cases, OVA and Complete Freund's Adjuvant 
(CFA) were injected into the scruff the following day. This induction phase was followed by acute 
inflammation in the joints triggered by challenge with heat aggregated OVA (HAO) in the footpads. 
In the experiment with Kaede mice, joints were photoswitched 3 days after challenge and popliteal 
lymph nodes (pLN) and joints were harvested the next day for flow cytometry analysis. In the 
experiment with WT mice, treatments with anti-JAM-A mAb BV11 were conducted in days 0, 2, 4 
and 6 after HAO injections. The pLNs were harvested on day 7 for flow cytometry analysis. 
For Th1 polarization, APCs acquired from leftover cells following CD4+ T cell 
isolation and from fresh spleens of C57BL/6 mice were initially treated with 50 
µg/mL mitomycin (Sigma-Aldrich) diluted in complete medium and incubated for 
1 hour at 37oC and 5% CO2. APCs were then washed three times in complete 
medium and incubated with isolated CD4+ T cells from OTII mice in a 1:5 ratio in 
complete medium containing 1 µg/mL pOVA, 10 ng/mL IL-12 (Bio-Techne), and 5 
µg/mL murine monoclonal anti-IL-4 antibody (2BScientific, clone 11B11). Cells 
were incubated in 75 cm2 vented flasks (Corning) at 37oC, 5% CO2. After 72 hours, 
the amount of Th1 cells obtained was estimated by the percentage of CD4+ Vα2+ 
Vβ5+ cells obtained in a flow cytometry analysis along with the use of trypan blue 
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and haemocytometer in which only large cells were counted. The expression of 
CD45.1 was also confirmed in the flow cytometry analysis. Cells were then re-
suspended in PBS and 200 µL of this suspension containing 1x106 Th1 cells was 
injected intravenously into WT or Kaede mice, depending on the experiment. 
Tissue culture grade OVA was diluted in PBS and prepared with Complete Freund’s 
Adjuvant (CFA) (Sigma Aldrich) in a 1:1 ratio to make a 1 µg/µL final concentration 
of OVA. The emulsion was injected subcutaneously into the scruff in 100 µL 24 
hours after the adoptive transfer of Th1 cells. Ten days later, 100 µg heat 
aggregated OVA (HAO) was injected in the hind footpad. HAO was prepared by 
dissolving OVA (Sigma Aldrich) at 20 mg/mL in PBS, 200 µL aliquots were placed 
in 1.5 mL Eppendorf tubes and incubated at 100oC for 2 hours. The suspension was 
then centrifuged at 10,000 g for 5 min and the supernatant removed. A wash with 
PBS was performed and the heat-aggregated OVA was resuspended in PBS. Aliquots 
were stored at –20C until use. Prior to use an aliquot was transferred to a 
GentleMACS C-tubes (Miltenyi Biotec) and 1.8 mL of PBS added to make a 
concentration of 2 mg/mL. The HAO was then homogenised using a gentleMACS 
Dissociator (Miltenyi Biotec) and the suspension was considered as appropriate 
when it could pass through a 25-gauge needle. WT mice that were subjected to 
the breach of self-tolerance model of arthritis were treated every 48 hours (days 
0, 2, 4 and 6) with 100 µg (200 µL) of anti-JAM-A mAb BV11 or Rat IgG2b Isotype 
Control. Clinical scores as well as footpad thickness, measured using a C-Series 
IP67 electronic calliper (Kroeplin GmbH), were measured on a daily basis until the 
7th day after the HAO challenge. On day 7, 80 µL peripheral blood from the tail 
vein was harvested and placed in an Eppendorf with 1 mL FACS Buffer (PBS, 2% 
FBS and 1 mM EDTA). Peripheral blood mononuclear cells (PBMC) were then 
stained and analysed by flow cytometry as described in section 2.4. WT mice were 
then kept housed in the CRF for further analysis of the arthritis clinical response 
after a second footpad challenge. This analysis is not covered in this present work, 
as the experiment was still ongoing at the time. 
Kaede mice were also subjected to the breach of self-tolerance arthritis model. 
Cells from Kaede mice express a photoconvertible protein (Kaede green) that can 
be excited with a 488 nm laser249. On the day prior to harvesting, cells from the 
joints were photoconverted with a 12X S06J blu-ray diode with a 405-G-2-glass 
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lens (DTR’s Laser Shop) emitting at 405 nm with mean power of 600–650 mW. The 
photoconversion modifies the conformation of the transgenic protein, changing its 
fluorescence properties. The photoconverted cells are called Kaede red cells and 
present fluorescent proteins that can be excited with 561 nm lasers. The time of 
laser exposure was previously optimized in the lab52. Each foot was exposed for 5 
seconds in three different parts on both the ventral and dorsal sides of the hind 
paw, in a total of 30 seconds per foot. Photoconversion was only performed once 
per animal. All Kaede mice were euthanized 4 days after the HAO challenge and 
had their pLNs and joints harvested. The skin and muscle were removed from the 
feet, and the ankle and joints teased apart. Joints and pLNs were separately 
digested with 2.68 mg/mL Collagenase D (Roche) in PBS using a shaker at 110 rpm 
at 37oC for 30 min. pLN samples were washed and pooled per mouse, cells 
obtained from pLNs were enumerated using a haemocytometer and were then 
stained for subsequent flow cytometry analysis. Joints were homogenised in 
gentleMACS C tubes using the gentleMACS Dissociator. The tissue was then filtered 
using a 70 µm strainer and centrifuged at 400 g for 5 min at 4oC. The pellet was 
resuspended in PBS and joints were pooled per mouse. An aliquot of the cell 
suspension was used to count live cells by excluding trypan blue positive cells, 
whereas the rest was added to a 96-well plate to be stained for flow cytometry 
analysis. 
2.4 Flow Cytometry 
2.4.1 Viability Staining 
Plates containing cells were centrifuged at 400 g for 5 min at 4oC. Cells were then 
resuspended in 100 µL diluted Fixable Viability Dye (eBioscience) and incubated 
for 15 min at 4oC. Dilutions were 1:1000 for Viability Dyes eFluor 450 or eFluor 780 
and 1:500 for Viability Dye eFluor 506. Cells were washed twice with PBS before 
extracellular staining was initiated. 
2.4.2 Extracellular Staining 
After cells were stained with viability dye and washed, the suspensions were 
incubated with 50 µL Fc receptor (FcR) block (produced in-house using 
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supernatant from 2.4G2 cell line supplemented with 5% mouse serum) for 10 min 
at 4oC to block non-specific binding of antibodies to the Fc receptors. Antibodies 
(Table 2-1) were diluted in FACS Buffer and 50 µL was added to the cells and 
incubated for further 30 min at 4oC. When biotinylated antibodies were used, cells 
were washed and an extra step of 20 min incubation containing FACS Buffer and 
Streptavidin was performed at 4oC. Cells were then washed again in FACS Buffer 
and re-suspended in 200 µL FACS Buffer before running on BD LSRII, BD LSR 
Fortessa or BD FACSCelesta. 
2.4.3 Intracellular Staining 
To detect intracellular cytokines, the supernatant of co-cultures from 96-well 
plates was removed and 100 µL of a stimulation mixture was added, containing 20 
ng/mL phorbol myristate acetate (PMA) (Sigma Aldrich), 1 µg/mL ionomycin 
(Sigma Aldrich) and 1:1000 GolgiPlug (BD Biosciences) and cells were incubated 
for 4 hours at 37oC and 5% CO2. Cells were then stained for viability and 
extracellular markers as described in sections 2.4.1 and 2.4.2, respectively, and 
later fixed in 100 µL Cytofix/Cytoperm (BD Biosciences) for 20 min at 4oC and 
washed with 100 µL Perm/Wash Buffer (BD Biosciences). This buffer was also used 
to dilute the appropriate antibodies in the concentrations stated in Table 2-1. 
Following addition of antibodies, cells were incubated for 30 min at 4oC and 
washed twice with FACS Buffer before being re-suspended in 200 µL FACS Buffer 
and analysed in the flow cytometers. 
For intracellular detection of transcription factors, cells were fixed directly in the 
96-well plates with 100 µL FoxP3 Transcription Factor Fixation/Permeabilization 
buffer (eBioscience) for 1 hour at 4oC. Cells suspensions were then washed with 
Permeabilization Buffer (eBioscience) and incubated with a mixture containing 
appropriate antibodies diluted in Permeabilization Buffer and incubated for 30 
min at 4oC. Before being conducted to flow cytometry analysis, cells were washed 
with FACS Buffer and re-suspended in 200 µL FACS Buffer. 
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2.4.4 Data Analysis 
Data were analysed using FlowJo 10.6.2 software (Treestar). Gates indicating 
positive or negative populations were based on the background staining of 
fluorescence minus one (FMO) controls or FMO controls with addition of the 
corresponding isotype control antibody, when indicated. To generate tSNE plots, 
the total population of cells excluding doublets and dead cells was downsized with 
the plugin DownSample v3.2 to 2x105 events per biological replicate. The 
biological replicates were concatenated with the marker of interest being 
selected before the final tSNE analysis was performed.  
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Table 2-1. Antibodies and other reagents used for flow cytometry 
 
Marker Fluorochrome Clone Concentration Manufacturer 
B220 (CD45R) PE-Cy7 RA3-6B2 1:200 eBioscience 
CD11a PE M17/A 1:200 eBioscience 
CD11b Super Bright 600 M1/70 1:200 eBioscience 
CD11c BV421 N418 1:200 BioLegend 
CD11c PE-Cy7 N418 1:200 BioLegend 
CD19 Alexa Fluor 700 eBio1D3 1:200 eBioscience 
CD3 APC-Cy7 17A2 1:200 BioLegend 
CD3 V500 500A2 1:200 BD Biosciences 
CD3 FITC 145-2C11 1:200 BioLegend 
CD4 APC RM4.5 1:200 BD Biosciences 
CD4 BUV805 GK1.5 1:200 BD Biosciences 
CD4 eFluor 450 RM4.5 1:200 eBioscience 
CD4 FITC GK1.5 1:200 eBioscience 
CD44 APC IM7 1:400 eBioscience 
CD44 BUV395 IM7 1:200 BD Biosciences 
CD44 PE IM7 1:400 eBioscience 
CD45 BUV395 30-F11 1:200 BD Biosciences 
CD45.1 APC A20 1:200 eBioscience 
CD45.1 APC-eFluor 780 A20 1:200 eBioscience 
CD45.1 PE A20 1:200 eBioscience 
CD62L APC-eFluor 780 MEL-14 1:200 eBioscience 
CD8 Alexa Fluor 700 53-6.7 1:200 BioLegend 
CD8 PE-Cy7 53-6.7 1:200 eBioscience 
CD86 FITC GL1 1:200 BD Biosciences 
CD86 PE-Cy7 GL1 1:200 BD Biosciences 
CEACAM1 (CD66a) BV421 CC1 1:200 BioLegend 
CEACAM1 (CD66a) PE CC1 1:200 BioLegend 
FoxP3 BV421 MF-14 1:200 BioLegend 
IFN-γ PE XMG1.2 1:200 BD Biosciences 
IFN-γ PE-Cy7 XMG1.2 1:200 eBioscience 
IL10 BV421 JES5-16E3 1:200 BioLegend 
IL17 APC 17B7 1:200 eBioscience 
JAM-A (CD321) Biotin H202-106 1:200 eBioscience 
JAM-A (CD321) PE H202-106 1:200 BD Biosciences 
Ki67 Alexa Fluor 488 SolA15 1:200 eBioscience 
Ly6G APC RB6-8C5 1:200 eBioscience 
MHCII APC M5/114.15.2 1:400 eBioscience 
MHCII APC-Cy7 M5/114.15.2 1:400 BioLegend 
MHCII BV510 29G 1:200 BD Biosciences 
MHCII PerCP-Cy5.5 M5/114.15.2 1:400 BioLegend 
NK1.1 APC-Cy7 PK136 1:200 BioLegend 
PDCA1 (CD317) APC eBio129c 1:200 eBioscience 
RORγt APC AFKJS-9 1:200 eBioscience 
Streptavidin BV421 - 1:100 BioLegend 
Streptavidin PE-Cy7 - 1:100 eBioscience 
T-bet PE-Cy7 4B10 1:200 eBioscience 
TIM-3 (CD366) PE RMT3-23 1:200 eBioscience 
TNF-α Alexa Fluor 488 MP6-XT22 1:200 eBioscience 
YAe Biotin eBioY-Ae 1:200 eBioscience 
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2.5 Enzyme-Linked Immunosorbent Assay (ELISA) 
For all ELISAs, High Binding Assay 96-well Plates (Corning) were used. Absorbance 
measurements were performed using a Sunrise Absorbance Reader (Tecan). The 
washing buffer in all assays consisted of 0.05% Tween 20 (Sigma Aldrich) in PBS 
(PBS-T). 
2.5.1 Cytokine Measurement 
Cytokine concentrations were measured in the co-culture supernatants by ELISA 
using ELISA MAX Standard Sets for Mouse IL-4, IL-6, IL-10, IL-17 and IFN-γ 
(BioLegend) according to the manufacturer’s instructions. The absorbance was 
measured at 450 nm with subtraction of wavelengths from readings at 570 nm. 
Background absorbance was removed from all samples by subtracting the mean of 
blank wells. Titrations to identify appropriate concentrations of supernatants, 
aiming for optical density (OD) values between 0.5 and 2.5 to ensure that the 
cytokine concentrations were within the range of the standard curve, were 
performed before the final ELISA assays were performed. Standards of the 
commercial kits were also included in the analysis in order to build a standard 
curve in GraphPad Prism 7 software. Cytokine concentrations were determined by 
extrapolating the unknown values from the standard curve. 
2.5.2 Anti-Collagen II (CII) and Anti-OVA Antibodies Measurement 
ELISA was used to detect anti-OVA and anti-CII antibodies in serum from mice that 
underwent the breach of self-tolerance arthritis model was conducted as 
previously described170. Blood was collected from mice in 1.5 mL Eppendorf 
microcentrifuge tubes (Greiner Bio-One) and serum was extracted by allowing the 
blood to clot at room temperature for 6 hours and centrifuging it at 10,000 g for 
5 min. Serum was transferred to new Eppendorf tubes and frozen at -20oC. High 
binding plates were coated with 50 µL of 20 µg/mL OVA (Sigma Aldrich) or 4 µg/mL 
bovine collagen II (Sigma Aldrich) diluted in carbonate buffer (Sigma Aldrich) and 
incubated overnight at 4°C. Plates were washed, blocked with 100 µL animal free 
serum (Vector Laboratories) for 1 hour at 37oC and washed again. Sera were 
initially diluted in PBS at 1:50 for anti-CII and 1:200 for anti-OVA detections, added 
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to the plates in duplicates and serial dilutions were performed. The final volume 
in each well was 100 µL. The plates were incubated for 1 hour at 37oC and later 
washed. In plates for detection of anti-CII antibodies, a positive control from 
arthritic mice from an experiment previously performed was used, while serum 
from one of the mice of the present experiment was used in all plates, in order to 
normalize the data across plates. To detect anti-CII antibodies, plates were 
incubated with rabbit anti-mouse whole IgG antibody conjugated to horseradish 
peroxidase (HRP) (Sigma Aldrich) diluted to 1:10000 in PBS for 1 hour at 37oC. For 
the detection of anti-OVA antibodies, plates were incubated with biotin-
conjugated goat anti-mouse IgG1 (1:5000) or IgG2c (1:10000) for 1 hour at 37oC, 
washed and incubated with ExtrAvidin-Peroxidase (Sigma Aldrich) (1:10000) for 30 
min at 37oC. All plates were then washed and 100 µL SigmaFAST OPD solution 
(Sigma Aldrich) was added before plates were incubated for 5-30 min, protected 
from light, at room temperature. Sulphuric acid at 10% was used to stop the 
reactions and the absorbance was read at 492 nm.  
2.6 Imaging 
Widefield and confocal microscopy were used according to the requirements of 
the assay. Widefield microscopy is a technique in which the whole sample is 
illuminated, and light is emitted and gathered from many focal planes, and was 
used to visualize cell clusters and tissue sections. The moving pinhole in confocal 
microscopes intercepts most of the out-of-focus light and allows detection of light 
only in one focal plane, also known as z-stack. Confocal microscopy was used for 
visualization of individual cell-cell interactions. 
2.6.1 Widefield Microscopy 
The EVOS FL Auto 2 Imaging System Fluorescence Microscope (Invitrogen) 
equipped with EVOS LED light cubes equivalent to channels DAPI (357/44 nm 
excitation, 447/60 nm emission), GFP (470/22 nm excitation, 510/42 nm emission), 
RFP (531/40 nm excitation, 593/40 nm emission) and Cy5 (628/40 nm excitation, 
692/40 nm emission) was used to acquire fluorescence images. Light directly from 
the condenser was used, to acquire brightfield. 
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Isolated CD4+ T cells were stained with CFSE as described in section 2.2.3 and 
BMDCs were stained with 5 µM CellTracker Red CMTPX Dye (Invitrogen) in warm 
PBS for 30 min at 37oC 5% CO2. BMDCs were then re-incubated for further 10 min 
in complete medium and washed twice. 4x103 BMDCs and 4x104 T cells (1:10 ratio) 
were co-cultured in 384-well black tissue culture-treated assay plates with flat 
clear bottom (Corning) in a final volume of 30 µL complete medium and incubated 
at 37oC and 5% CO2. Treatments consisted of anti-JAM-A antibody clone BV11 or 
its isotype control, both at 20 µg/mL. Cell clusters were visualized one or two 
days after the co-culture set-up for fluorescence or brightfield images, 
respectively. For fluorescence images, CFSE fluorescence was detected with the 
GFP filter and CMTPX fluorescence was detected with the Cy5 filter. Two scans 
from a 10x objective lens were made per well and exported to be analysed 
separately. To acquire brightfield images, acquisition was automated and tile 
scans from a 10x objective lens were merged using the built-in EVOS FL Auto 2 
software to obtain the images that were then exported and analysed. 
LNs from C57BL/6 mice were harvested in cold PBS and frozen in OCT compound 
(Tissue-Tek) using a Thermo Shandon Cryotome FE cryostat (Thermo Fisher) and 
stored at -80oC. In the cryostat, 8-10 µm sections were cut, adhered to Superfrost 
Microscope slides (Thermo Fisher) and stored at -20oC. Before being stained, 
sections were thawed and fixed in acetone for 10 min at room temperature. Slides 
were washed with PBS-T. The regions of interest were marked with an ImmEDGE 
Hydrophobic Barrier Pen (Vector Laboratories) and slides were left to dry at room 
temperature. Slides were put in a humidity chamber and non-specific binding was 
blocked with Protein Block Serum-Free (Dako) for 10 min at room temperature. 
An Avidin/Biotin Blocking Kit (Vector Laboratories) was used to block endogenous 
biotin by incubating the sections with Avidin D for 15 min at room temperature, 
washing it and incubating it with Biotin for a further 15 min. Sections were washed 
and incubated with a mixture containing antibodies against the markers of interest 
directly conjugated to fluorophores or to biotin diluted in PBS, for 30 min at room 
temperature. The sections were again washed and incubated with Streptavidin 
conjugated to a fluorophore for 30 min at room temperature. Sections were dried, 
mounted in VECTASHIELD® Antifade Mounting Medium (Vector Laboratories) with 
the addition of a coverslip, sealed in the slide with nail polish, before being 
analysed using the EVOS microscope. 
 
 
65 
2.6.2 Confocal Microscopy 
BMDCs pre-pulsed with pOVA and CD4+ T cells were cultured in 96-well culture 
plates in a final volume of 100 µL complete medium at 1:10 BMDC:T cell ratio for 
24 hours at 37oC 5% CO2. Cells were then fixed directly in the plates with 2% PFA 
for 20 minutes at room temperature to preserve clusters. Cells were washed in 
PBS, stained as described in section 2.4.2 and resuspended in FACS Buffer. 
Antibodies used were: FITC-conjugated anti-CD4 mAb (clone GK1.5), APC-
conjugated anti-CD11c mAb (clone N418), BV421-conjugated anti-MHCII mAb 
(clone HL3) and PE-conjugated anti-JAM-A mAb (H202-106). All antibodies were 
used at a 1:200 concentration. A volume of 100 µL was then added to uncoated µ-
Slide I (Ibidi) and left to settle for 2 hours at 4oC before being analysed with a 
ZEISS Cell Observer Spinning Disc Confocal Microscope (Carl Zeiss) using a 63x 
objective lens and filters capable of detecting DAPI, GFP, RFP and Cy5 channels. 
2.6.3 Image Analysis 
All images were analysed using Fiji open-source software252. For images of cell 
clusters acquired with EVOS’ brightfield, images were converted to 8-bit files, 
contrast was enhanced in 4% and the plugins Gray Morphology and Sharpen were 
applied to make clusters more visible. Fiji’s Ellipse tool was used to detect the 
limits of visible cell clusters. The regions of interest were then measured and 
exported to a spreadsheet. In Microsoft Excel, a formula was used to automate 
the application of a threshold to exclude cell aggregates smaller than 2000 µm2, 
as clusters were defined as cell aggregates with area of at least 2000 µm2. 
Images of cell clusters acquired with EVOS’ fluorescence filters were subjected to 
a colocalization analysis. Images were converted to 8-bit files and a threshold was 
applied to remove background noise. The Pearson's correlation coefficient and the 
Mander's overlap coefficient of images from the GFP and Cy5 channels were 
calculated with the EzColocalization plugin253. Immunofluorescence images of LNs 
were submitted to Fiji’s Unsharp filter (2 pixels radius, mask weight 0.6), its 
pseudo-colours were changed by arranging channels and the graphs for 
fluorescence intensity were obtained with the Plot Profile tool. 
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For the analysis of individual BMDC-T cell cluster, the synapse area and the rest 
of the cell membrane were determined by using the Polygon Selection tool. The 
fluorescence intensities of both areas were then measured, and the ratio was 
obtained by dividing the intensity from the synapse area by the rest of the cell 
membrane. 
2.7 Statistical Analysis 
Results are expressed as mean ± standard deviation (SD) of technical replicates, 
or biological replicates when indicated. All statistical analyses were performed 
using GraphPad Prism 7 software. Appropriate normality tests were performed to 
detect normal distribution. For comparing 2 groups, a variable for more than 2 
groups and two variables for more than 2 groups the Student t test, one-way 
ANOVA and two-way ANOVA were performed, respectively. P values shown as 
*p<0.05, ** p<0.01, ***p<0.005, ****p<0.0001. 
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Chapter 3 Selection of Candidate Molecules 
3.1 Introduction 
CD4+ T cell interactions with DCs are pivotal in adaptive immune responses and 
there is increasing interest in discovering molecules that would promote or disrupt 
these interactions. To screen candidate molecules for testing my hypothesis that 
blockade of their pathways can disrupt CD4+ T cell-DC interactions, I took 
advantage of transcriptomic data previously generated in our laboratory using a 
murine model of inflammatory arthritis. To acquire the gene data that was used 
to select these potential candidates, experiments using the breach of tolerance 
model of arthritis170 in Kaede mice249, as described in Chapter 2 (section 2.3.3) 
were performed by the former laboratory members Drs Robert Benson and 
Catriona Prendergast (unpublished data). Immune cells from joints and pLNs 
obtained four days after footpad challenge were sent for genetic sequencing. 
Individual transcriptomic data from three biological replicates were processed and 
analysed, generating a list of 4,507 differentially regulated genes between joints 
and LNs. In order to generate a list that was joint-specific, the same disease model 
was conducted in Kaede mice but instead of a footpad challenge, mice were 
challenged in the ear pinna followed by photoswitching (Figure 3-1). The auricular 
LN was harvested to detect Kaede red migratory cells in addition to the ear pinna. 
Viable, Kaede red immune cells from these tissues were sent for sequencing. 
Finally, a joint-specific differentially regulated gene list containing 217 genes 
from non-migratory cells was generated by subtracting the genes of the non-
specific inflamed site from the list acquired in the previous experiment.  
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Figure 3-1. Schematic representation of experiments previously performed in the laboratory 
that generated a joint-specific differentially regulated gene list 
Adapted from Robert A. Benson and Catriona Prendergast unpublished data. The breach of self-
tolerance model of arthritis was performed in Kaede mice as described in Chapter 2 (section 2.3.3). 
Upon induction of the disease model experiment, cells from LNs and joints were harvested and 
sent for gene sequencing. Gene expression between cells that did not migrate to the LNs (joint-
retained cells) and cells that migrated to the LNs (LN cells) were compared. In the first experiment 
(top diagram), gene sequencing generated a list containing 4,507 genes that were upregulated in 
the joint in comparison to LNs. In the second experiment (bottom part), gene sequencing 
generated a list of genes that were upregulated in a skin site in comparison to LNs. Then, genes 
that were present in both lists were excluded from the first gene list to finally generate a joint-
specific differentially regulated gene list containing 217 genes. 
From the set of 217 genes, pathway analysis revealed lists of genes related to 
distinct regulatory functions. A small list of 15 genes relevant to leukocyte 
migration pathways (Figure 3-2) was used to select candidates to test my 
hypothesis. Focus was given to upregulated genes from cells that were retained 
in the joints, as I believe that molecules encoded by these genes might be relevant 
in antigen presentation that occurs in the arthritic joint106. In addition, these 
molecules might play a role in the retention of leukocytes in the inflamed joints 
that are one of the causes of symptoms in RA patients171, and therapeutic 
targeting these molecules might be an useful tool in symptomatic treatment of RA 
patients, as discussed in Chapters 1 (sections 1.7.1 and 1.8.3) and 6. However, at 
the time when this Thesis was being written, the data of absolute values of gene 
expression was not found. As such, it is not possible to know if the expression of 
these genes was, for example, lower than 100, which would mean a low expression 
that would possibly not be biologically relevant. Therefore, the interpretation of 
gene upregulation using only z-scores requires precaution. 
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Figure 3-2. Identification of a joint-specific differentially regulated gene related to leukocyte 
migration 
Adapted from Robert A. Benson and Catriona Prendergast unpublished data. The figure shows a 
graph of relative expression of the 15 genes involved in leukocyte migration in the joint migrated, 
joint non-migrated, skin migrated and skin non-migrated populations. 
To support the foundation of my hypothesis that the upregulation in the 15 genes 
is related to an upregulation in molecules encoded by these genes on the surface 
of CD4+ T cells or DCs, I analysed the proportion of different immune cell types in 
the whole population. By looking at lineage markers for B cells (CD19+), T cells 
(CD3+), Neutrophils (CD11b+ Ly6G+) and DCs (CD11c+), I concluded that the 
majority of cells sent for RNAseq analysis were neutrophils, although there was 
also a considerable population of DCs (data not shown). I therefore gathered 
information from a gene bank (Immunological Genome Project, Gene Skyline, 
Microarray)254 to analyse the expression profiles of the 15 genes related to 
leukocyte migration in T cells, DCs and neutrophils from spleens and LNs of 
C57BL/6 mice. Values for gene expression determined by microarray are shown in 
Table 3-1, where intervals based on the thresholds suggested by the gene bank 
relative to trace (0-5), very low (5-20) and low (20-80) expression are not 
highlighted, whereas medium (80-800), high (800-8000) and very high (>8000) 
intervals are highlighted in green, yellow and red, respectively. The analysis of 
these expression profiles showed that the genes expressed by DCs or CD4+ T cells 
at medium, high or very high levels were ANXA1, CD177, CEACAM1, CX3CR1, F11R 
and MMP9. Noting that neutrophils were the more frequently found cell type, I 
used the threshold suggested by the gene bank to exclude genes that were more 
highly expressed in arthritic joint neutrophils than any subtype of DC or CD4+ T 
cell. These were ANXA1 and MMP9 genes. 
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Table 3-1. Expression profiles of upregulated genes from joint non-migratory immune cells 
that are involved in leukocyte migration pathways 
 
Gene 
Symbol 
Cell 
Type 
 
ProbeSet 
Naive CD4+ 
T cell 
Memory CD4+ 
T cell CD8+ DC CD11b+ DC 
CD8- 
pDC Neutrophil 
Spleen LN Spleen LN Spleen LN Spleen LN Spleen Synovial 
Fluid 
ANGPT1 10428376 17 17 17 20 21 18 35 23 32 24 
ANXA1 10466606 27 25 50 36 564 593 240 128 32 1778 
CD34 10352905 38 38 40 39 46 47 72 43 41 54 
CD177 10560886 79 79 83 91 80 96 109 81 141 410 
CEACAM1 10561008 39 37 35 35 83 77 163 246 1103 940 
CX3CR1 10597743 80 85 117 103 235 123 297 302 92 134 
ELANE 10364535 45 49 42 52 57 49 61 46 57 75 
EPX 10389654 32 34 37 37 38 41 42 38 29 48 
F11R 10351623 38 40 36 46 57 103 100 810 37 80 
FN1 10355403 37 36 34 48 43 51 60 68 40 968 
JAM2 10436666 43 48 46 49 47 48 58 57 43 67 
MMP9 10478633 50 63 113 64 62 68 218 53 45 4266 
S100A8 10493831 27 29 34 35 31 33 44 44 38 7740 
S100A9 10499861 49 44 50 53 65 52 78 46 65 11321 
SELP 10351206 39 36 51 42 43 38 60 39 33 136 
From the list of 4 gene candidates that were left, an analysis of the availability of 
reagents for molecules encoded by each one of these genes was done. To date, 
the only candidate that has no commercially available agonist or antagonist 
reagents offered by the main companies that serve our laboratory (Thermo Fisher, 
BioLegend, BD Biosciences, Abcam, Sigma Aldrich) is the molecule CD177, also 
known as NB1. Lastly, a brief literature review was performed to gather 
information about the 3 candidates that met the established technical 
requirements: CEACAM1, CX3CR1 and F11R. Final selection was based on existing 
literature about surface expression by the immune cells of interest, preliminary 
results on manipulation of these molecules on the context of T cell-DC interactions 
and effects on manipulation in disease models, such as RA. For the purpose of this 
chapter, CEACAM1 was studied. 
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3.1.2 Carcinoembryonic Antigen-Related Cell Adhesion Molecule 
1 (CEACAM1) 
CEACAM1, also known as CD66a, is a cell-cell adhesion molecule, a member of the 
carcinoembryonic antigen (CEA) family and part of the IgSF255,256. This molecule 
was first described as a biliary glycoprotein found in human hepatic bile257,258 and 
is expressed by several cell types, such as epithelial, endothelial and immune 
cells259,260. CEACAM1 is a transmembrane protein that has a cytoplasmatic tail and 
an extra-cellular region formed by an amino-terminal variable domain followed 
by up to three immunoglobulin C2 (IgC2)-like constant domains261. In mice and 
humans, 4 and 11 isoforms of CEACAM1 have been identified, respectively262. 
These variants differ in the number of extracellular domains and length of their 
cytoplasmatic tail. CEACAM1-4L, for example, contains 4 extracellular domains 
and a long cytoplasmatic tail, whereas CEACAM1-4S is formed by the same number 
of extracellular domains but has a short cytoplasmatic tail261,262. 
CEACAM1 can undergo homophilic (CEACAM1-CEACAM1) or heterophilic 
interactions with other members of the CEA family (CEACAM5, 6 and 8) in 
humans257 or TIM-3 in humans263 and mice264. In addition, CEACAM1 was also shown 
to function as an innate receptor for a number of pathogens in humans and mice, 
such as bacteria and viruses265–274. CEACAM1-4L and -4S are the isoforms capable 
of mediating homophilic binding275–277, and the short form was shown to bind less 
avidly to immobilized CEACAM1 molecules in comparison to the long form278. 
Variants containing a long cytoplasmatic tail are reported to generally have 
inhibitory functions261, whereas those with a short tail have been implicated in 
interactions with the cytoskeleton279,280. However, distinct cellular responses are 
promoted by CEACAM1 isoforms that play a role in signalling functions. This is 
suggested to be dependent on the balance between monomeric and dimeric 
forms281, as many of these variants undergo dimerization. Additionally, the 
expression profile of isoforms varies according to cell type, phase of growth and 
activation status and may also dictate the fate of cellular outcomes driven by 
CEACAM1 binding as stimulation or inhibition260,282,283. 
CEACAM1 extra-cellular domains are essential for its intercellular functions in 
leukocytes. In B cells, CEACAM1 regulates BCR induced activation283, cell survival 
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and is required for protective antiviral antibody production284. CEACAM1 is 
expressed by activated neutrophils285 and plays a role in cell survival signals that 
prevent apoptosis286 and in cytokine production287. In NK cells, CEACAM1 is also 
expressed upon cell activation288 and is required for NK cytotoxic activity289,290. In 
DCs, anti-CEACAM1 stimulation was found to promote maturation, induce 
chemokine secretion and increase IL-6 and IL-12 production291. CEACAM1 is stored 
in T cell intracellular compartments and activated T cells can express CEACAM1 
on their surface as rapidly as 30 minutes. Expression levels can be enhanced by 
addition of IL-2260, IL-7 and IL-15 following stimulation with concanavalin A (ConA) 
or anti-CD3 stimulation292,293. A few studies suggest that CEACAM1 plays a role in 
T cell proliferation and cytokine production. T cells from CEACAM1 deficient mice 
show increased proliferation and secretion of IL-2 and IFN-γ upon different stimuli 
both in vitro and in vivo261. Treatment with different anti-CEACAM1 mAb clones 
were found to inhibit anti-CD3-induced lymphocyte proliferation260,294 and IL-2 
production294. Additionally, one of these clones were also found to decrease IL-4 
and increase IFN-γ secretion by antigen-primed CD4+ T cells in vitro291, suggesting 
that CEACAM1 may play a role in Th1 differentiation. Alternatively, treatment 
with a different mAb clone increased T cell activation and secretion of IFN-γ and 
TNF-α induced by anti-CD3 stimulus293, illustrating the complexity of determining 
CEACAM1’s role as either a stimulatory or inhibitory receptor. Nevertheless, 
mechanisms of action, such as recruited ligands, and possible effects of CEACAM1 
blockade on T cells during priming in vivo remains uncertain. 
CEACAM1 is upregulated in several pathological conditions, such as viral295 and 
bacterial296,297 infections, bowel inflammation298, vascular inflammation299,300 and 
is already considered a biomarker for many kinds of cancer301,302. CEACAM1 is 
suggested as a promising therapeutic target in melanoma, lung, colorectal and 
pancreatic cancers301,303,304 and has been tested in a few animal models of 
inflammatory diseases. In a model of myocardial infarction, mice lacking CEACAM1 
had lower mortality rate and improved cardiac function in comparison to WT 
mice300, although the possible attribution of these effects to T cell immune 
regulation was not studied. In a model of multiple sclerosis, treatment with 
CEACAM1-Fc fusion protein inhibited the disease severity, whereas treatment with 
an anti-CEACAM1 mAb increased the gravity of the pathology305. These therapeutic 
effects were found to be dependent on invariant NK cell mechanisms influencing 
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the secretion of IL-17 and IFN-γ cytokines. In two models of inflammatory bowel 
diseases (IBD), treatment with anti-CEACAM1 mAb inhibited development of TNBS 
or oxazolone-induced colitis306, an effect that was most pronounced if the 
antibody was administered after the induction phase. This protective effect was 
attributed to decreased Th1 polarization suggested by a reduction in the secretion 
of IFN-γ and intracellular expression of T-bet by lamina propria mononuclear cells. 
Preliminary work has been previously published on the effects of manipulation of 
CEACAM1 pathways on T cell proliferation260,294 and cytokine secretion291,293,294 in 
vitro. However, effects of its blockade on T cell activation, proliferation and 
differentiation during antigen presentation in vivo remain to be studied. 
Furthermore, preclinical studies on CEACAM1 as a potential therapeutic target for 
other autoimmune disorders, such as lupus and arthritis, are still unexplored. 
Thereby, CEACAM1 showed to be a promising target for the aims proposed in this 
thesis and was the first molecule to be tested. 
3.2 Results 
3.2.1 CEACAM1 is Expressed by DCs 
Prior to analysing the effects of CEACAM1 blockade on the crosstalk between CD4+ 
T cells and DCs, it was important to confirm that this marker is expressed by one 
or both of these cell types. For that, cells from spleens and LNs of WT mice were 
harvested and analysed by flow cytometry as detailed in Chapter 2. First, a 12-
colour panel was developed to detect CD4+ T cells, cDC1, cDC2 and pDC 
populations, in which markers for identification of the different subtypes of DCs 
were based on Ford LB, et al. reports307. Then, this optimised 12-colour panel was 
used to identify the populations of interest in a gate strategy showed in Figure 3-
3A, and the expression of CEACAM1 was determined on these different populations 
(Figure 3-3B), in which gates were based on the fluorescence emitted by its 
isotype control (Figure 3-3C). The expression of CEACAM1 in these cells was also 
quantified (Figure 3-3D). Additionally, the expression of TIM-3, a CEACAM1 ligand 
described in mice264, was determined on CD4+ T cells (Figure 3-3E), using its 
isotype control fluorescence intensity to determine gates (Figure 3-3F). 
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Figure 3-3. CEACAM1 expression on murine CD4+ T cells and DCs 
Immune cells from C57BL/6 mice were analysed by flow cytometry for the expression of CEACAM1 
and TIM-3. (A) Gating strategy from a 12-colour flow cytometry panel for identification of CD4+ T 
cells, plasmacytoid DCs (pDC), conventional DCs type 1 (cDC1) and conventional DCs type 2 (cDC2) 
in cells from lymph nodes (LN) gated based on fluorescence minus one (FMO) controls. After 
selecting leukocytes by size and granularity, doublets and dead cells were excluded. To detect 
CD4+ T cells, events that were negative for the B cell lineage marker B220 and the DC lineage 
marker CD11c were selected and CD4+ T cells were detected by expression of CD3 and CD4. To 
detect DCs, NK1.1- CD3- events were gated. CD11clow PDCA1+ B220+ CD11b- events were 
considered as pDCs. Conventional DCs were considered as CD11chigh MHCII+, and events were 
separated between CD8+ (cDC1) and CD11b+ (cDC2) cells. (B) Representative dot plots of CEACAM1 
expression (C) or its isotype control on CD4+ T cells or on different subtypes of DCs from spleens 
and LNs and (D) quantification of CEACAM1+ cells. (E) Representative dot plots of TIM3 expression 
(F) or its isotype control on CD4+ T cells from spleens and LNs (CD3+ CD4+). Gates on B and D show 
specific binding based on the fluorescence emitted from its matched isotype controls shown on C 
and E, respectively. Data are representative of an experiment performed in biological triplicates. 
Most CEACAM1+ cells were CD11c- B220+ (84.7% ± 2.86 in LNs and 78.6% ± 1.39 in 
spleens), possibly reflecting B cell populations. DCs expressed different levels of 
CEACAM1, depending on its subtype or lymphoid organ in which they populated. 
Nearly all pDCs expressed high levels of CEACAM1. Conventional DCs type 2 also 
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expressed CEACAM1 in high proportions, especially LN resident cDC2. Populations 
of cDCs1 also expressed CEACAM1. On the other hand, only a small proportion of 
naïve CD4+ T cells expressed CEACAM1. The CEACAM1 ligand TIM-3 was not 
detected on naïve CD4+ T cells. I then investigated the expression of CEACAM1 
and TIM-3 on primed CD4+ T cells. 
3.2.2 CEACAM1 is Upregulated on Antigen-Stimulated CD4+ T 
cells 
To investigate whether CEACAM1 is upregulated on CD4+ T cells upon antigen 
stimulation, mature BMDCs were cultured as described in Chapter 2 and pulsed or 
not with pOVA to be co-cultured with naïve OTII CD4+ T cells. CD4+ cells were 
then analysed by flow cytometry at co-culture set-up (0 hours) and 24, 48 and 72 
hours. For the flow cytometric analysis, expression of the surface marker CD44 
was used to identify activated T cells308 (Figure 3-4A). For the detection of T cells, 
the CD4 marker was used. Generally, 10-20% of CD4+ T cells from naïve spleens 
and LNs of OTII mice are CD44high (Caio S. Bonilha unpublished observations), 
whereas cultures that have received antigen stimulation had higher proportions 
of CD44high and were considered as activated T cells. Surface expression of 
CEACAM1 on T cells was determined (Figure 3-4B), in which gates were based on 
the fluorescence emitted by its isotype control (Figure 3-4C), and its proportions 
were compared between T cells that have received antigen stimulation and T cells 
that were cultured with BMDCs that were not carrying antigen (Figure 3-4D). 
Expression of TIM-3 was also determined on activated CD4+ T cells in the different 
time points (Figure 3-4E), using its isotype control fluorescence intensity to 
determine gates (Figure 3-4F). 
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Figure 3-4. CEACAM1 and TIM-3 expression on CD4+ T cells upon priming 
CD4+ T cells from OTII mice were cultured with OVA peptide (pOVA)-pre-pulsed bone marrow 
derived dendritic cells and analysed for the expression of CEACAM1 and TIM-3 in different time 
points after the co-culture set-up. (A) Representative dot plots of CD44 expression on unstimulated 
and OVA-stimulated CD4+ T cells with gating on CD44high cells. (B) Representative dot plots of 
CEACAM1 expression on unstimulated and OVA-stimulated CD4+ T cells (C) or its isotype control 
on OVA-stimulated CD4+ T cells and (D) quantification of CEACAM1+ cells with comparison between 
the two different groups 0, 24, 48 and 72 hours after priming. (E) Representative dot plots of TIM-
3 expression on unstimulated and OVA-stimulated CD4+ T cells (F) or its isotype control on OVA-
stimulated CD4+ T cells. Gates show specific binding based on its matched isotype control. Results 
are expressed as mean ± SD of an experiment performed in triplicates. Statistical differences were 
determined using a two-way ANOVA. ***p ≤ 0.001, ****p ≤ 0.0001. 
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CD4+ T cells cultured with pOVA-pre-pulsed BMDCs were successfully primed as 
shown by a time dependent increase in the frequency of CD44high populations. In 
contrast, T cells that didn’t receive antigen stimulation failed to upregulate this 
marker. A low frequency of CEACAM1-expressing cells was found on CD4+ T cells 
cultured with BMDCs not carrying antigen and with pOVA-pulsed-BMDCs 24 hours 
after co-culture set-up. The proportions of CEACAM1-expressing cells on CD4+ T 
cells that were incubated 48 and 72 hours with antigen-pulsed-BMDCs were higher 
in comparison to CD4+ T cells that were incubated with BMDCs not carrying antigen 
for the same periods of time. TIM-3 was not detected on naïve or activated CD4+ 
T cells, as dot plots from cells that were incubated with fluorophore-conjugated 
anti-TIM-3 antibody showed a similar pattern of those that were incubated with 
its isotype control. 
3.2.3 CEACAM1 is Highly Expressed by BMDCs 
The last step before analysing the effects of CEACAM1 blockade on CD4+ T cells 
priming was to verify if BMDCs express this marker. BMDCs were cultured for 7 
days and analysed by flow cytometry for the expression of CD86, a marker for DCs’ 
maturity309, and CEACAM1 (Figure 3-5A). To mature BMDCs, LPS stimulation was 
given from day 6 to 7, before analysis. The proportion of cells expressing CEACAM1 
was quantified and compared between immature and mature BMDCs (Figure 3-5B). 
Isotype control antibodies for the CD86 and CEACAM1 antibody clones were used 
to identify specific binding. 
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Figure 3-5. CEACAM1 expression on BMDCs 
BMDCs were cultured for 7 days and analysed by flow cytometry for the expression of CEACAM1. 
(A) Representative histograms of expression of CD86 (left side) and CEACAM1 (right side) on 
immature (black unfilled) or mature BMDCs (red unfilled) or in BMDCs stained with matched isotype 
controls (grey-shaded). (B) Comparison of the proportion of CEACAM1+ cells from immature and 
mature BMDCs gated according to its isotype control. Results are expressed as mean ± SD of an 
experiment performed in triplicates. Statistical difference was determined using an unpaired 
Student’s t test. p = non-significant. 
The expression of CD86 showed that LPS-stimulated BMDCs achieved full 
maturity310,311. CEACAM1 was expressed on similar levels on both immature and 
mature BMDCs, with no significant difference between these two populations. This 
experiment validated the use of BMDCs for CEACAM1 functional assays, as these 
cells expressed similar levels as some populations of DCs found in vivo, such as LN 
cDC2. 
3.2.4 Treatment with Anti-CEACAM1 Monoclonal Antibody (mAb) 
CC1 During Antigen Presentation has No Effect on CD4+ T 
Cells Priming 
After demonstrating that DCs and BMDCs express CEACAM1, I could utilise my in 
vitro assay to test if blockade of CEACAM1 with anti-CEACAM1 mAb CC1 changes 
the outcomes of T cells upon priming. BMDCs pre-pulsed with pOVA were cultured 
with CFSE-labelled, naive OTII CD4+ T cells in complete medium in the presence 
of anti-CEACAM1 mAb CC1 or isotype control for 72 hours and analysed by flow 
cytometry. Cells that have divided were identified using CFSE dilution (Figure 3-
6A). This is based on the rationale that daughter cells emit half of the CFSE 
fluorescence of the mother cell. In addition, cells that divided three times were 
also analysed (Figure 3-6B). To assess T cell activation, the proportion of CD44high 
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cells were also determined (Figure 3-6C). In addition, supernatants from these 
cultures were kept for the detection of IFN-γ by ELISA (Figure 3-6D). This analysis 
aimed to validate the CC1 mAb for its use in functional assays by replicating results 
from the literature that showed that CEACAM1 manipulation with the use of 
another anti-CEACAM1 clone (mAb AgB10) increased IFN-γ secretion by antigen-
specific T cells291. 
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Figure 3-6. Effects of anti-CEACAM1 mAb CC1 on CD4+ T cell activation and proliferation 
CFSE-labelled CD4+ T cells from OTII mice were cultured with OVA peptide (pOVA)-pre-pulsed bone 
marrow-derived dendritic cells in the presence of anti-CEACAM1 mAb (CC1) or its isotype control 
for 72 hours and analysed by flow cytometry and ELISA. (A) Representative histograms of CFSE 
fluorescence intensity on CD4+ cells (left side) and quantification of CD4+ T cells that have divided 
based on the gating of CFSE fluorescence intensity (right side). (B) Representative dot plots of 
CFSE fluorescence intensity on CD4+ cells with gating on fluorescence equivalent to three divisions 
(left side) and quantification of CD4+ T cells that have divided three times (right side). (C) 
Representative histograms of CD44 fluorescence intensity on CD4+ cells (left side) and 
quantification of CD4+ T cells that are CD44high (right side). (D) Quantification of IFN-γ 
concentration present in the co-cultures’ supernatants detected with ELISA. Results are expressed 
as mean ± SD of an experiment performed in triplicates. Statistical differences in all graphs were 
determined between anti-CEACAM1-treated group and the two other groups that received antigen 
stimulation using a one-way ANOVA. p = non-significant for all comparisons. 
The group treated with anti-CEACAM1 mAb CC1 did not show any significant 
difference in T cell activation and proliferation in comparison to the isotype 
control or to the untreated OVA-stimulated groups. In addition, no difference was 
found on the concentration of IFN-γ from culture supernatants. This either 
suggests that the antibody was not blocking CEACAM1 pathways or that it was not 
binding to its specific target for unknown reasons. To address the question of 
whether the purified CC1 mAb was binding to CEACAM1, I pre-treated BMDCs with 
the CC1 mAb. After 30 minutes, I incubated BMDC with a fluorophore conjugated 
CC1 antibody of the same clone and evaluated if the pre-treatment was able to 
inhibit binding of the conjugated antibody (Figure 3-7). 
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Figure 3-7. Assessment of the capacity of purified anti-CEACAM1 mAb CC1 to block fluorophore 
conjugated anti-CEACAM1 ligation to CEACAM1 
Day-7 immature BMDCs were used to analyse if the purified anti-CEACAM1 mAb CC1 was binding 
to the specific target. Dot plots of CEACAM1 expression in untreated unstained control, untreated 
positive control stained with fluorophore-conjugated anti-CEACAM1 antibody and purified anti-
CEACAM1 mAb CC1 pre-treated and stained with fluorophore-conjugated anti-CEACAM1 antibody 
are shown. 
The purified anti-CEACAM1 mAb CC1 was able to block ligation of the fluorophore 
conjugated, anti-CEACAM1 CC1 mAb, indicating that the purified antibody that 
was being used for functional assays was able to bind to its specific target. 
Approaches to obtain alternative CEACAM1 reagents were tried and are described 
in the Discussion section of this chapter (section 3.3). I then moved to an 
alternative approach to manipulate CEACAM1 expression on BMDCs to use these 
cells in my functional assays. 
3.2.5 siRNA Targeting CEACAM1 Gene Has Minimal Impact on 
CEACAM1 Expression on BMDCs 
As previously shown, CEACAM1 is expressed in high levels by DCs and BMDCs but 
in low levels by CD4+ T cells. Genetically manipulated BMDCs that express low 
levels of CEACAM1 could be used in functional assays aiming to determine the role 
of CEACAM1 in the interactions between T cells and DCs. For this genetic 
manipulation, I chose the siRNA technique. Immature BMDCs were transfected 
with CEACAM1 siRNA and different concentrations of Lipofectamine 2000, a 
transfection reagent that has previously been shown to work for BMDCs312,313. Cells 
were then harvested 72 hours after the transfection and analysed by flow 
cytometry for the expression of CEACAM1 (Figure 3-8A). CD11c was used as a DC 
marker to identify the target population. For the control group, siRNA targeting 
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GFP, a gene responsible for encoding the GFP fluorescent protein and that is not 
present in the system, was used. The expression of CEACAM1 on CD11c+ cells was 
then compared between groups (Figure 3-8B). 
 
Figure 3-8. CEACAM1 siRNA effects on BMDC CEACAM1 expression 
Day-7 immature BMDCs were transfected with siRNA targeting the CEACAM1 gene or the GFP gene 
(control) and different concentrations of Lipofectamine 2000 for 72 hours to be analysed by flow 
cytometry for the expression of CEACAM1. (A) Representative dot plots of CEACAM1 expression on 
CD11c+ cells. (B) Quantification of the proportion of CEACAM1+ cells and comparison between 
CEACAM1 siRNA and GFP siRNA groups. Results are expressed as mean ± SD of triplicate cultures 
from two independent experiments. Statistical differences were determined using a two-way 
ANOVA. *p ≤ 0.05, ***p ≤ 0.001. 
BMDCs transfected with siRNA targeting the CEACAM1 gene showed a small but 
statistically significant reduction in expression of CEACAM1 with both 
concentrations of Lipofectamine 2000. However, the decrease was minimal and 
would be unlikely to be biologically relevant in the context of my assays. Other 
attempts with changes in the protocol were performed aiming to obtain a greater 
decrease and are discussed in the next section (3.3). 
3.3 Discussion 
Conventional DCs type 2 are subtype of DC that are known to have dominant role 
in antigen presentation in the context of MHCII molecules6,32 and that I showed to 
express high levels of CEACAM1. CEACAM1 was also expressed at lower levels on 
cDC1 and at higher levels on pDCs. CEACAM1 could play a role in intercellular 
interactions between leukocytes by homophilic binding, or between CEACAM1 and 
other potential surface ligands, such as TIM-3262–264. Naïve CD4+ T cells express 
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CEACAM1 in low proportions, something that was previously reported314 and 
confirmed by my experiments, and undetectable levels of TIM-3, the only 
heterophilic ligand for CEACAM1 described in mice to this date264,301. Although a 
positive control for TIM-3 staining was not used in the experiments in this thesis, 
the literature reports lack of TIM-3 expression on splenic CD4+ T cell of 12-week 
old C57BL/6 mice315. This study have used the same mAb clone that was used in 
my experiments (RMT3-23), that have proven specific ligation to TIM-3263. 
However, the expression of other ligands described in humans, such as CEACAM5, 
CEACAM6 or CEACAM8261 was not investigated. Considering that the literature 
suggests that CEACAM1 blockade could have an impact on DC-T cell crosstalk291,316 
and that other ligands may have not been discovered yet, I pursued the 
investigation of whether CEACAM1 plays a role on CD4+ T cell priming. Antigen 
stimulated CD4+ T cells expressed higher levels of CEACAM1 in comparison with 
naïve cells, supporting results from the literature that showed increased CEACAM1 
surface expression in T cells stimulated with anti-CD3 antibodies or ConA292. This 
upregulation may suggest that CEACAM1 may play a role in T cell effector 
functions and that homophilic binding could be important in secondary encounters 
of effector T cells with APCs carrying specific antigen. 
Purified anti-CEACAM1 mAb CC1 was acquired from a commercial source that 
indicated this product had an impact in functional assays similar to those I wished 
to perform. To investigate if this mAb clone was able to block CEACAM1 
intercellular interactions, I tried to replicate results from the literature that 
described a decreased secretion of IFN-γ upon blockade during priming in vitro291. 
For this, I used an assay with OTII naïve CD4+ T cells and BMDCs that I had 
demonstrated expressed high levels of CEACAM1. Anti-CEACAM1 mAb CC1 was not 
able to affect the secretion of IFN-γ measured in the co-culture supernatants. 
Additionally, although CEACAM1 blockade by treatment with anti-CEACAM1 mAb 
clones D14HD11 and 4/3/17 were previously found to inhibit anti-CD3-induced 
proliferation in vitro260,294, no effects on proliferation or activation were found 
with treatment of anti-CEACAM1 mAb CC1 in my assay. To ensure that the purified 
antibody was binding to its specific target, I performed an experiment that showed 
that treatment with the purified antibody inhibited the ligation of a fluorophore 
conjugated anti-CEACAM1 antibody. It is possible that mAb CC1 might have a 
stimulatory effect in the system, as a distinct mAb (HD11) was found to increase 
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T cell activation mediated by an anti-CD3 mAb293. Perhaps, this could be addressed 
by repeating my in vitro assay with the use of a suboptimal concentration of 
antigen, to allow a margin for stimulation to be detected, since only an optimal 
concentration of antigen was used. However, before this was done, results from 
experiments that were being performed by other lab members were revealed. 
The former lab members Drs Robert A. Benson and Catriona Prendergast 
performed experiments including the breach of self-tolerance model of arthritis, 
which is extensively discussed within this thesis, using the mAb CC1. No 
differences were found between anti-CEACAM1 mAb CC1 and the isotype control 
in any of their in vitro experiments (unpublished data not shown). Also, no 
differences were found in clinical and pathological measurements and on markers 
for CD4+ T cell activation from treated mice in comparison to the control group 
under induction of the RA murine model (unpublished data not shown). These 
results suggest that the mAb CC1 was not having any effect in in vitro or in vivo 
systems. These findings are supported by a study from 2018 that found no or 
minimal anti-tumour effect under treatment with mAb CC1 in vivo317 but 
contradicted by a previous study that showed beneficial effects on a murine model 
of colitis under treatment of this same mAb clone in comparison to an isotype 
control306. This study from 2018 used protein and cell-based ELISA assays to show 
that the mAb CC1 is not able to block CEACAM1 homophilic interactions317. 
As reliable sources for reagents with proven efficacy for disruption of CEACAM1 
pathways could not be identified, I tried to inhibit CEACAM1 expression on BMDCs 
by employing siRNA. In theory, siRNA silencing of CEACAM1 in BMDCs could have 
been used for in vitro and in vivo assays which could show the possible effects of 
blockade of CEACAM1 ligation in the interactions between T cells and BMDCs. I 
transfected siRNA targeting the CEACAM1 gene to BMDCs in an attempt to silence 
CEACAM1 mRNA expression that would lead to a decrease in CEACAM1 surface 
expression. Although reverse transcription-polymerase chain reaction (RT-PCR) 
was not used to show that the transfection was able to affect the expression of 
mRNA molecules, I concluded that the transfection was successful as it could 
affect the expression of CEACAM1 on BMDCs. However, although CEACAM1 half-
life is relatively short (26-40 hours)318, the decrease found in my experiments was 
minimal, as a substantial proportion of the transfected cells were still expressing 
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CEACAM1. In addition, my attempts to improve these results by modifying 
different variables of the protocol (cell number seeded, concentration of siRNA, 
concentration of the transfection reagent and presence of absence of LPS 
treatment to induce cell maturation) were not successful. An intervention aiming 
for transfection at a time point earlier than 7 days after initiation of BMDCs culture 
could not only affect CEACAM1 surface expression but possibly other undiscovered 
pathways relevant to BMDCs differentiation in which this molecule may play a role. 
In addition, a tool that could possibly promote a bigger change on the expression 
of surface molecules in a short period of time that is to induce full cell maturation 
with 24-hour LPS stimulation after siRNA transfection was not successful for 
CEACAM1 siRNA on BMDCs. This tool was successful in other studies in which siRNA 
targeted other genes, such as genes that encode CD40319,320, CD80 and CD86312,313. 
It is believed that this approach was successful for these molecules because they 
are quickly upregulated on the cells surface upon BMDC maturation, which does 
not occur with CEACAM1 as showed in section 3.2.3 of this chapter. 
The same study that showed that anti-CEACAM1 mAb CC1 is not able to block 
homophilic binding demonstrated that fragment-antigen-binding (Fab) fragments 
generated from digestion of this antibody clone were able to block homophilic 
binding on a cell-based assay317. However, this was only performed after work 
with another candidate molecule was advanced, and focus was given to these 
studies. As such, approaches of digesting anti-CEACAM1 mAb CC1 for generation 
of Fab fragments could base future work. 
The balance of CEACAM1 isoforms found in affected tissues from different 
pathological conditions are fundamental for distinguishing CEACAM1 potential 
targeting263,321–323. The possible classification of CEACAM1 as a T cell co-
stimulatory/inhibitory molecule is dependent of this isoform balance, which may 
difficult potential therapies for cancer/autoimmune diseases. In addition, given 
CEACAM1 expression in different cell types, its manipulation may affect diverse 
pathways (endothelial cell-endothelial cell, leukocyte-endothelial cell, leukocyte-
leukocyte). As such, studies utilising cell-selective CEACAM1 deletion may point 
important pathway-specific roles in distinct pathological conditions. 
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As I had taken the study of CEACAM-1 as far as possible with the reagents available 
I next progressed to another candidate gene identified in our screen. Considering 
the potential of these molecules based on the expression profiles shown in the 
first section of this chapter, in which F11R gene expression seems to be much 
higher on CD11b+ DCs than in neutrophils from the synovial fluid of arthritic mice, 
I decided to test my hypothesis and focus my study on the molecule encoded by 
F11R, which is the subject of the next chapter. 
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Chapter 4 JAM-A Contributes to CD4+ T cell 
Effector Functions During Priming in vitro 
4.1 Introduction 
The junctional adhesion molecule-A (JAM-A), also called junctional adhesion 
molecule-1 (JAM-1), is a molecule encoded by the F11R gene. The F11R gene was 
identified from the list of 15 genes relevant to leukocyte migration pathways, as 
explained in Chapter 3 (section 3.1). In summary, the breach of tolerance RA 
model was performed in WT mice and migratory and non-migratory cells from 
inflamed joints and pLNs were sent for transcriptomic analysis, in which 
differentially regulated genes were identified. The F11R gene was upregulated in 
non-migratory immune cells from the joint, suggesting that JAM-A expression by 
joint non-migratory immune cells could also be upregulated. Due to the nature of 
induction of inflammation in this disease model, as well as the fact that antigen 
presentation can occur in arthritic joints106, I hypothesized that JAM-A can play a 
role in the interactions between T cells and APCs. Moreover, F11R is the only gene 
from the list of 15 genes that is more expressed in DCs (CD11b+ DCs from LNs) 
than in neutrophils from the synovial fluid of arthritic mice (see section 3.1). This 
data was important in the decision to choose this candidate, as immune cells sent 
for pathway analysis were composed of a higher proportion of neutrophils than T 
cells or DCs, suggesting that the different regulation found in the F11R gene was 
not influenced by neutrophils, but could have been influenced by a higher 
proportion of DCs or an upregulation of gene expression within DC populations. 
Studies that manipulated JAM-A in vitro were reviewed and I then proceeded to 
examine its role using the assays and approaches described in previous chapters. 
4.1.1 Junctional Adhesion Molecule-A (JAM-A) 
JAM-A is part of the junctional adhesion molecules (JAM) family, member of the 
IgSF, and received its first denomination as F11 receptor (F11R), a receptor 
expressed on the surface of human platelets324. It was only a few years later that 
this molecule was detected in intercellular junctions of endothelial and epithelial 
cells325. Besides these cell types, JAM-A is also expressed by immune cells, such 
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as monocytes325 and DCs326,327. JAM-A is a transmembrane glycoprotein that is 
present as a homodimer on the cells surface. Homodimers are structures formed 
by two independent but identical chains that, in the case of JAM-A, are connected 
to form a domain called D1328. This domain is responsible for JAM-A interactions 
with other JAM-A molecules328–330, whereas the membrane-proximal D2 domain 
attaches the molecule to the JAM-A-expressing cell surface and interacts with 
other ligands such as LFA-1328. JAM-A can undergo homophilic interactions (JAM-
A-JAM-A)331 that can occur between epithelial-epithelial cells, endothelial-
endothelial cells325,332 or platelets-endothelial cells333,334 and heterophilic 
interactions. In heterophilic interactions, JAM-A can bind to other members of the 
JAM family (JAM-B and JAM-C)335, LFA1329,330 and CD9336,337. JAM-A-LFA1 ligation 
was described in interactions between LFA1-expressing human Jurkat T cells and 
JAM-A-expressing endothelial cells330. This T cell line expresses high levels of JAM-
A, suggesting that JAM-A homophilic interactions can also occur between T cells 
and the endothelium. Evidence however shows that JAM-A-LFA1 ligation is 
stronger than JAM-A-JAM-A binding and that this pathway reduces the dynamic 
strength of JAM-A homophilic interactions338. Although immunoprecipitation 
assays revealed precipitants of JAM-A and the β3 integrin (CD61) from an 
endothelial cells lysates337, suggesting a direct interaction between these 
molecules, it was later found that this interaction was dependent on CD9, as 
absence of this tetraspanin inhibited JAM-A coimmunoprecipitation with β3 
integrin337. Other immunoprecipitation assays suggest that JAM-A could also bind 
to the αIIb integrin (CD41)339. In addition to these ligands, JAM-A also works as a 
receptor for a few strains of murine and human viruses340–342. 
JAM-A plays important roles in endothelial cell migration336,337,343 and barrier 
functions332, and a few studies have evaluated the effects of JAM-A blockade in 
the interactions between these cells and leukocytes in vitro. Treatment with anti-
JAM-A mAb BV11 inhibited spontaneous and chemokine-induced monocyte 
transmigration through endothelial cell monolayers325. The JAM-A-LFA1 pathway 
was found to contribute to neutrophil and T cell transmigration. Disruption of this 
pathway inhibited IL-8- and chemokine-mediated neutrophil transmigration, 
although no impact on cell arrest was found330,344. Treatments with anti-JAM-A 
antibody and a JAM-A-Fc fusion protein were able to inhibit chemokine-induced 
LFA1-dependent transendothelial migration of human CD4+ CD45RO+ memory T 
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cells330,345. Treatment with anti-JAM-A mAb H202.106 decreased splenic pDCs 
transmigration through layers of HEV cells without affecting pDCs adhesion 
capacity346. Although these studies in monocytes, neutrophils, memory T cells and 
pDCs suggest that JAM-A blockade could have a negative impact on leukocyte 
migration, cDCs seem to respond differently. cDCs express high levels of this 
transmembrane protein compared with pDC326,327, allowing JAM-A homophilic 
intercellular ligations to possibly occur. BMDCs treated with anti-JAM-A mAb BV11 
showed increased random motility in vitro326. This same effect was found on 
BMDCs from JAM-A deficient mice in comparison with WT BMDCs. JAM-A disruption 
by gene depletion in BMDCs promoted increased transmigration across monolayers 
of lymphatic endothelial cells, but not through microvascular endothelial cells. 
These JAM-A deficient BMDCs expressed similar levels of maturation markers 
(CD80 and CD86), surface molecules related to DC migration (CD11a, CD11b, 
CD11c, CD62L, JAM-B and JAM-C) and antigen uptake capacity in comparison with 
WT BMDCs, suggesting that JAM-A may not participate in early stages of DCs 
differentiation and maturation. Another study showed higher transmigration of 
BMDCs expressing normal levels of JAM-A through layers of endothelial cells from 
JAM-A KO mice in comparison with endothelial cells from JAM-A KO mice 
reconstituted with full-length JAM-A cDNA347. These studies suggest that while DC 
JAM-A participates in DC trafficking through the lymphatics, JAM-A expressed by 
endothelial cells play a dominant role in DC migration through peripheral tissues. 
JAM-A is known to be involved in the regulation of endothelial-endothelial and 
leukocyte-endothelial cell interactions, but its importance in interactions 
between leukocytes remains unclear. Although preliminary work has been 
published reporting unaltered IFN-γ secretion by antigen-primed CD4+ T cells in 
response to JAM-A KO BMDCs compared with WT BMDCs347, JAM-A may still 
regulate interactions between T cells and APCs at a cell-cell level and influence 
their activation, proliferation and differentiation. In this chapter, the involvement 
of JAM-A in the interactions between CD4+ T cells and DCs during antigen 
presentation in vitro is investigated. 
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4.2 Results 
4.2.1 JAM-A is Expressed by DCs 
Before analysing the effects of JAM-A blockade on CD4+ T cells during antigen 
presentation, I evaluated the expression of JAM-A on CD4+ T cells and different 
subtypes of DCs. Spleens and LNs from WT mice were harvested, digested with 
Collagenase D for a higher yield of adherent cells, stained with fluorophore-
conjugated antibodies and analysed by flow cytometry. The optimised 12-colour 
panel described in Chapter 3 (Section 3.2.1) was used to analyse JAM-A expression 
on populations expressing lineage markers (Figure 4-1A), or more specifically on 
CD4+ T cells, cDC1, cDC2 and pDC populations (Figure 4-1B), with the use of an 
isotype control for the detection of JAM-A specific binding (Figure 4-1C). The 
proportion of JAM-A+ cells from specific leukocyte subsets was quantified (Figure 
4-1D), as well as from MHCII+ cells expressing different levels of CD11c (Figure 4-
1E, F). 
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Figure 4-1. JAM-A expression on murine CD4+ T cells and DCs 
Immune cells from C57BL/6 mice were analysed by flow cytometry for the expression of JAM-A. 
(A) tSNE analysis of immune cells (CD45+) from lymph nodes (LN) based on polychromatic flow 
cytometry data including JAM-A, CD11c, MHCII, CD11b, B220, NK1.1 and CD3 expression profiles 
highlighting the population expressing the highest levels of JAM-A. (B) Representative dot plots of 
JAM-A expression (C) or its isotype control on CD4+ T cells (B220- CD11c- CD3+ CD4+), type 1 
conventional DCs (cDC1) (CD3- NK1.1- CD11chigh MHCII+ CD8+ CD11b-), type 2 conventional DCs 
(cDC2) (CD3- CD11chigh MHCII+ CD8- CD11b+) and plasmacytoid DCs (pDCs) (CD3- NK1.1- CD11clow 
PDCA1+ B220+ CD11b-), from spleens and LNs. Gates on B show populations expressing JAM-A based 
on the fluorescence emitted from its isotype control shown on C. (D) Quantification of JAM-A+ 
events in distinct leukocyte subsets. (E) Gating strategy for identification of MHCII+ cells 
expressing different levels of CD11c (negative, low or high) and (F) quantification of the proportion 
of JAM-A+ cells in these populations. Data are representative of an experiment performed in 
biological triplicates. 
The tSNE analysis on immune cells from LNs showed some characteristics of the 
LN resident JAM-A+ population. The heatmap shows that LN resident JAM-A+ 
leukocytes (CD45+) are mostly composed of MHCII+, CD11c+ and CD11b+ cells, and 
that only a small part of B220+ cells express JAM-A, suggesting that the JAM-A-
expressing population is mainly formed by DCs and partly by B cells. In addition, 
only a small proportion of NK (NK1.1+) and T cells (CD3+) appear to express JAM-
A. JAM-A expression on specific leukocytes subsets was also analysed. CD4+ T cells 
from both spleens and LNs expressed low levels of JAM-A. On the other hand, all 
DC subsets expressed substantial levels of JAM-A. LN cDC2 was the subset that 
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expressed the highest levels and allowed the identification of a JAM-Ahigh cDC2 
population. LN resident cDC1 and cDC2 seem to express higher levels than splenic 
cDC1 and cDC2, respectively. Both LN and spleen pDCs expressed low levels of 
JAM-A. The analysis of MHCII+ cells expressing different levels of CD11c showed 
that CD11clow MHCII+ cells that look to be present in the LNs in higher frequency 
than in the spleens express high levels of JAM-A. These cells also express high 
levels of CD11b, suggesting that they could be macrophages. However, the use of 
macrophage lineage markers would be necessary to distinguish these cell 
populations in a more reliable way. 
Lymphoid organs are connected to secondary organs through lymphatic and blood 
vessels. The expression of some adhesion molecules were shown to vary 
substantially across different lymphoid organs323. As such, I analysed JAM-A 
expression on CD4+ T cells from spleens, different LNs (inguinal, brachial, 
superficial cervical, mesenteric) and Peyer’s patches (Figure 4-2). 
 
Figure 4-2. JAM-A expression on CD4+ T cells from different lymphoid organs 
CD4+ T cells from different lymphoid organs of C57BL/6 mice were analysed by flow cytometry for 
the expression of JAM-A. (A) Representative dot plots of JAM-A expression (B) or its isotype control 
on CD4+ T cells (CD3+ CD4+) from spleens, inguinal, brachial, superficial cervical and mesenteric 
lymph nodes (LN) and Peyer’s patches. Gates show populations expressing JAM-A based on the 
fluorescence emitted from its isotype control (not shown). Data are representative of an 
experiment performed in biological triplicates. 
 
 
97 
Similar proportions of JAM-A+ cells were found on CD4+ T cells populations from 
spleen, inguinal LN, brachial LN, superficial cervical LN, mesenteric LN and 
Peyer’s patches. As JAM-A intercellular ligation can occur between JAM-A 
molecules from the different interacting cells338 and the experiments in this 
Chapter section showed that, although a high proportion of DCs express JAM-A, 
only a small proportion of CD4+ T cells express JAM-A, I then decided to analyse 
if CD4+ T cells express a potential ligand for JAM-A. 
4.2.2 Naïve CD4+ T Cells Express a Potential Ligand for JAM-A 
As DCs express JAM-A, but only a small part of CD4+ T cells express this surface 
protein, I analysed the presence of a potential ligand for JAM-A on the surface of 
CD4+ T cells. LFA1, a known ligand for JAM-A330, is composed by an alpha (CD11a) 
and a beta (CD18) chain. CD18 is also a component of MAC-1 (CD11b/CD18), a 
receptor that is expressed on T cell surface348. As CD11a is only described to be 
part of LFA1349, this alpha chain was used for the detection of LFA1 on the surface 
of T cells. Immune cells from spleens and LNs of WT mice were stained with CD3, 
CD4 and CD11a (Figure 4-3). CD4+ T cells from both spleen and LNs expressed high 
levels of CD11a. 
 
Figure 4-3. Expression of CD11a on murine CD4+ T cells 
CD4+ T cells from spleens and lymph nodes of C57BL/6 mice were analysed by flow cytometry for 
the expression of CD11a. Histograms show CD11a expression (unfilled) or its matched isotype 
control (grey-shaded). Data are representative of an experiment performed in biological triplicates. 
4.2.3 Antigen-Primed CD4+ T cells Express Low Levels of JAM-A 
To evaluate whether activated CD4+ T cells express JAM-A, splenocytes from WT 
mice were incubated with soluble anti-CD3 and anti-CD28 agonistic antibodies for 
72 hours. As such, after being harvested, cells were stained with CD4 for 
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identification of CD4+ cells, CD44 for detection of the cells’ activation status 
(Figure 4-4A) and JAM-A (Figure 4-4B). 
 
Figure 4-4. JAM-A expression on CD4+ T cells upon agonistic antibodies stimulation 
Splenocytes from C57BL/6 mice were stimulated with anti-CD3 and anti-CD28 antibodies for 72 
hours and CD4+ T cells were analysed by flow cytometry for the expression of JAM-A. (A) 
Representative histograms of CD44 expression on unstimulated, anti-CD3-stimulated and anti-CD3 
+ anti-CD28-stimulated splenocytes with gating on CD44high cells. (B) dot plots of JAM-A expression 
on CD4+ T cells from unstimulated, anti-CD3-stimulated and anti-CD3 + anti-CD28-stimulated 
splenocytes with gating on JAM-A+ cells based on the fluorescence of its isotype control (not 
shown). Data are representative of an experiment performed in triplicates. 
Cells that were co-stimulated with anti-CD28 mAb expressed higher levels of CD44 
than the group in which co-stimulation was absent. JAM-A was nearly 
undetectable on CD4+ T cells from all groups. As no other co-stimulation that 
occur during antigen presentation was present in the analysed assay, I decided to 
analyse JAM-A expression on antigen-primed CD4+ T cells using an APC-dependent 
system. 
In order to analyse JAM-A expression on CD4+ T cells activated by antigen, naïve 
OTII CD4+ T cells were incubated for different time periods with pOVA-pre-pulsed 
BMDCs. CD4+ cells were then harvested and analysed by flow cytometry and 
antigen experienced T cells were identified by CD44 expression (Figure 4-5A). 
Surface expression of JAM-A on T cells was also determined (Figure 4-5B) and its 
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proportions were compared between T cells incubated with antigen pulsed or 
control BMDC (Figure 4-5D). Expression of CD11a, a potential ligand for JAM-A was 
also determined on cultures that received antigen stimulation at different time 
points (Figure 4-5E), using its isotype control fluorescence intensity to determine 
gates (Figure 4-5F). 
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Figure 4-5. Expression of JAM-A and its potential ligands on activated CD4+ T cells 
CD4+ T cells from OTII mice were cultured with OVA peptide (pOVA)-pre-pulsed bone marrow-
derived dendritic cells and analysed by flow cytometry for the expression of JAM-A and CD11a are 
different time points following activation. (A) Representative dot plots of CD44 expression on 
unstimulated and OVA-stimulated CD4+ T cells with the percentage of CD44high cells indicated. (B) 
Representative dot plots of JAM-A expression on unstimulated and OVA-stimulated CD4+ T cells (C) 
or its isotype control on OVA-stimulated CD4+ T cells and (D) quantification of JAM-A+ cells with 
comparison between the two different groups 24, 48 and 72 hours after priming. (E) Representative 
dot plots of CD11a expression on unstimulated and OVA-stimulated CD4+ T cells (F) or its isotype 
control on OVA-stimulated CD4+ T cells. Gates show specific binding based on matched isotype 
control. Results are expressed as mean ± SD of an experiment performed in triplicates. Statistical 
differences were determined using a two-way ANOVA. ****p ≤ 0.0001. 
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CD4+ T cells cultured with pOVA-pulsed BMDCs were successfully primed. The 
frequency of CD44high cells increased across time on the group that received 
antigen stimulation, reaching its peak of expression three days after initial contact 
between the cell types. In contrast, T cells that didn’t receive antigen stimulation 
did not upregulate CD44. JAM-A was expressed in low levels on naïve CD4+ T cells 
and on early activated CD4+ T cells. However, antigen stimulation for 48 and 72 
hours resulted in higher expression of JAM-A in comparison with non-antigen 
stimulated CD4+ T cells. Both naïve and activated CD4+ T cells expressed CD11a, 
and it was possible to notice an upregulation of CD11ahigh populations on cells that 
were exposed to antigen across time. 
To analyse if the increase on JAM-A+ cells on antigen-primed CD4+ T cell cultures 
in comparison with unstimulated cultures could have been driven by cytokines 
released by these activated cells during or shortly after priming, I used a second 
approach in which naïve and activated cells were present in the same well. 
Isolated naïve CD4+ T cells from OTII and WT mice were concomitantly cultured 
with BMDCs pre-pulsed with pOVA, whereas other co-cultures did not receive 
antigen. Cells were harvested 72 hours later, stained and analysed by flow 
cytometry. As all immune cells from OTII mice express CD45.1, this marker was 
used to identify WT (CD45.1-) and OTII (CD45.1+) cells within the same culture 
before analysing them for CD44 expression (Figure 4-6A). Surface expression of 
JAM-A was also detected (Figure 4-6B) using the fluorescence intensity of its 
isotype control to identify specific binding (Figure 4-6C). Frequencies of JAM-A+ 
populations from OTII CD4+ T cells in cultures containing pOVA-pulsed BMDCs were 
compared to WT CD4+ T cells in cultures containing pOVA-pulsed BMDCs, to OTII 
CD4+ T cells in cultures containing control BMDCs or to WT CD4+ T cells in cultures 
containing control BMDCs (Figure 4-6D).  
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Figure 4-6. JAM-A expression on naïve or antigen-primed OTII CD4+ T cells and naïve wild-type 
(WT) CD4+ T cells 
CD4+ T cells from OTII and C57BL/6 mice were cultured together with OVA peptide (pOVA)-pre-
pulsed bone marrow-derived dendritic cells for 72 hours and analysed by flow cytometry for the 
expression of JAM-A. (A) Representative dot plots of CD44 expression on OTII (CD45.1+) or WT 
(CD45.1-) CD4+ T cells from co-cultures with or without OVA with gating on CD44high cells. (B) JAM-
A expression (C) or its isotype control on OTII (CD45.1+) or WT (CD45.1-) CD4+ T cells from co-
cultures with or without OVA with gating on JAM-A+ cells based on its isotype control. (D) 
Quantification of JAM-A+ cells from the CD4+ populations and comparison between the CD45.1+ 
OVA group and the other groups. Results are expressed as mean ± SD of an experiment performed 
in triplicates. Statistical differences were determined using a two-way ANOVA. ***p ≤ 0.001, ****p 
≤ 0.0001. 
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The frequency of CD44high populations demonstrated that CD45.1+, but not 
CD45.1- CD4+ T cells, were successfully activated when present in wells with 
pOVA-pulsed BMDCs. In addition, both CD45.1+ and CD45.1- CD4+ T cells incubated 
with BMDCs that were not carrying antigen did not upregulate CD44. Activated 
CD45.1+ CD4+ T cells expressed higher levels of JAM-A in comparison with CD45.1+ 
and CD45.1- CD4+ T cells that did not receive antigen and to CD45.1- CD4+ T cells 
that were present in the same wells as the activated CD45.1+ T cells. 
4.2.4 JAM-A is Expressed by BMDCs 
Before analysing the effects of JAM-A blockade on CD4+ T cell priming, it was 
important to verify if BMDCs express this surface protein, as this would be the DC 
type to be used for functional assays. BMDCs were cultured for 7 days. Immature 
BMDCs were not stimulated, whereas mature BMDCs received 24-hours LPS 
stimulation, from day 6 to 7, before being analysed. Cells were then harvested 
and analysed by flow cytometry for the expression of CD86, to indicate maturation, 
and JAM-A (Figure 4-7A). The proportion of cells expressing JAM-A was quantified 
and compared between immature and mature BMDCs (Figure 4-7B). 
 
Figure 4-7. JAM-A expression on BMDCs 
BMDCs were cultured for 7 days and analysed by flow cytometry for the expression of JAM-A. (A) 
Representative histograms of expression of CD86 (left side) and JAM-A (right side) on immature 
(black unfilled) or mature BMDCs (red unfilled) or in BMDCs stained with isotype controls (grey-
shaded). (B) Comparison of the proportion of JAM-A+ cells from immature and mature BMDCs gated 
according to its isotype control. Results are expressed as mean ± SD of an experiment performed 
in triplicates. Statistical differences were determined using an unpaired Student’s t test. ****p ≤ 
0.0001. 
 
 
105 
JAM-A was widely expressed on both immature and mature BMDCs. However, it 
was expressed on a higher proportion of mature BMDCs. This experiment validated 
the use of BMDCs for functional assays aiming to manipulate JAM-A, as these cells 
expressed similar levels as some populations of DCs found in vivo, such as LN 
resident cDC2. 
4.2.5 JAM-A is Present on the Site of Interaction During CD4+ T 
Cell Priming 
The analysis of the localisation of JAM-A on the DC surface during antigen 
presentation could suggest whether this molecule could be important in the 
interactions between DCs and T cells. OTII CD4+ T cells were cultured with BMDCs 
pulsed with pOVA for 24 hours. After being harvested, cells were stained and 
analysed by confocal microscopy. Cells were stained with CD4 for detection of 
CD4+ T cells, CD11c, MHCII and JAM-A. MHCII is known to be strongly recruited to 
the immune synapse 350,351, therefore cell doublets in which translocation of MHCII 
to the site of interaction (SI) with the T cell was evident were identified, as 
described in Chapter 2 (section 2.6.2), and images from a z-stack plane were 
acquired for the analysis of protein expression across the BMDC membrane (Figure 
4-8A). Isotypes were used to detect specific binding for all markers. The ratio of 
the MFI between the SI and the rest of the BMDCs membrane from MHCII, CD11c 
and JAM-A was calculated (Figure 4-8B) and JAM-A ratio was compared with MHCII 
and CD11c ratios. 
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Figure 4-8. JAM-A localisation on BMDC surface during CD4+ T cells priming 
CD4+ T cells from OTII mice were cultured with OVA peptide (pOVA)-pre-pulsed BMDCs for 24 hours 
and analysed by confocal microscopy for the expression of CD11c, MHCII and JAM-A. (A) 
Representative confocal image stacks of CD4+ T cell recorded in the green channel (CD4, mAb 
GK1.5) in contact with a BMDC identified by its expression of CD11c (mAb N418) recorded in the 
red channel and MHCII (mAb HL3) recorded in the blue channel and JAM-A (right side) (mAb H202-
106) or its isotype control (left side) recorded in the yellow channel. (B) Quantification of the ratio 
between the BMDC’s membrane median fluorescence intensity (MFI) from the inside and the 
outside of the site of interaction (SI) and comparison between JAM-A and MHCII or CD11c. Results 
are expressed as mean ± SD of eight doublets with translocation of MHCII to the SI from one 
experiment. Statistical differences were determined using a one-way ANOVA. ns = non-significant, 
****p ≤ 0.0001. 
 
 
107 
JAM-A was detected on the surface of BMDCs and not on the surface of CD4+ T 
cells that were interacting with these cells, supporting the findings from the 
previous flow cytometry-based experiments. The analysis of the MFI ratio between 
the inside and outside of the SI showed a higher concentration of MHCII inside the 
SI in comparison with CD11c, demonstrating MHCII translocation during antigen 
presentation. This analysis also showed that JAM-A ratio was near 1, a similar rate 
as CD11c. Although there is no apparent recruitment of JAM-A into the SI, this 
molecule is still present on the surface of BMDCs in the SI during antigen 
presentation. 
4.2.6 Anti-JAM-A mAb Treatment During Antigen Presentation in 
vitro Attenuates CD4+ T Cell Activation and Proliferation 
To allow margin for an increase in T cell activation and proliferation possibly 
caused by anti-JAM-A treatment to be seen, JAM-A disruption experiments were 
performed in optimal and suboptimal antigen stimulation conditions. To identify 
appropriate suboptimal and optimal concentrations of antigen and T cells-DCs 
ratio, pOVA and BMDC titration was performed using a co-culture assay, as 
described in Chapter 2 (section 2.2.4). The percentage of CD44high (Figure 4-9A), 
representing antigen-experienced cells, divided (Figure 4-9B) and four times 
divided (Figure 4-9C) CD4+ T cells, based on CFSE fluorescence intensities, were 
taken into consideration for the definition of appropriate cell ratios and 
suboptimal/optimal concentrations of antigen. 
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Figure 4-9. Optimisation of cell ratios and antigen concentration on CD4+ T cell activation and 
proliferation in BMDC-T cell co-cultures 
CFSE-labelled CD4+ T cells from OTII mice were cultured with BMDCs pre-pulsed with different 
concentrations of OVA peptide (pOVA) and at different cells’ ratio for 72 hours and analysed by 
flow cytometry for CD44 expression and CFSE fluorescence intensity. (A) Quantification of CD44high 
cells from the CD4+ populations. (B) Quantification of cells that have divided based on the CFSE 
fluorescence intensity from the CD4+ populations. (C) Quantification of cells that have divided 
four times from the CD4+ populations. Data are from an experiment performed in triplicates. 
Increasing doses of antigen were able to activate CD4+ T cells in increasing 
proportions, and co-cultures that had more DCs seemed to activate more T cells. 
This was also observed when analysing cells that have divided, with exception of 
the highest concentration of antigen (5 µg/mL) at 1:5 BMDC:T ratio that had lower 
division rate in comparison with the same concentration of antigen but different 
cell ratios and to 1 µg/mL at 1:5 ratio. The analysis of four times divided cells 
showed that cultures that had less BMDCs had more cell proliferation when higher 
concentrations of antigen were used (1 and 5 µg/mL). To maintain the same 
conditions to experiments previously performed in our laboratory, the cell ratio 
chosen to be used for the next experiments was 1:10. The concentration of antigen 
chosen to reflect optimal conditions was 1 µg/mL, as it was able to achieve near 
maximum T cell activation and maximum T cell proliferation. For suboptimal 
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conditions, 0.05 µg/mL was chosen, as this concentration was able to induce 
roughly half of CD4+ T cells to activate and divide. For simplification, the optimal 
concentration of antigen is referred as OVAhigh in this thesis, whereas the 
suboptimal concentration is referred as OVAlow. 
To identify reagents to block JAM-A function, I analysed the reagents used in the 
literature. The anti-JAM-A mAb BV11 has been extensively used for both for in 
vitro325,326,330 and in vivo224,325,352–356 studies in mice. Recently, a novel antagonistic 
JAM-A peptide called peptide 4D capable of blocking JAM-A homophilic 
interactions has been developed333. This peptide was able to inhibit platelet 
adhesion to cytokine-inflamed endothelial cells and was also tested in in vivo 
studies357,358, suggesting it could also be a promising reagent to be used for the 
experiments in this thesis. For in vitro work addressed in this chapter, I decided 
to work with the BV11 mAb clone. 
After showing that DCs and BMDCs express JAM-A and CD4+ T cells express a 
potential ligand for JAM-A, I performed in vitro assays to test if blockade of JAM-
A pathways during priming could promote changes in the outcome of CD4+ T cells. 
BMDCs pre-pulsed with optimal and suboptimal concentrations of pOVA were 
cultured with CFSE-labelled OTII naïve CD4+ T cells in the presence of anti-JAM-A 
mAb BV11 or its isotype control (purified rat IgG2bκ mAb RTK4530) for 72 hours 
and analysed by flow cytometry. Cells that have divided were identified using 
CFSE fluorescence intensity, quantified and compared between groups that have 
received the same concentration of antigen (Figure 4-10A). To assess T cell 
activation, CD44high cells were gated, quantified and also compared between 
groups that were stimulated under the same conditions (Figure 4-10B). 
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Figure 4-10. JAM-A blockade in vitro attenuates CD4+ T cell activation and proliferation 
CFSE-labelled CD4+ T cells from OTII mice were cultured with bone marrow-derived dendritic cells 
pre-pulsed with suboptimal (OVAlow) or optimal (OVAhigh) concentrations of OVA peptide (pOVA) in 
the presence of anti-JAM-A mAb (BV11) or its isotype control for 72 hours and analysed by flow 
cytometry for CD44 expression and CFSE fluorescence intensity. (A) Representative histograms of 
CFSE fluorescence intensity on CD4+ cells (left side) and quantification of CD4+ T cells that have 
divided based on the gating of CFSE fluorescence intensity (right side). (B) Representative 
histograms of CD44 fluorescence intensity on CD4+ cells (left side) and quantification of CD4+ T 
cells that are CD44high (right side). Results are expressed as mean ± SD of hexaplicate cultures from 
three independent experiments. Statistical differences between groups that received the same 
concentration of antigen were determined using a two-way ANOVA. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 
0.001. 
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CD4+ T cells under stimulation with the optimal concentration of antigen achieved 
nearly full activation and cells stimulated with the suboptimal concentration of 
pOVA were less activated, whereas T cells in groups that did not receive antigen 
did not upregulate CD44. Isotype-treated and untreated groups showed similar 
levels of T cell activation and proliferation. Treatment with anti-JAM-A mAb BV11 
during antigen presentation attenuated CD4+ T cell activation and proliferation 
under both concentrations of antigens in comparison with the isotype control 
groups as well as to the untreated groups. Considering that these effects were 
small and might not be biologically relevant, other approaches to evaluate if JAM-
A blockade impacts CD4+ T cell-DC interactions were performed. Besides T cell 
activation and proliferation, T cell differentiation is key for successful 
manipulation of T-cell responses, as different subsets secrete distinct cytokines 
that play specific roles in several pathological conditions359. Therefore, I next 
analysed if JAM-A plays a role on CD4+ T cell differentiation. 
4.2.7 Anti-JAM-A mAb Treatment During Antigen Presentation in 
vitro Impacts T-bet expression and IL-17 secretion by CD4+ 
T Cells 
Cell culture supernatants from the previous experiment were analysed by ELISA. 
The presence of cytokines that could suggest CD4+ T cell differentiation towards 
specific subsets was investigated. IFN-γ (Figure 4-11A), IL-4 (not shown), IL-10 
(Figure 4-11B) and IL-17 (Figure 4-11C) that are secreted in high levels by Th1, 
Th2, Treg and Th17 cells74, respectively, were analysed. The concentrations were 
quantified and compared between groups that were stimulated under the same 
concentrations of pOVA. 
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Figure 4-11. JAM-A blockade in vitro increases IL-17 secretion by CD4+ T cells 
CD4+ T cells from OTII mice were cultured with bone marrow-derived dendritic cells pre-pulsed 
with suboptimal (OVAlow) or optimal (OVAhigh) concentrations of OVA peptide (pOVA) in the 
presence of anti-JAM-A mAb (BV11) or its isotype control for 72 hours and the supernatants’ co-
cultures were analysed by ELISA for the presence of different cytokines. (A) Quantification of IFN-
γ, (B) IL-10 and (C) IL-17 concentrations with comparisons between groups that received the same 
concentration of antigen. Results are expressed as mean ± SD of hexaplicate cultures from three 
independent experiments. Statistical differences were determined using a two-way ANOVA. **p ≤ 
0.01, ***p ≤ 0.001. 
In both concentrations of antigen and for all cytokines, levels from untreated and 
isotype-treated groups were similar. IL-4 was not detected in the co-culture 
supernatants when utilising the commercial kit that has a sensitivity of 2 pg/mL. 
IFN-γ and IL-17 were detected in higher concentrations in the supernatants from 
cultures that received antigen in comparison with the ones from unstimulated 
cells. No differences in IFN-γ and IL-10 secretion were found between groups that 
received the same concentration of antigen. Although no differences in IL-17 
concentrations were found between groups under the suboptimal condition, anti-
JAM-A mAb BV11 treatment increased the secretion of IL-17 under the optimal 
concentration of pOVA in comparison with both isotype-treated and untreated 
groups. These findings suggested that JAM-A blockade could promote CD4+ T cell 
differentiation towards a Th17 subset. 
To further analyse JAM-A blockade effects on CD4+ T cell differentiation, I 
cultured OTII CD4+ T cells with BMDCs pulsed with suboptimal and optimal 
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concentrations of pOVA treated with anti-JAM-A mAb BV11 or its isotype control 
for 72 hours and analysed the expression of transcription factors that regulate the 
fate of T cell subsets. After being harvested, cells were stained for CD4, CD44 (not 
shown) and the transcription factors that are characteristic of Th17, Th1 and Treg 
cells: RORγt (Figure 4-12A), T-bet (Figure 4-12B) and FoxP3 (Figure 4-12C), 
respectively. The frequencies of RORγt+, T-bet+ and FoxP3+ cells within the CD4+ 
population were quantified and compared between groups treated with anti-JAM 
and groups treated with the isotype control or untreated groups. 
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Figure 4-12. JAM-A blockade in vitro decreases T-bet expression in CD4+ T cells 
CD4+ T cells from OTII mice were cultured with bone marrow-derived dendritic cells pre-pulsed 
with suboptimal (OVAlow) or optimal (OVAhigh) concentrations of OVA peptide (pOVA) in the 
presence of anti-JAM-A mAb (BV11) or its isotype control for 72 hours and analysed by flow 
cytometry for the expression of different transcription factors. (A) Representative dot plots of 
RORγt, (B) T-bet and (C) FoxP3 intracellular expression on CD4+ T cells (left side) and 
quantification of cells with specific staining of the transcription factors based on the fluorescence 
emitted by its matched isotype controls (right side). Comparisons were made within groups with 
the same concentration of antigen between anti-JAM-A treated group and untreated or isotype-
treated groups. Results are expressed as mean ± SD of an experiment performed in hexaplicates. 
Statistical differences were determined using a two-way ANOVA. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. 
Analysis of the CD44 expression showed that antigen stimulated CD4+ T cells were 
successfully activated at similar levels as previous experiments, whereas cells that 
did not receive antigen continued to be naïve. This was reflected in a higher 
proportion of RORγt+ and T-bet+, but not FoxP3+ cells, in groups that received 
antigen in comparison with the unstimulated groups. Both treatments with isotype 
and anti-JAM-A antibodies decreased the proportion of CD4+ RORγt+ cells in 
comparison with untreated groups in both suboptimal and optimal conditions. 
However, anti-JAM-A mAb BV11 treatment increased the proportion of CD4+ 
RORγt+ cells in comparison with isotype-treated groups in both concentrations of 
antigen. Although isotype controls are antibodies against irrelevant antigen, they 
can still engage Fc receptors present on the surface of activated CD4+ T cells that 
participate in the differentiation of these cells into effector cell populations360, 
which may explain the isotype effects found in my assay. Anti-JAM-A treatment 
decreased the proportion of T-bet expressing CD4+ T cells in comparison with both 
isotype-treated and untreated groups under both suboptimal and optimal 
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conditions. Under optimal conditions the level of CD4+ FoxP3+ T cells was similar 
among groups. Under suboptimal conditions, anti-JAM-A treatment decreased the 
proportion of CD4+ FoxP3+ T cells in comparison with the untreated group but 
increased its proportion in comparison with the isotype control group. It was also 
possible to notice that the isotype treatment affected the proportion of FoxP3+ 
cells in comparison with the untreated group. These results suggest that disruption 
of JAM-A pathways may play a role in Th1 differentiation by participating in 
upregulation of T-bet expression. 
Since anti-JAM-A treatment was not able to affect IFN-γ secretion, detected in 
the culture supernatants, but decreased T-bet intracellular expression in CD4+ T 
cells, I decided to analyse if antigen-stimulated T cells produce more IFN-γ when 
treated with anti-JAM-A during priming. CD4+ T cells were again cultured with 
BMDCs carrying different amounts of antigen and treated with anti-JAM-A mAb 
BV11 or its isotype control for 72 hours. Cells were then harvested and stained for 
detection of surface CD4 and intracellular IFN-γ (Figure 4-13A). Frequencies of 
CD4+ IFN-γ+ T cells (Figure 4-13B) and the MFI from the IFN-γ+ populations (Figure 
4-13C) were quantified and compared between anti-JAM-A-treated groups and 
isotype-treated or untreated groups. 
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Figure 4-13. The impact of JAM-A blockade in vitro in CD4+ T cell IFN-γ production 
CD4+ T cells from OTII mice were cultured with bone marrow-derived dendritic cells pre-pulsed 
with suboptimal (OVAlow) or optimal (OVAhigh) concentrations of OVA peptide (pOVA) in the 
presence of anti-JAM-A mAb (BV11) or its isotype control for 72 hours and analysed by flow 
cytometry for IFN-γ intracellular expression. (A) Representative dot plots of IFN-γ expression on 
CD4+ cells gated according to its isotype control. (B) Quantification of the proportion of CD4+ T 
cells expressing IFN-γ. (C) Quantification of the IFN-γ median fluorescence intensity (MFI) from 
the IFN-γ+ population. Results are expressed as mean ± SD of hexaplicate cultures from three 
independent experiments. Statistical differences between anti-JAM-A-treated group and other 
groups that received the same concentration of antigen were determined using a two-way ANOVA. 
*p ≤ 0.05, **p ≤ 0.01, ****p ≤ 0.0001. 
The proportion of IFN-γ+ cells were higher with increasing concentrations of 
antigen. Under suboptimal conditions, the proportion of IFN-γ+ CD4+ T cells were 
similar between groups, but anti-JAM-A increased the MFI of these IFN-γ+ 
populations in comparison with isotype-treated cells. Under optimal conditions, 
the proportion of IFN-γ+ CD4+ T cells was higher in the group treated with anti-
JAM-A in comparison with the untreated group but not to the isotype-treated 
group. In this matter, the isotype control also increased the proportion of IFN-γ+ 
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events. However, the IFN-γ MFI from cells treated with anti-JAM-A mAb was higher 
than the ones from both untreated and isotype-treated groups under optimal 
conditions. 
4.2.8 Anti-JAM-A mAb Treatment During Antigen Presentation in 
vitro Impacts DC-T cell Cluster Formation 
From the fact that JAM-A is a molecule that promotes cell-cell adhesion325, I 
hypothesised that JAM-A blockade could reduce DCs and T cell interactions. I first 
analysed the capacity of cells to form clusters under JAM-A blockade during 
antigen presentation. For that, OTII CD4+ T cells were cultured with BMDCs pulsed 
with different concentrations of pOVA and under treatment of anti-JAM-A mAb 
BV11 or its isotype control. A preliminary experiment was done analysing cells 24 
hours after the co-cultures set-up, but there were no significant differences 
between the negative (unstimulated) and positive control (OVAlow and OVAhigh) 
groups (not shown). Because cells responded better after 48 hours of the co-
culture set-up, evidenced by the significant difference of number and total area 
of clusters from negative and positive control groups, I used this time point for 
the experiment in this section. Live cells were then analysed with the brightfield 
channel of a widefield microscope. Clusters that were defined as cell aggregates 
with at least 2000 µm2 were identified (Figure 4-14A) and its numbers (Figure 4-
14B), mean areas (Figure 4-14C), total area (Figure 4-14D) were quantified as 
described in Chapter 2 (section 2.6.4). These parameters from anti-JAM-A-treated 
groups were compared to the ones from isotype-treated and untreated groups that 
were stimulated under the same condition of antigen. The frequency distribution 
of clusters from anti-JAM-A- and isotype-treated groups that were submitted to a 
high concentration of antigen was also analysed (Figure 4-14E). 
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Figure 4-14. JAM-A blockade in vitro affects BMDC-T cell cluster formation 
CD4+ T cells from OTII mice were cultured with bone marrow-derived dendritic cells pre-pulsed 
with suboptimal (OVAlow) or optimal (OVAhigh) concentrations of OVA peptide (pOVA) in the 
presence of anti-JAM-A mAb (BV11) or its isotype control for 48 hours and analysed by widefield 
microscopy. (A) Representative images of whole wells containing cell cultures showing elliptical 
selections of cell aggregates with at least 2000 µm2 in yellow. (B) Quantification of number, (C) 
mean area and (D) total area of clusters with comparisons within groups with the same 
concentration of antigen between anti-JAM-A treated group and untreated or isotype-treated 
groups. (E) Frequency distribution of the clusters area under optimal concentration of antigen and 
treated with anti-JAM-A mAb or its isotype control. Results are expressed as mean ± SD of an 
experiment performed in hexaplicates. Statistical differences were determined using a two-way 
ANOVA or an unpaired Student’s t test. *p ≤ 0.05, **p ≤ 0.01, *** ≤ 0.001, **** ≤ 0.0001. 
Cell clustering was higher in groups that were stimulated with antigen than in 
unstimulated groups. The isotype control increased the total number of clusters 
in both concentrations of antigen and the total area of clusters under suboptimal 
activation conditions. However, under suboptimal conditions, groups treated with 
anti-JAM-A had similar number and total area of clusters in comparison with 
untreated groups, but lower number and total area of clusters in comparison with 
isotype-treated groups. No differences were found between groups on the mean 
area of clusters under the suboptimal condition. Under optimal conditions, groups 
treated with anti-JAM-A treatment had similar number but higher area of clusters 
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in comparison with untreated groups but a lower number and similar total area of 
clusters in comparison with isotype-treated groups. Anti-JAM-A treated cultures 
had a higher mean area of clusters in comparison with both untreated and isotype-
treated groups under optimal conditions. The frequency distribution analysis 
showed that anti-JAM-A treatment decreased the number of clusters smaller than 
4000 µm2 in comparison with the isotype-treated group. These effects in cluster 
formation in comparison between anti-JAM-A- and isotype-treated cells supported 
the hypothesis that specific disruption of JAM-A pathways in the context of the 
presence of IgG (e.g. recruitment of Fc receptors) could be affecting T cell-DC 
interactions. I then analysed the contact area of these cell types under priming 
after JAM-A blockade. 
4.2.9 Anti-JAM-A mAb Treatment During Antigen Presentation in 
vitro Does Not Affect DC-T Cell Area of Interaction 
To evaluate if disruption of JAM-A pathways during T cell priming affects the area 
of interaction between T cells and DCs, CFSE-labelled OTII CD4+ T cells were 
cultured with CMTPX-labelled BMDCs pulsed with optimal and suboptimal 
concentrations of antigens. Cultures were treated with anti-JAM-A mAb BV11 or 
its isotype control. Live cells were analysed 24 hours later using fluorescence 
widefield microscopy for detection of CFSE-labelled T cells in the green channel 
and CMTPX-labelled BMDCs in the red channel (Figure 4-15A). To evaluate the co-
localization between green and red channels, two indexes were used: the 
Pearson’s correlation index (PCC) (Figure 4-15B) that only takes into consideration 
the proportion of the image that has overlap between channels and the Manders’ 
overlap coefficient (MOC) (Figure 4-15C) that takes into consideration the 
proportion of the area in which one colour is present but the other is not361. In 
practical terms, the MOC would consider the proportion of T cells that are not in 
contact with DCs, whereas the PCC would only consider the area of the DC that is 
in contact with T cells. This time point was chosen due to the fact that there is 
virtually no T cell proliferation by this point, therefore results on the co-
localization analysis would reflect cell interaction only. Comparisons of PCC e MOC 
indexes were done between groups that received the same concentration of 
antigen. 
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Figure 4-15. JAM-A blockade in vitro does not affect BMDC-T cell interactions 
CFSE-labelled CD4+ T cells from OTII mice were cultured with CMTPX-labelled bone marrow-
derived dendritic cells (BMDC) pre-pulsed with suboptimal (OVAlow) or optimal (OVAhigh) 
concentrations of OVA peptide (pOVA) in the presence of anti-JAM-A mAb (BV11) or its isotype 
control for 24 hours and analysed by widefield fluorescence microscopy. (A) Representative images 
of regions containing the highest concentration of cells showing CD4+ T cells in the green channel 
and BMDCs in the red channel. (B) Colocalization analysis between the green and the red channels 
showing the Pearson’s correlation index and (C) the Manders’ overlap coefficient. Results are 
expressed as mean ± SD of hexaplicate cultures from two independent experiments. Statistical 
differences between groups that received the same concentration of antigen were determined 
using a two-way ANOVA. p = non-significant for all comparisons. 
Both PCC and MOC indexes were higher on groups that were stimulated with 
antigen in comparison with unstimulated groups, suggesting increased physical 
interaction between T cells and BMDCs when antigen was present in the system. 
No significant differences were found on both co-localisation indices when 
comparing groups that were stimulated under the same condition. 
4.3 Discussion 
The analysis of JAM-A expression in immune cells in vivo revealed that JAM-A is 
expressed on a large proportion of LN cDC2, a subtype of DCs that plays a dominant 
role in antigen presentation6,32. A considerable proportion of other subtypes of 
DCs express JAM-A, such as LN cDC1 and splenic cDC2 and cDC1. The higher 
expression on cDC2 populations in comparison with cDC1 is also observed in other 
lymphoid organs besides LNs and spleen, such as Peyer’s patches362. Low 
proportions of both splenic and LN pDCs are JAM-A+. This finding is supported by 
a study that showed expression of JAM-A in a small proportion of murine pDCs 
from spleen, mesenteric LN, peripheral LN and blood346. Although a high 
proportion of some T cell lines can express JAM-A, such as Jurkat T cells330, I 
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showed that only a small proportion of naïve CD4+ T cells from spleen, LNs 
(inguinal, brachial, superficial cervical, mesenteric) and Peyer’s patches of 
C57BL/6 mice express JAM-A. These findings suggest that JAM-A homophilic 
binding is unlikely to happen during the first encounter of antigen by the T cells. 
In vitro experiments showed that CD4+ T cells express low or undetectable levels 
of JAM-A when stimulated with anti-CD3 and anti-CD28 agonistic antibodies for 3 
days. However, a higher proportion of CD4+ T cells stimulated with antigen by 
BMDCs in vitro for 48 and 72, but not 24 hours, expressed JAM-A in comparison 
with unstimulated T cells. To address if this upregulation could be driven by the 
cytokines that were released by activated T cells or BMDCs during or after priming, 
I used an in vitro system in which both naïve and antigen specific activated CD4+ 
T cells were present in the same well for comparison. I analysed the expression of 
JAM-A on cultures containing both OTII and WT isolated CD4+ T cells and antigen-
pulsed BMDCs. After 72 hours, a higher percentage of activated OTII CD4+ T cells 
expressed JAM-A in comparison with WT CD4+ T cells that were present in the 
same wells. Altogether, these findings suggest that JAM-A upregulation on 
activated CD4+ T cells is dependent on contact dependent signals from the APC 
during antigen presentation other than CD28-CD80/CD86, and that JAM-A may play 
a role on CD4+ T cell effector functions. 
Although only a small population of naïve CD4+ T cells express JAM-A, most of 
them express a potential ligand for JAM-A. In vivo naïve CD4+ T cells express high 
levels of integrin CD11a, the alpha chain of LFA1, a known ligand for JAM-A330. 
Furthermore, upon activation, CD4+ T cells upregulate CD11a expression. Integrins 
such as LFA1 exist in an inactivated state on the cell surface and, upon stimulus, 
these molecules undergo a conformational change that enables them to interact 
with extracellular ligands363. However, although some mAb clones can specifically 
detect the active conformation of LFA1364, the mAb clone that was used in my in 
vitro experiments to detect CD11a (M17/A) does not distinguish between 
activated and resting forms of LFA1. Nevertheless, the expression of active LFA1 
on both naïve and memory CD4+ T cells is described in the literature365. While 
further JAM-A ligands were not investigated in this present Chapter, T cells also 
express other potential ligands for JAM-A. Although JAM-B is not expressed by 
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leukocytes366, JAM-C is expressed by naïve and mitogen-activated human T cells367 
and CD9 is expressed by naïve murine and human CD4+ T cells368–370. 
After showing that BMDCs express JAM-A and in higher proportions on mature cells, 
supporting findings from the literature326, I analysed the location of JAM-A on the 
SI with the T cell. Although JAM-A was not concentrated in the SI as has been 
observed for MHCII, the molecule was present in the SI during antigen presentation, 
suggesting it could be available for binding with potential ligands from the T cells 
surface. To analyse if JAM-A could play a role in determining T cell outcomes 
during priming, I cultured antigen-pulsed BMDCs with OTII naïve CD4+ T cells and 
analysed their activation status as well as division rate. Treatment with anti-JAM-
A mAb BV11 attenuated CD4+ T cell activation and proliferation both on 
suboptimal and on optimal conditions of antigen, suggesting that JAM-A may play 
a role in T cell priming. 
To analyse if JAM-A plays a role on CD4+ T cell differentiation, I first analysed 
cytokines from the supernatant of co-cultures from the previous experiment to 
identify cytokines that are mainly produced by Th1 (IFN-γ), Th2 (IL-4), Treg (IL-
10) and Th17 (IL-17) cells. Although IL-4 was not detected, the levels of IFN-γ and 
IL-10 were similar across groups that were stimulated with the same 
concentrations of antigen. This is supported by a study that showed no differences 
on IFN-γ concentrations from the supernatant of OVA-primed OTII CD4+ T cells by 
BMDCs from JAM-A KO mice in vitro 5 days after co-culture set-up in comparison 
with WT BMDCs347. However, JAM-A blockade increased the secretion of IL-17 
under the optimal concentration of antigen, suggesting an increased 
differentiation of Th17 cells. To address this question, I performed the same in 
vitro experiment but with focus on looking for transcription factors that control T 
cell differentiation. As expected, JAM-A blockade promoted a small but significant 
increase in the proportion of CD4+ T cells expressing RORγt, the master 
transcription factor of Th17 cells74, supporting the finding of increased IL-17 
secretion detected in the culture supernatants. However, this effect was only 
found in comparison to isotype-treated cells, as treatment with this IgG against 
irrelevant antigen decreased the percentage of RORγt+ cells in comparison to 
untreated cells. Interestingly, previous literature describes a 4.5-fold increase on 
absolute number of CD4+ IL-17+ T cells in the colonic lamina propria of JAM-A-
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deficient mice in comparison with WT mice371. In addition, I also demonstrated a 
small increase in the proportion of CD4+ T cells expressing FoxP3, the main 
transcription factor of Treg cells74, after JAM-A blockade under suboptimal 
conditions. Again, this effect was only found in comparison to isotype-treated cells, 
ad not to untreated cells. Treatment with the isotype control antibody decreased 
the proportion of FoxP3+ cells. In support to the increased proportion of FoxP3+ 
cells in anti-JAM-A groups in comparison to isotype-treated groups, previous 
literature showed a small but significant increase on the absolute number of 
FoxP3+ T cells in the lamina propria of JAM-A-deficient mice in comparison with 
WT mice371, possibly suggesting that JAM-A blockade could influence pathways 
that supress Treg differentiation. 
Induction of CD4+ T cell differentiation towards specific Th subsets is usually 
followed by inhibition of other subsets. T-bet, for example, is described to 
interact with promoters of the RORC gene, responsible for encoding RORγt, and 
supress Th17 differentiation76. As such, the expression of T-bet on T cells after 
JAM-A blockade during priming was also analysed. JAM-A blockade decreased the 
proportion of T-bet expressing CD4+ T cells, suggesting that recruitment of JAM-
A intercellular ligation is required for optimal Th1 differentiation. 
In contrast to the observed decrease in the proportion of T-bet-expressing cells, 
no differences in IFN-γ secretion measured from the co-culture supernatants 
between the anti-JAM-A- and the isotype-treated group were found. I further 
evaluated the capacity of these T cells to produce IFN-γ by intracellular 
measurement. Although the proportion of CD4+ IFN-γ+ T cells was not changed 
with treatment of anti-JAM-A, this population of IFN-γ producers showed a small 
but significant increased capacity to produce IFN-γ. However, in order to compare 
the results from the experiment that detected IFN-γ from the supernatant with 
the experiment that detected intracellular IFN-γ, it is important to consider the 
technicalities of the two different methods that were utilised. While ELISA has a 
high technical variation, evidenced by a higher SD that constantly follows this kind 
of experiment, the detection of intracellular cytokines is a more precise method. 
However, after being harvested, these cells were re-stimulated in vitro with PMA, 
a protein kinase C activator, and ionomycin, a calcium ionophore that increases 
intracellular calcium concentration, to encourage their cytokine production that 
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are kept in intracellular compartments driven by the treatment of a protein 
transport inhibitor (Brefeldin A). Although this method is widely used for the 
detection of the intracellular cytokine by flow cytometry, these cells are now re-
stimulated, and therefore, the effects caused by the initial treatment with anti-
JAM-A could be lost or diminished. 
As JAM-A is an adhesion molecule that provides firm attachment to cells325, I 
hypothesised that the effects seen on CD4+ T cell outcome after JAM-A blockade 
during antigen presentation could be driven by an impaired cell-cell interaction. 
First, I analysed the capacity of T cells and DCs to form clusters under treatment 
with anti-JAM-A mAb BV11. This analysis showed that, although the isotype control 
mAb increased the number and total area of clusters under suboptimal conditions, 
opposing effects were found when comparing the isotype-treated group with the 
anti-JAM-A-treated group. Under suboptimal conditions, anti-JAM-A treatment 
was able to decrease the number of clusters and its total area in comparison with 
cells treated with its isotype control mAb. Under optimal conditions, JAM-A 
blockade also decreased the number of clusters, but because the area of the 
clusters was in general larger, the total area occupied by them was unchanged in 
comparison with the isotype-treated group. I believe that the physical disruption 
caused by specific disruption of JAM-A pathways in an environment with abundant 
IgG could be related to a delay on cell interactions caused by JAM-A intercellular 
ligation blockade. After priming T cells, DCs have to detach from T cells to prime 
other cells or to play other immunomodulatory roles. Therefore, blockade of an 
adhesion molecule such as JAM-A could be modifying parameters as for example, 
surface or time of these intercellular interactions, consequently impairing this 
process and possibly delaying it. However, these live cells were analysed 48 hours 
after priming, when T cell proliferation already occurs. Therefore, the analysis of 
these clusters doesn’t reflect just the physical interaction between the cell types, 
but also takes into consideration the number of T cells that are present in the 
system. To tease apart the bias of proliferation from the analysis of T cells-DC 
interactions, I measured cell interactions 24 hours after priming with 
fluorescence-dyed cells and analysed the overlap between both channels relative 
to each cell type. Both co-localization indexes, PCC and MOC were unchanged 
with treatment of anti-JAM-A mAb BV11. I considered employing confocal 
microscopy to analyse the area of contact with a higher precision. However, these 
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experiments analyse only static images of a specific moment in the co-culture, 
whereas JAM-A blockade could be possibly affecting the time of interaction 
between the cells or perhaps the quality of the crosstalk, parameters that would 
be difficult to measure with the instruments that are available in the laboratory. 
As blockade of JAM-A during CD4+ T cell priming impacted in T cell activation and 
proliferation, I therefore identified JAM-A as a regulator of CD4+ T cell activation. 
Although effects of JAM-A blockade only attenuated but not inhibited T cell 
proliferation and activation, this molecule could play an important role on CD4+ 
T cell activation in vivo. In addition, JAM-A seems to drive CD4+ T cell 
differentiation towards Th1, a subset that is linked to the development of 
autoimmunity76. As having an attenuation effect in T cell activation, its blockade 
could be possibly useful as a therapeutic for inflammatory diseases, and its 
promotion could be studied as treatment targeting cancer cells. Before evaluating 
the potential of JAM-A as a therapeutic target in a disease model, I analysed the 
effects of JAM-A blockade on CD4+ T cell outcomes during antigen presentation in 
the complexity of the murine in vivo environment, that is the subject of the next 
Chapter. 
  
 
 
129 
Chapter 5 JAM-A Contributes to CD4+ T cell 
Effector Functions During Priming in vivo 
5.1 Introduction 
In the last Chapter, I demonstrated that blockade of JAM-A affects DC-T cell 
cluster formation, T cell activation, proliferation, differentiation and cytokine 
secretion. In addition to DCs and other leukocytes, JAM-A is expressed by 
endothelial and epithelial cells in intercellular tight junctions325. Moreover, TNFα- 
and IFNγ-stimulated endothelial cells redistribute JAM-A from these intercellular 
junctions to the apical surface, increasing its support for leukocyte adhesion330,372. 
Therefore, studies on disruption of JAM-A pathways aiming to investigate the 
interactions between leukocytes in vivo must also consider the effect of disrupting 
leukocyte-endothelial cell interactions. 
A few studies have assessed the effects of JAM-A blockade in vivo in the 
interactions between leukocytes and endothelial cells. Treatment with anti-JAM-
A mAb BV11 decreased leukocyte transendothelial migration through cremaster 
venules induced by IL-1β, but not by the chemoattractants leukotriene B4 (LTB4) 
or platelet-activating factor (PAF)354. The same response pattern was observed in 
JAM-A deficient mice in comparison with WT mice. This decrease in leukocyte 
transendothelial migration through venous tissues was found to be mediated by 
JAM-A expressed by endothelial cells, but not by leukocytes. On the other hand, 
an increased granulocyte infiltration was found in the colonic mucosa of JAM-A KO 
mice in comparison with WT animals373. More recently, mice with selective loss of 
JAM-A in myelomonocytic cells, cells that can differentiate into monocytes, 
macrophages and CD8+ or CD8- DCs374, were used to investigate JAM-A role on 
JAM-A-expressing leukocytes during inflammation. These mice showed no 
difference in neutrophil recruitment into the peritoneum and macrophage 
chemokine production in response to LPS and zymosan, in comparison with control 
mice375. However, these parameters were significantly reduced in JAM-A-/- mice 
stimulated by these inflammatory mediators. On the other hand, mice with 
selective loss of JAM-A in intestinal epithelial cells resulted in increased intestinal 
permeability, reduced peritoneal neutrophils migration and macrophage 
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chemokine production. These findings suggest that JAM-A expression in the 
epithelium is fundamental for JAM-A role in myeloid cells-mediated inflammation. 
DCs migrate from inflamed tissues to specialized lymphoid organs, where antigen 
presentation and activation of naïve T cells occurs6. BMDCs from JAM-A deficient 
mice showed increased migration from FITC-painted skin to the draining LN326. In 
addition, a study showed higher transmigration of JAM-A-expressing BMDCs 
through layers of JAM-A-/- endothelial cells in comparison with endothelial cells 
from JAM-A-/- mice reconstituted with full-length JAM-A cDNA347. These studies 
suggest that disruption of JAM-A pathways could affect endogenous DC migration 
and therefore impact the amount of antigen presented in the LN. In this chapter, 
I aimed to investigate whether JAM-A blockade affects CD4+ T cell activation, 
proliferation and differentiation in vivo by employing an adoptive transfer model. 
5.2 Results 
5.2.1 JAM-A is Expressed on T Cell and Medullary Areas of Mouse 
Lymph Nodes (LN) 
To analyse some of the factors that can influence DC entry in the LN under JAM-A 
blockade during CD4+ T cell priming in vivo, the expression of JAM-A was analysed 
on histological sections of murine LNs. Mesenteric LNs were harvested and cryo- 
sections stained for the identification of the markers B220, lymphatic vessel 
endothelial receptor 1 (LYVE1) and JAM-A (Figure 5-1A). Regions suggesting B cell 
follicles were identified by expression of B220, a B cell lineage marker. LYVE1 is 
found primarily on lymphatic endothelial cells376 and was used to detect the 
medullary region of the LN. The MFI across a longitudinal region of the section 
covering all areas of the section was also analysed (Figure 5-1B). 
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Figure 5-1. JAM-A localization in a murine lymph node (LN) 
Sections from a naïve mesenteric LN from C57BL/6 mice were analysed by widefield fluorescence 
microscopy for the expression of JAM-A, B220 and LYVE1. (A) Representative image of a section 
through a LN indicating B cell follicles (F), T cell region (T) and the medulla (M). Regions were 
identified with B220 (mAb RA3-6B2) in red, LYVE1 (mAb ALY7) in green and JAM-A (mAb H202-106) 
in grey. (B) Histograms of B220, LYVE1 and JAM-A mean fluorescence intensity (MFI) from a 
longitudinal 8 µm section of the LN that covered all three regions. Isotype controls were used to 
certify specific binding. Data are representative of three independent experiments.  
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LYVE1 was highly expressed in the LN medulla, as well as a smaller cortical region 
that can possibly be the local of an insertion of an afferent lymphatic vessel. The 
area in which B220 and LYVE1 were less expressed was identified as the T cell 
area of the LN. Analysis as described in chapter 2.6.4 showed that JAM-A is 
expressed in the T cell area of the LN, where DCs contact T cells to present antigen. 
However, JAM-A is highly expressed in external areas of the LN, and in the 
medullary area, suggesting that JAM-A blockade in vivo could influence the 
interactions between leukocytes and endothelial cells. 
5.2.2 siRNA Targeting F11R Gene Has Limited Impact on JAM-A 
Expression on BMDCs 
JAM-A blockade in vivo could not only potentially affect the interactions between 
T cells and DCs, but it would also possibly disrupt leukocyte-endothelial cell 
interactions. To tease apart these effects, I tried to employ a technique that 
would influence the expression of JAM-A only on leukocytes. As JAM-A is expressed 
in high levels by DCs and BMDCs but in low levels by CD4+ T cells. BMDCs 
genetically manipulated to express low levels of JAM-A could be pulsed with 
antigen and be used to challenge mice, aiming to specifically disrupt JAM-A 
pathways during antigen presentation in vivo. For this genetic manipulation, the 
siRNA technique was used as described in detail in Chapter 2 (section 2.2.5). Cells 
were harvested 72 hours after the transfection to be analysed by flow cytometry 
for the expression of JAM-A (Figure 5-2A). CD11c was used as a DC marker to 
identify the target population. For the control group, I used siRNA targeting GFP, 
a gene responsible for encoding the GFP fluorescent protein, a molecule that is 
not present in the system. The expression of JAM-A on CD11c+ cells was then 
compared between groups (Figure 5-2B). 
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Figure 5-2. F11R siRNA minimally affects bone marrow-derived dendritic cells (BMDC) JAM-A 
expression 
Day-7 immature BMDCs were transfected with siRNA targeting the F11R gene or the GFP gene 
(control) and Lipofectamine 2000 for 72 hours and analysed by flow cytometry for the expression 
of JAM-A. (A) Representative dot plots of JAM-A expression on CD11c+ cells. (B) Quantification of 
the proportion of JAM-A+ cells and comparison between F11R siRNA and GFP siRNA groups. Results 
are expressed as mean ± SD of triplicate cultures from three independent experiments. Statistical 
differences were determined using an unpaired Student’s t test. **p ≤ 0.01. 
BMDCs transfected with siRNA targeting the F11R gene expressed statistically 
significantly lower levels of surface JAM-A. However, the small decrease suggests 
that the use of these transfected cells would possibly not be biologically relevant 
in the context of in vivo experiments. Additional attempts with changes to the 
protocol were performed aiming to further reduce the expression of JAM-A, such 
as different concentrations of cells, transfection reagent and siRNA. All changes 
in the protocol however resulted in similar effects as seen in the present 
experiment. 
5.2.3 The impact of anti-JAM-A mAb Treatment in vivo in CD4+ T 
Cell Activation and Proliferation 
As an alternative approach, we assess the effects of antibody mediated JAM-A 
blockade on CD4+ T cell responses in vivo. Although I have shown in Chapter 4 
that JAM-A blockade attenuated CD4+ T cell activation and proliferation in vitro, 
immunological components that are not present in in vitro studies, such as cell 
migration, have a role on antigen presentation in vivo. The literature reports 
increased migration of BMDCs generated from JAM-A-deficient mice from inflamed 
skin tissues to draining LNs326. As such, a possible increase on T cell activation 
and/or proliferation under conditions of JAM-A manipulation during priming in vivo 
could be expected. To allow for an increase in these parameters to be observed, 
I first performed an OVA titration to select a suboptimal antigen dose. CFSE-
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labelled naïve CD4+ T cells from OTII mice were transferred to WT mice, as 
described in Chapter 2 (section 2.3.1). The next day, mice were challenged in the 
hind footpads with different doses of OVA (0, 0.05, 0.5 and 5 µg). LPS was also 
administered to induce non-specific inflammation and stimulate DC trafficking377. 
The pLNs were harvested 72 hours after challenge and analysed by flow cytometry. 
OTII CD4+ T cells were identified by its expression of CD45.1 and CD4 (Figure 5-
3A). Cell division was assessed based on CFSE fluorescence intensity (Figure 5-3B) 
and cell activation was determined by the expression of CD44 (Figure 5-3C). 
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Figure 5-3. Determination of a suboptimal dose of antigen in the adoptive transfer model 
CFSE-labelled immune cells from lymph nodes (LN) and spleens of OTII mice were adoptively 
transferred to C57BL/6 mice that were challenged with footpad injections of LPS and different 
doses of OVA. Popliteal lymph nodes (pLN) were harvested 72 hours later and analysed by flow 
cytometry for the expression of CD44 and CFSE. (A) Gating strategy for identification of OTII CD4+ 
T cells (CD4+ CD45.1+) showing the frequency of these cells when different doses of antigen are 
used. (B) Histograms of CFSE fluorescence intensity on OTII CD4+ cells with gating on divided cells. 
(C) Representative histograms of CD44 fluorescence intensity on OTII CD4+ cells with gating on 
CD44high cells. Data are representative of an experiment performed in duplicate. 
The increasing doses of OVA promoted activation and proliferation of the 
adoptively transferred CD4+ T cells in increasing proportions, evidenced by the 
frequency of CD44high populations, the proportion of CD45.1+ CD4+ cells found in 
LNs and the CFSE fluorescence intensity of the OTIIs populations. Although 0.5 and 
5 µg have induced T cell activation in similar proportions, T cells challenged with 
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the first concentration have divided in a lower proportion. As such, I chose to 
perform the next experiment with 0.5 µg of antigen. 
To evaluate the effects of JAM-A blockade during antigen presentation on the 
induction of CD4+ T cell responses, the adoptive transfer model was performed 
again as described in Chapter 2 (section 2.3.1). CFSE-labelled, OTII naïve CD4+ T 
cells were adoptively transferred to WT mice, that were challenged in the hind 
footpads with LPS and 0.5 µg OVA. The animals were treated with anti-JAM-A mAb 
BV11 or its isotype control, as described in Chapter 2 (section 2.3.1). The pLNs 
were harvested 72 hours after challenge and had their cells counted (Figure 5-4A) 
and analysed by flow cytometry. OTII CD4+ T cells were identified by its expression 
of CD45.1 and CD4 (Figure 5-4B) and the proportion (Figure 5-4C) and absolute 
number (Figure 5-4D) of OTII T cells were calculated. To evaluate if the treatment 
promoted a change in the accumulation of adoptively transferred non-CD4 cells in 
the pLNs, the proportion (Figure 5-4E) and numbers (Figure 5-4F) of adoptively 
transferred cells that were CD4- was also analysed. 
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Figure 5-4. JAM-A blockade in vivo impact in leukocyte accumulation in the LN 
CFSE-labelled immune cells from lymph nodes (LN) and spleens of OTII mice were adoptively 
transferred to C57BL/6 mice that were challenged with footpad injections of LPS and OVA in the 
presence of anti-JAM-A mAb (BV11) or its isotype control. Popliteal lymph nodes (pLN) were 
harvested 72 hours later and analysed by flow cytometry for the expression of CD44 and CFSE. (A) 
Quantification of cell numbers by cell counting with a haemocytometer. (B) Representative dot 
plots of CD4 and CD45.1 expression on cells with gating on adoptively transferred OTII CD4+ T cells 
(CD4+ CD45.1+) or CD4- (CD4- CD45.1+) cells. (C) Quantification of the proportion or (D) absolute 
number of OTII CD4+ cells. (E) Quantification of the proportion or (F) absolute number of 
adoptively transferred CD4- cells. Results are expressed as mean ± SD of an experiment performed 
in biological replicates (n = 4). Statistical differences between groups that received antigen were 
determined using a one-way or a two-way ANOVA. *p ≤ 0.05. 
Anti-JAM-A mAb treatment decreased the total number of cells from pLNs, in 
comparison with the isotype control group, but not to the untreated group. The 
proportion and number of CD4+ CD45.1+ cells were unaltered under treatment 
with anti-JAM-A. However, although the proportions of CD4- adoptively 
transferred cells were not different across groups, JAM-A blockade decreased the 
total number of these cells in comparison with the isotype-treated group, 
suggesting that the treatment could impact the accumulation of non-CD4 
leukocytes in the pLNs when comparing to isotype-treated cells. The viability of 
cells was also analysed as described in section 2.4.1 (not shown), but no 
differences in cell death were found. 
To analyse the proliferation of the OTII cells, their CFSE fluorescence intensity 
was analysed (Figure 5-5A) and compared (Figure 5-5B). In addition, peaks based 
in the number of divisions were identified (Figure 5-5C) and compared between 
groups that have received antigen stimulation (Figure 5-5D). 
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Figure 5-5. The impact of JAM-A blockade in vivo in CD4+ T cell proliferation 
CFSE-labelled immune cells from lymph nodes (LN) and spleens of OTII mice were adoptively 
transferred to C57BL/6 mice that were challenged with footpad injections of LPS and OVA in the 
presence of anti-JAM-A mAb (BV11) or its isotype control. Popliteal lymph nodes (pLN) were 
harvested 72 hours later and analysed by flow cytometry for the expression of CFSE. (A) 
Representative histograms of CFSE fluorescence intensity on OTII CD4+ cells (CD4+ CD45.1+) with 
gating on divided cells and (B) quantification of OTII CD4+ T cells that have divided based on the 
gating of CFSE fluorescence intensity. (C) Representative histograms of CFSE fluorescence intensity 
on OTII CD4+ cells with identification of division peaks (D0 to D5). (D) Quantification of OTII CD4+ 
T cells that have divided based on its number of divisions. Results are expressed as mean ± SD of 
an experiment performed in biological replicates (n = 4). Statistical differences between the anti-
JAM-A-treated and the isotype-treated groups were determined using a one-way or a two-way 
ANOVA. *p ≤ 0.05, **p ≤ 0.01, ****p ≤ 0.0001. 
The administration of OVA promoted proliferation of OTII CD4+ T cells in all groups 
that received antigen, while only a small proportion of cells were CFSE- in the 
unstimulated group. JAM-A blockade decreased the overall proliferation of CD4+ 
T cells from pLNs of anti-JAM-A-treated mice in comparison with cells from 
isotype-treated animals, but not with cells from untreated mice. The detailed 
analysis of proliferation peaks by number of divisions showed that a higher 
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proportion of cells from anti-JAM-A-treated mice underwent 0 or 2 divisions in 
comparison with the isotype control group. Additionally, anti-JAM-A mAb 
treatment decreased the proportion of cells that divided 4 or 5 times when 
compared with cells from mice treated with the isotype control. However, no 
differences were found in comparison with anti-JAM-A-treated and untreated 
mice. 
In addition to proliferation rates, the status of cell activation was also analysed 
in cells from the present study. For that, OTII cells were analysed for the 
expression of CD44 and CD62L. Phenotypes suggesting naïve (CD44lowCD62L+) and 
memory (CD44highCD62L-) CD4+ T cells378 were identified (Figure 5-6A) and their 
proportions (Figure 5-6B and D) and absolute numbers (Figure 5-6C and E) were 
compared across groups that were challenged with OVA. In addition, 
CD44highCD62L+ cells, likely suggesting a recent recognition of cognate antigen by 
upregulation of CD44 but still maintaining normal levels of CD62L, were also 
analysed (Figure 5-6F and G).  
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Figure 5-6. JAM-A blockade in vivo does not affect CD4+ T cell activation 
CFSE-labelled immune cells from lymph nodes (LN) and spleens of OTII mice were adoptively 
transferred to C57BL/6 mice that were challenged with footpad injections of LPS and OVA in the 
presence of anti-JAM-A mAb (BV11) or its isotype control. Popliteal lymph nodes (pLN) were 
harvested 72 hours later and analysed by flow cytometry for the expression of CD44. (A) 
Representative histograms of CD44 and CD62L expression on OTII CD4+ cells (CD4+ CD45.1+). (B) 
Quantification of the proportion or (C) absolute number of OTII CD4+ T cells that are 
CD44lowCD62L+. (D) Quantification of the proportion or (E) absolute number of OTII CD4+ T cells 
that are CD44highCD62L-. (F) Quantification of the proportion or (G) absolute number of OTII CD4+ 
T cells that are CD44highCD62L+. Results are expressed as mean ± SD of an experiment performed 
in biological replicates (n = 4). Statistical differences between groups that received antigen were 
determined using a one-way or a two-way ANOVA. p = non-significant for all comparisons. 
The administration of OVA induced activation of OTII CD4+ T cells, evidenced by 
the lower proportion of naïve and higher proportion of memory T cells compared 
to the unstimulated group. Anti-JAM-A mAb treatment did not affect the 
proportions nor the numbers of naïve, memory or CD44highCD62L+ cells. As whole 
OVA was used for challenging mice and this, as well as other proteins, require 
antigen processing, a process that involves the degradation of proteins within the 
APCs cytoplasm351 and that produces a range of different peptides that may react 
with endogenous T cells through specific antigen recognition or cross-
reactivity379,380, I also analysed the activation status of CD4+ CD45.1- cells (not 
shown). No differences were found in the activation status of endogenous CD4+ 
cells. 
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5.2.4 Anti-JAM-A mAb Treatment in vivo Does Not Affect CD4+ T 
Cell Differentiation 
To analyse if JAM-A blockade in vivo can modify CD4+ T cell differentiation 
patterns, I analysed the expression of key transcription factors for T cell 
differentiation into Th17 (RORγt) (Figure 5-7A, B and C), Th1 (T-bet) (Figure 5-7D, 
E and F) and Treg cells (Figure 5-7G, H and I). 
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Figure 5-7. JAM-A blockade in vivo does not affect CD4+ T cell differentiation 
CFSE-labelled immune cells from lymph nodes (LN) and spleens of OTII mice were adoptively 
transferred to C57BL/6 mice that were challenged with footpad injections of LPS and OVA in the 
presence of anti-JAM-A mAb (BV11) or its isotype control. Popliteal lymph nodes (pLN) were 
harvested 72 hours later and analysed by flow cytometry for the expression of different 
transcription factors. (A) Representative dot plots of RORγt expression on OTII CD4+ cells (CD4+ 
CD45.1+) or (B) its isotype control and (C) quantification of RORγt+ cells. (D) Representative dot 
plots of T-bet expression on OTII CD4+ cells or (E) its isotype control and (F) quantification of T-
bet+ cells. (G) Representative dot plots of FoxP3 expression on OTII CD4+ cells or (H) its isotype 
control and (I) quantification of FoxP3+ cells. Gates show specific binding based on matched 
isotype control. Results are expressed as mean ± SD of an experiment performed in biological 
replicates (n = 4). Statistical differences between groups that received antigen were determined 
using a one-way ANOVA. p = non-significant for all comparisons. 
The analysis shows that anti-JAM-A mAb treatment did not affect the proportion 
of OTII CD4+ T cells expressing any of the analysed transcription factors (RORγt, 
T-bet and FoxP3). The MFI of populations expressing the studied transcription 
factors was also analysed (not shown). No differences were found between the 
isotype-treated and the anti-JAM-A treated groups. 
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5.3 Discussion 
In Chapter 4, I demonstrated that blockade of JAM-A pathways in vitro in the 
context of the presence of IgG (e.g. recruitment of Fc receptors) during antigen 
presentation disrupts cell cluster formation, attenuates T cell activation and 
proliferation and affects T cell differentiation and cytokine secretion. However, 
many factors can affect CD4+ T cell-DC interactions in vivo, such as interactions 
with other cell types and cell migration. In this chapter, I have analysed the 
effects of JAM-A blockade on T cell priming in vivo. JAM-A expression could be 
demonstrated in T cell and medullary areas of murine LNs. In addition, JAM-A was 
also detected in an area of the LN that suggests insertion of an afferent vessel. 
Afferent vessels might be used by the DCs to enter the LN following their migration 
from inflamed tissues6. Accordingly, treatment with an anti-JAM-A mAb in vivo 
may not only possibly affect the interactions between T cells and DCs but could 
also influence DC migration, by disrupting interactions between DCs and 
endothelial cells. To tease apart migration effects from T cell-DC interactions in 
vivo, I employed siRNA. This technique, aiming to induce downregulation of the 
F11R gene, could lead to decrease of JAM-A expression on the DCs surface. 
However, transfection of siRNA targeting the F11R gene only minimally impacted 
the expression of surface JAM-A on BMDCs. Technical modifications were 
performed in following siRNA experiments, such as attempts with different cell 
numbers that would influence cell confluency and could have an impact in the 
expression of JAM-A, however, no substantial knockdown effects were obtained. 
As shown in Chapter 4 (section 4.2.4), mature BMDCs express higher levels of JAM-
A in comparison with immature cells. This difference was similar to that observed 
in the siRNA experiment between “siRNA F11R”-transfected BMDCs and the control 
group. Although I did not perform post-transfection experiments to determine 
mRNA levels, my findings suggest that the transfected cells maintained their JAM-
A levels as when they were immature, possibly due to the lack of F11R mRNA for 
synthesis of new JAM-A molecules. Nevertheless, the effects of the JAM-A 
knockdown on BMDCs were considered insufficient for their use in in vivo 
experiments aiming to disrupt JAM-A pathways. 
As an alternative approach to look at the effects of JAM-A blockade on CD4+ T cell 
priming in vivo, I decided to use the anti-JAM-A mAb BV11. OTII CD4+ T cells were 
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adoptively transferred to WT mice and OVA was given in their footpads 
accompanied by LPS as adjuvant to induce non-specific inflammation and 
stimulate DC migration377. Three days later, their pLNs were harvested for analysis 
of T cell activation and proliferation. After selecting a dose of antigen that 
achieved suboptimal T cell proliferation, I performed an experiment treating mice 
with anti-JAM-A mAb BV11 or its isotype control. Treatment with anti-JAM-A mAb 
decreased the total number of cells in the pLNs in comparison to treatment with 
its isotype control, as well as the number of CD4- adoptively transferred cells 
(CD45.1+). However, no differences in the proportion or number of OTII CD4+ cells 
were found. As only transferred cells were CFSE-labelled, it was not possible to 
analyse the proliferation of endogenous immune cells. These results, along with 
no differences in cell death being found, raise interesting points, such as whether 
JAM-A blockade affects leukocyte entry or exit in the LNs. These questions will 
motivate follow-up migration experiments using cell fate mapping tools such as 
Kaede mice249. 
The impact of JAM-A blockade on in vivo OTII CD4+ T cell proliferation, activation 
and differentiation was also analysed. Although a positive impact on cell 
proliferation could have been expected due to a report in the literature showing 
increased DC migration from an inflamed tissue to the draining LN326, in vivo 
treatment with anti-JAM-A mAb attenuated the proliferation of CD4+ T cells when 
comparing to the isotype-treated group, as supported by my in vitro studies in 
Chapter 4. More specifically, OTII T cells from mice treated with anti-JAM-A 
underwent 4 or 5 divisions in lower proportions in comparison to the isotype-
treated group. Although treatment with anti-JAM-A mAb decreased the number of 
adoptively transferred CD4- cells, the impact in CD4+ T cell proliferation was not 
reflected in the absolute number of OT-II CD4+ cells from pLNs. Cell accumulation, 
a parameter that was analysed by the proportion/number of OTII cells in the LNs 
is influenced by other parameters besides cell proliferation, such as cell death, 
apoptosis and migration. My analysis did not show differences in cell death; 
however, the available markers from the flow cytometry analysis did not allow an 
evaluation on cell apoptosis and migration. In addition, no differences in the 
proportions or numbers of naïve (CD44lowCD62L+), memory (CD44highCD62L-) or 
recently primed (CD44highCD62L+) T cells were found, suggesting that the 
treatment did not impact CD4+ T cell activation. 
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No effect on CD4+ T cell differentiation was found, evidenced by similar 
proportions of RORγt+, T-bet+ or FoxP3+ cells in the anti-JAM-A and isotype-
treated groups. These findings differ from my in vitro experiment in Chapter 4 
that showed impact of JAM-A blockade in CD4+ T cell differentiation. This 
difference can be explained by a few hypotheses. In vivo JAM-A blockade may 
have altered the motility and/or migration of DCs, as suggested by a report in the 
literature326, and therefore indirectly induced changes in the quantity or quality 
of T cell-DC crosstalk during antigen presentation that could have affected T cell 
outcomes differently than in in vitro assays. In addition, BMDCs used in vitro 
express different surface markers than the heterogenous population that 
comprises endogenous DCs47,54. These, therefore, deliver distinct quantity or 
quality of signals that may affect CD4+ T cell differentiation differently. Lastly, 
danger signals induced by LPS stimulus on cells expressing TLR2 and/or TLR4, such 
as some endothelial cells that release IL-6 under LPS stimulation381, may also 
affect CD4+ T cell differentiation differently. Further studies are needed to 
address these questions. 
The results in this Chapter indicate that anti-JAM-A treatment in vivo in the 
context of the presence of IgG (e.g. recruitment of Fc receptors) may impact the 
interactions between CD4+ T cells and DCs, as differences in cell proliferation may 
result from changes in the quantity or quality of signals exchanged by these cell 
types during their interactions. However, no differences in T cell activation were 
found. As such, the changes observed in cell division rates might be a product of 
an impact in other immune components, such as in the profile of cytokines 
released by other immune cells that can influence cell expansion, including IL-2, 
a potent T cell growth factor382, or an impact in cell apoptosis. In addition, it is 
important to note that there were no differences in T cell proliferation when 
comparing anti-JAM-A treated with untreated mice. Nevertheless, further studies 
will analyse the mechanisms in which JAM-A is involved in T cell priming in vivo. 
Due to the ability of JAM-A manipulation to disrupt CD4+ T cell-DC interactions in 
vitro, as showed in Chapter 4, I analysed the impact of anti-JAM-A mAb treatment 
in a breach of self-tolerance model of arthritis, as shown in the next Chapter. 
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Chapter 6 JAM-A as a Therapeutic Target for 
Rheumatoid Arthritis 
6.1 Introduction 
The F11R gene, responsible for encoding the JAM-A molecule, was chosen from a 
list of upregulated genes on non-migratory joint immune cells in comparison with 
migratory immune cells in a murine RA model, as explained in Chapter 3 (section 
3.1). This gene upregulation may reflect a higher expression of JAM-A protein on 
immune cells from these inflamed joints. I have demonstrated in Chapter 4 that 
JAM-A blockade in vitro attenuates CD4+ T cell activation and proliferation. In 
addition, JAM-A blockade in an adoptive transfer model decreased proliferation 
of adoptively transferred CD4+ T cells, as shown in Chapter 5. Several molecules 
involved in T cell-APC signalling have been studied as therapeutic target for 
inflammatory diseases and cancer, including RA, as extensively described in 
Chapter 1. As such, these findings suggest that JAM-A blockade in RA could affect 
T cell activation in the arthritic joint and/or leukocyte migration to the LNs, 
possibly impacting on the disease development and/or severity. 
Several drugs are available for treatment of RA. These include analgesics, non-
steroidal anti-inflammatory drugs (NSAID), disease-modifying antirheumatic drugs 
(DMARD), glucocorticoids and biological agents, such as abatacept, a blocker of 
the CD28-CD80/CD86 T cell co-stimulatory pathway200,383,384. However, no cure for 
RA is currently known, and many patients do not respond to conventional 
treatments385. As such, there is considerable unmet clinical need and increasing 
interest in the discovery of new pathways that can be targeted for treatment and 
management of this disease. In this chapter, I investigated JAM-A as a potential 
therapeutic target for RA. The data presented in the preceding chapters suggest 
that JAM-A can mediate the accumulation of immune cells in inflamed joints by 
allowing strong leukocyte adhesion to the inflamed endothelial cells, and may 
participate in the breach of self-tolerance found in RA through its expression by 
DCs (Figure 6-1). I therefore hypothesised that JAM-A blockade could affect the 
breach of tolerance by disrupting interactions between autoreactive T cells and 
DCs, and by possibly inducing migration of leukocytes out of inflamed joints, 
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decreasing their accumulation in the joints and ultimately leading to a faster 
resolution or attenuation of clinical disease. The breach of self-tolerance murine 
model of arthritis170 was performed as described in Chapter 2 (Section 2.3.3) in 
Kaede mice for identification of JAM-A protein expression on immune cells from 
inflamed joints, as well as in WT mice for analysis of potential therapeutic effects 
following manipulation of JAM-A during the disease phase of induction. 
 
Figure 6-1. Proposed model for a functional role for JAM-A in the breach of self-tolerance in 
RA 
Whilst JAM-A may contribute to disease through multiple cell types and signalling processes, 
mechanisms of DC trafficking mediated by JAM-A and their indirect effects in immune responses 
might play a key role in the breach of self-tolerance that occurs in the induction and/or 
development of RA. (A) JAM-A may assist the accumulation of immune cells in the inflamed 
synovium by enhancing leukocyte adhesion to the inflamed endothelia. (B) The accumulation of 
DCs increases the availability of self-antigen not only in the arthritic joint, where antigen 
presentation can occur, but also in the draining LN, by DCs carrying self-antigen captured in the 
affected tissue. (C) This abundance of self-antigens possibly leads to the activation of a higher 
proportion of self-antigen specific T cells. (D) The induction of adaptive immune responses against 
self-antigens leads to (E) inflammation and tissue destruction characteristic of autoimmune 
diseases. 
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6.2 Results 
6.2.1 JAM-A is Upregulated on Non-Migratory Immune Cells from 
Inflamed Joints 
As demonstrated in Chapter 3 (section 3.1), the F11R gene was found to be 
upregulated in non-migratory leukocytes from inflamed joints. To investigate if 
JAM-A protein is also upregulated on the surface of these cells, I performed the 
same experimental procedure that generated the gene data, as described in 
Chapter 2 (section 2.3.2). For this experiment, instead of using WT mice as host 
animals, Kaede mice expressing a photoconvertible green protein in all its cells 
were used249. Prior the harvest day, the hosts’ feet were exposed to a laser for 
photoconversion of the green fluorescent protein (Kaede green) to red (Kaede 
red)249. Four days after the footpad challenge with HAO, joints and pLNs were 
harvested, digested and stained with fluorophore-conjugated antibodies. The 
expression of JAM-A was analysed by flow cytometry in two different panels one 
for myeloid cells (CD45, CD11b, CD11c, MHCII, Ly6G) and another for lymphoid 
cells (CD45, CD3, CD4, CD8 and CD19). Photoswitched cells (Kaede red cells, as 
described in section 2.3.2) were selected (Figure 6-2A) for the analysis and 
comparison of JAM-A expression on Kaede red cells from the joints, referred as 
non-migratory cells, with Kaede red cells from pLNs, referred as migratory cells 
(Figure 6-2B, C, D). Levels of surface JAM-A were analysed on cells expressing 
lineage markers (Figure 6-2E, F). JAM-A expression was also analysed in cells that 
were present in the joint since the photoswitch event (Kaede red) and that 
infiltrated in the inflamed tissue by the cull day (Kaede green) (Figure 6-2G, H). 
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Figure 6-2. JAM-A expression on immune cells from inflamed joints and popliteal lymph nodes 
Immune cells from the joints and popliteal lymph nodes (pLN) of Kaede mice that were submitted 
to the breach of self-tolerance model of arthritis were analysed by flow cytometry for the 
expression of JAM-A. (A) Dot plots showing the identification of photoconverted (Kaede red) cells 
gated according to a non-photoswitched mouse (not shown). (B) Representative dot plots of JAM-
A expression on CD45+ Kaede red cells, (C) quantification of the proportion JAM-A+ population and 
(D) quantification of JAM-A median fluorescence intensity (MFI) from the JAM-A+ population. (E) 
tSNE analysis of concatenated CD45+ Kaede red cells from joints and pLNs of all mice based on 
polychromatic flow cytometry data including JAM-A, CD11b, Ly6G, CD11c and MHCII expression 
profiles and (F) heatmap of the immune cells from joints or pLNs of a representative mouse. (G) 
Gating strategy of Kaede green or Kaede red events in cells from the joints and (H) quantification 
of JAM-A+ populations with comparison between Kaede green and Kaede red cells. Gates were 
made according to the fluorescence emitted by JAM-A isotype control (not shown). Results are 
expressed as mean ± SD of an experiment performed in biological replicates (n = 5). Statistical 
differences were determined using a paired Student’s t test. *p ≤ 0.05. 
The analysis of the JAM-A MFI showed that the amount of JAM-A expressed on the 
surface of leukocytes between migratory and non-migratory leukocytes was not 
significantly different. However, a higher proportion of non-migratory cells 
expressed JAM-A in comparison with migratory leukocytes. This data supports the 
RNAseq data mentioned in Chapter 3 (section 3.1), in which F11R expression was 
found to be increased in joint cells in comparison with cells that migrated to the 
LNs. The analysis of the tSNE plots indicated that the major part of the JAM-A-
expressing population was composed by CD11b+ cells, partially also being MHCII 
and CD11c, but not Ly6G. It is possible to note that the majority of these CD11b+ 
cells are CD11c-, possibly reflecting macrophage populations. However, 
macrophage lineage markers, such as F4/80 would be necessary to classify these 
events in a more reliable way. It was also possible to notice that the major part 
of the population of JAM-A expressing Kaede red leukocytes that was present in 
the joints could not be seen in cells from the pLNs. The analysis of JAM-A 
expression on cells that were in the joint since the photoswitch event (Kaede red) 
in comparison to the ones that infiltrated in the joint by the cull day (Kaede green) 
showed no significative difference. 
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Following a more comprehensive analyses of JAM-A expression in specific cell 
types from the previous experiment, the expression of JAM-A in CD11chigh MHCII+ 
cells (Figure 6-3A, B), classified as cDCs, and CD11clow CD11b- cells (Figure 6-3C, 
D), referred here as pDCs, was evaluated. In addition, I analysed the expression 
of JAM-A on pDCs from the migratory population and compared it with the 
expression on LN resident pDCs (Kaede green cells) (Figure 6-3E, F, G). For 
analysing CD4+ T cells, cells were gated as CD4+ CD19- and CD8-, as the CD3 
staining was not satisfactory. I therefore analysed JAM-A expression on CD4+ cells 
(Figure 6-3H, I) and also on CD19+ cells (Figure 6-3J, K), a lineage marker for B 
lymphocytes, cells that can also work as APCs, as detailed in Chapter 1. 
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Figure 6-3. JAM-A expression on immune cell subsets from inflamed joints and popliteal lymph 
nodes 
Immune cells from the joints and popliteal lymph nodes (pLN) of Kaede mice that were submitted 
to the breach of self-tolerance model of arthritis were analysed by flow cytometry for the 
expression of JAM-A. (A) Representative dot plots of JAM-A expression on CD11chigh MHCII+ from 
CD45+ Kaede red cells and (B) quantification of JAM-A+ populations with comparison between cells 
found in joints and pLNs. (C) Representative dot plots of JAM-A expression on CD11clow CD11b- 
cells from CD45+ Kaede red cells and (D) quantification of JAM-A+ populations with comparison 
between cells found in joints and pLNs. (E) Representative dot plots of JAM-A expression on 
CD11clow CD11b- cells from Kaede green or (F) Kaede red cells and (G) comparison between the 
frequency of JAM-A+ cells on both populations. (H) Representative dot plots of JAM-A expression 
on CD4+ cells and (I) quantification of the JAM-A+ populations with comparison between cells 
found in joints and pLNs. (J) CD19+ cells from CD45+ Kaede red cells and (K) quantification of the 
JAM-A+ populations with comparison between cells found in joints and pLNs. Gates were made 
according to the fluorescence emitted by JAM-A isotype control (not shown). Results are expressed 
as mean ± SD of an experiment performed in biological replicates (n = 5). Statistical differences 
were determined using a paired Student’s t test. ns = non-significant, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 
0.001. 
The analysis of JAM-A expression on specific DC subtypes showed that a higher 
proportion of non-migratory cDCs expressed JAM-A in comparison with migratory 
cDCs. On the other hand, the proportion of non-migratory pDCs expressing JAM-A 
was significantly lower than migratory pDCs. The expression of JAM-A was also 
analysed on LN resident pDCs. These cells expressed JAM-A in lower proportions 
when compared with LN migratory pDCs. It is important to note that all cells from 
both these populations expressed MHCII. In addition to the cell analysis, the 
proportion of CD4+ cells expressing JAM-A was not different when comparing 
migratory and non-migratory populations. However, a higher proportion of CD19+ 
cells from non-migratory populations expressed JAM-A in comparison with 
migratory cells. 
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6.2.2 Anti-JAM-A mAb Treatment Does Not Affect Arthritis in a 
Breach of Self-Tolerance Murine Model of Arthritis 
The murine arthritis model was performed as described in Chapter 2 (section 
2.3.2). To increase the chances of a successful induction of RA in this model, the 
quality of polarised cells was analysed before being adoptively transferred to WT 
host mice. The transferred cell population was around 85% CD4+. From this 
population, approximately 98% expressed the OTII transgenic TCR (Vα2+ Vβ5+). 
70% of these had a Th1 polarised phenotype, as assessed by T-bet expression; a 
rate that was considered satisfactory when taking into consideration results 
obtained in previous experiments performed in our laboratory (unpublished data). 
Clinical scores (Figure 6-4A) and paw thickness (Figure 6-4B) were measured for 7 
days after the induction of joint inflammation as described in section 2.3.2. 
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Figure 6-4. JAM-A blockade in a murine model of early arthritis does not affect clinical disease 
C57BL/6 mice were submitted to the breach of self-tolerance model of arthritis and treated with 
anti-JAM-A mAb (BV11) or its isotype control in days 0, 2, 4 and 6 after HAO injections and the 
clinical course of arthritis was monitored for 7 days after the footpad challenge. (A) Quantification 
of mean clinical scores. (B) Quantification of mean paw thickness. Results are expressed as mean 
± SD of an experiment performed in biological replicates (n = 5). Statistical differences between 
the groups that were challenged with antigen were determined using a two-way ANOVA. p = non-
significant for all comparisons. 
 
A comparison between the negative (non-arthritic) and positive (arthritic) controls 
confirmed joint inflammation was induced after the HAO footpad injections170. 
Treatment with anti-JAM-A mAb did not affect mean clinical scores nor mean paw 
thickness in comparison to the isotype control. As no clinical effect was found in 
this early, acute model, we provided a second challenge, defined as a chronic 
model386 (HAO footpad injections in Freund’s incomplete adjuvant). This decision 
was based in a hypothesis that anti-JAM-A could have been affecting immune 
components that would be more pronounced in the context of a late model of RA, 
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such as the activation or proliferation of autoreactive T cells. As mice were not 
culled and their LNs were not available for the analysis of the activation and 
proliferation of CD4+ T cells, their blood was harvested for the analysis of PBMCs 
by flow cytometry. The activation status of peripheral blood CD4+ T cells was 
analysed by the expression of CD44 (Figure 6-5A) and compared between groups 
that received antigen (Figure 6-5B). 
 
Figure 6-5. JAM-A blockade in a murine model of early arthritis does not affect the activation 
of peripheral blood CD4+ T cells 
C57BL/6 mice were submitted to the breach of self-tolerance model of arthritis and treated with 
anti-JAM-A mAb (BV11) or its isotype control in days 0, 2, 4 and 6 after HAO injections and had 
their peripheral blood mononuclear cells (PBMC) analysed 7 days after the footpad challenge. (A) 
Representative histograms of CD44 expression on CD3+ CD4+ cells with gating on CD44high cells and 
(B) quantification of the proportion of CD4+ T cells that are CD44high. Results are expressed as 
mean ± SD of an experiment performed in biological replicates (n = 5). Statistical differences 
between groups that were challenged with antigen were determined using a two-way ANOVA. p = 
non-significant for all comparisons. 
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The activation of peripheral blood CD4+ T cells was not affected by anti-JAM-A 
mAb treatment. Before analysing the ability of JAM-A blockade during the 
induction of RA to affect breach of self-tolerance, I analysed the concentration of 
anti-OVA antibodies in the serum. Anti-OVA secretion could indicate a potential 
interference of the treatment in T cell-dependent B cell responses. The 
concentration of serum anti-OVA IgG1 (Figure 6-6A) and IgG2c (Figure 6-6B) were 
analysed by ELISA, as described in Chapter 2 (section 2.5.2). Both isotypes were 
analysed, as IgG1 is commonly stimulated during Th2-type immune responses and 
IgG2a/IgG2c are associated with Th1-type responses387. This way, the bias of a 
possible shift in Th1/Th2 differentiation would be addressed. 
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Figure 6-6. JAM-A blockade in a murine model of early arthritis does not affect the secretion 
of anti-OVA antibodies 
C57BL/6 mice were submitted to the breach of self-tolerance model of arthritis and treated with 
anti-JAM-A mAb (BV11) or its isotype control in days 0, 2, 4 and 6 after HAO injections and their 
plasma were analysed for the presence of anti-OVA antibodies by ELISA 7 days after the footpad 
challenge. (A) Quantification of the normalised optical density (OD) of anti-OVA IgG1 or (B) IgG2c 
antibodies. Results are expressed as mean ± SD of an experiment performed in biological replicates 
(n = 5). Statistical differences were determined using a two-way ANOVA. p = non-significant for all 
comparisons. 
No differences in the concentration of serum anti-OVA IgG1 or IgG2c were found 
between anti-JAM-A-treated and isotype-treated mice. These data support the 
hypothesis that JAM-A blockade does not affect T cell-dependent B cell activation. 
I, therefore, analysed anti-JAM-A’s ability to influence breach of tolerance in this 
animal model. The concentration of serum anti-CII was analysed by ELISA (Figure 
6-7), as described in Chapter 2 (section 2.5.2). 
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Figure 6-7. JAM-A blockade in a murine model of early arthritis does not affect the secretion 
of anti-collagen type II antibodies 
C57BL/6 mice were submitted to the breach of self-tolerance model of arthritis and treated with 
anti-JAM-A mAb (BV11) or its isotype control in days 0, 2, 4 and 6 after HAO injections and their 
plasma were analysed for the presence of anti-collagen type II (CII) antibodies by ELISA 7 days 
after the footpad challenge. The graph shows the quantification of the normalised optical density 
(OD) of the anti-CII antibody detection. Results are expressed as mean ± SD of an experiment 
performed in biological replicates (n = 5). Statistical differences between the anti-JAM-A-treated 
and the isotype-treated groups were determined using a two-way ANOVA. p = non-significant. 
 
The concentration of anti-CII antibodies was not affected by anti-JAM-A mAb 
treatment in comparison with the isotype control treatment, suggesting that JAM-
A blockade did not affect breach of tolerance in this model of early RA. 
6.3 Discussion 
DCs and T cells play a definitive role in the pathogenesis of RA, as described in 
sections 1.8.3 and 6.1 and previously shown in animal studies by our research 
group106,198,200,388–390, human genetic studies391–393 and clinical trials394–397. In 
addition, the accumulation of leukocytes is a major contributor to joint swelling 
and pain in RA patients398. JAM-A has been studied as a therapeutic target in a 
number of preclinical models of diseases characterised by accumulation of 
leukocytes in affected tissues. In a model of skin inflammation, systemic 
treatment with an anti-JAM-A mAb BV11 was able to inhibit monocyte infiltration 
upon chemokine administration in subcutaneous air pouches325. However, in a 
model of ear skin antigen-induced inflammation, JAM-A-/- mice displayed 
enhanced contact hypersensitivity326. The increase in ear swelling was associated 
with a higher migration of JAM-A-deficient DCs to LNs, possibly leading to 
increased activation of antigen specific T cells. Anti-JAM-A mAb BV11 was also 
used intravenously in a model of meningitis, attenuating cytokine-induced 
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meningitis353. This therapeutic effect was attributed to an inhibition of monocyte 
and neutrophil accumulation in the cerebrospinal fluid and neutrophil infiltration 
into the brain parenchyma. In a model of ischaemia-reperfusion injury, JAM-A 
genetic depletion or blockade with anti-JAM-A mAb BV11, supressed leukocyte 
transmigration through a cremaster muscle endothelium 354. In addition, in a 
serum-transfer arthritis model, treatment with anti-JAM-A mAb BV11 delayed the 
disease onset and partially ameliorated overall disease224, possibly by inducing 
leukocyte migration out of the affected joints, consequently decreasing its 
accumulation in the inflamed tissue. 
My findings that JAM-A has a role in the interactions between CD4+ T cells and 
DCs in addition to findings from the literature that JAM-A antagonism have 
promoted leukocyte migration out of inflamed tissues in several disease models, 
point to JAM-A as a potential therapeutic target for treatment of RA. F11R 
expression was upregulated in joint non-migratory leukocytes in a murine model 
of RA (unpublished data). To test the hypothesis that this upregulation in gene 
expression reflects a higher expression of JAM-A on the surface of immune cells, I 
performed the same experiment used for the detection of the F11R upregulation 
by using Kaede mice to allow tracking of immune cells from the joints to pLNs. 
Results from my experiment confirmed this hypothesis, showing a higher 
proportion of JAM-A+ cells from leukocytes that were arrested in the joints in 
comparison with immune cells that migrated to pLNs. In addition, no differences 
were found in the expression of JAM-A in cells that were in the joint in the moment 
of the photoswitch in comparison to cells that infiltrated after this event. These 
data suggest that JAM-A might hypothetically have a more pronounced role in 
retaining cells in the inflamed joint rather than in promoting leukocyte infiltration 
in the inflamed tissue. Evidence of JAM-A upregulation in hypoxic cells399,400 
suggest that the hypoxia present in the synovial tissue of RA patients401–405 could 
potentially lead to an increased JAM-A protein expression on cells from the 
inflamed joints of these patients. Recently, a study described increased 
expression of F11R mRNA on PBMCs of RA patients406. However, this upregulation 
could have been driven by the systemic inflammation itself, as this study used 
healthy individuals as the control group. 
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The analysis of lineage markers showed that most of the JAM-A+ populations from 
both joints and pLNs were composed by CD11b+ cells, while part was composed 
by MHCII+ cells but not Ly6G+ cells. This supports the data from gene bank, that 
neutrophils from synovial fluid of arthritic mice expressed minimal levels of F11R 
mRNA (section 3.1). The analysis of JAM-A expression on cDCs showed that cells 
that were in the joint expressed surface JAM-A in higher proportions than cDCs 
that migrated to the pLNs. In addition, CD19+ cells, suggesting B cells, which can 
also act as APCs, mainly in the context of Tfh differentiation100, also had their 
JAM-A expression analysed. A 3-fold increase was found on the proportion of 
CD19+ cells that were JAM-A+ in non-migratory populations in the joint, in 
comparison with migratory populations in the pLN. On the other hand, only a small 
proportion of CD4+ cells in both the joints and pLNs expressed JAM-A, in 
accordance with my in vitro findings reported in Chapter 4 that naïve and in vitro 
activated CD4+ T cells express low or undetectable levels of JAM-A. However, a T 
cell lineage marker (e. g. CD3) was not available in the flow cytometry analysis of 
this in vivo experiment. As such, these CD4+ cells could not only be CD4+ T cells 
but also other leukocytes that express CD4, such as monocytes and macrophages32. 
When analysing populations that were CD11clow CD11b- from the Kaede 
experiment, possibly suggesting populations of pDCs307,407, I found a 20-fold 
increase on the percentage of JAM-A expression on cells that migrated to the pLNs 
compared to the ones that stayed in the joints. Plasmacytoid DCs from both LNs 
and spleens express low levels of JAM-A in physiological conditions, as shown in 
Chapter 4 (section 4.2.1). To verify the reliability of the identification of the JAM-
A-expressing pDCs population, I compared the expression of JAM-A between pDCs 
that migrated to the LN to LN resident pDCs, which confirmed the low expression 
of JAM-A on LN pDCs that did not migrate from the joints. Our research group has 
previously reported pDCs as regulators of the breach of self-tolerance in the 
murine model of RA that was also used in this chapter. Selective pDC depletion in 
vivo was reported to increase lymphocyte autoimmune responses against anti-CII 
and enhanced the severity of the pathology388. While only a proportion of the pDC 
populations in my experiment expressed MHCII (17.68% ± 3.5 on joint non-
migratory, 48.7% ± 2.7 on pLN resident cells and 62.5% ± 10.8 on pLN migratory 
cells), all JAM-A+ pDCs from migratory cells and from pLN resident cells were 
MHCII+, although JAM-A could not be reliably detected on joint pDCs. 
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The different results of manipulating JAM-A in disease models shown in the 
literature seems to be related to the mechanisms of induction of inflammation in 
each chosen pre-clinical model. While JAM-A blockade promoted a worsening of 
clinical disease in a T cell-mediated model of skin inflammation326, JAM-A 
disruption ameliorated clinical disease in non-T cell-mediated models of 
inflammation, as mentioned in section 6.1. As such, JAM-A blockade in the murine 
model of RA used in this thesis could be expected to increase clinical scores by 
increasing the proportion of activated CD4+ T cells that play an important role in 
the induction of disease in this model. However, treatment with a JAM-A 
antagonist during the phase of induction could ameliorate disease by decreasing 
infiltration or retention of neutrophils that comprised the dominant leukocyte 
population found in the inflamed tissues and that also play a role in the induction 
of inflammation in arthritis. In addition, my studies in Chapters 4 and 5 showed 
that JAM-A blockade during priming could impact CD4+ T cell outcomes. Although 
a big part of the T cells in this disease model by the time when treatments were 
administered were already primed (Th1 polarised cells), the treatment could 
impact antigen presentation to autoreactive naïve CD4+ T cells. Additionally, in a 
model of RA in which mice receive serum from K/BxN mice, animals expressing 
transgenic TCR and MHCII and develop severe inflammatory arthritis169, treatment 
with anti-JAM-A mAb delayed the disease onset and partially ameliorated overall 
disease224. 
To analyse the potential therapeutic effects of blockade of JAM-A pathways in RA, 
the breach of self-tolerance model of arthritis was performed in WT mice. Anti-
JAM-A blockade did not affect clinical disease up to 7 days post-antigen footpad 
challenge. In addition, no differences were found in the activation status of 
peripheral blood CD4+ T cells. The analysis of T cells from pLNs would give a more 
precise idea of the effects of the treatment in the priming of autoreactive CD4+ 
T cells. However, a decision was made to extend the current experiment from an 
early to a late model of RA, as previously described by our research group386. 
Clinical disease will be again analysed after a second footpad challenge. Although 
my analysis of anti-CII antibodies suggests that the treatment did not have an 
impact on the breach of tolerance induced at this early stage, differences in the 
breach of self-tolerance may be more pronounced at later time-points. 
Presumably, the potential effects of anti-JAM-A treatment lies in disrupting 
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priming of naïve autoreactive T cells and the breach of tolerance could impact RA 
in later time points, as autoimmune components (e. g. anti-CII antibodies) are 
more pronounced following a second challenge386 and may play a bigger role in 
the pathology than possible changes in leukocyte recruitment. Nevertheless, the 
later model that is still running at the present time, in addition to other future 
work, such as studies to evaluate the effects of JAM-A manipulation in leukocyte 
accumulation in the inflamed joint, will answer this and other questions that may 
point JAM-A as a therapeutic target for RA. 
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Chapter 7 General Discussion and Future 
Directions 
The way a naïve CD4+ T cell encounters antigen presented by an APC for the first 
time dictates its fate as activated, apoptotic or anergic and influences other 
aspects of T cell biology (e. g. phenotype). In the centre of this crosstalk are 
surface molecules that support these intercellular interactions and provide 
stimulatory or inhibitory signals to the T cell. These molecules control not only T 
cell activation status but proliferation rate and differentiation into distinct T cell 
subsets. Additionally, disruption of pathways involving these molecules have been 
employed in several murine disease models and human diseases to achieve 
modulation of immune responses. As such, there is increasing interest in 
discovering new molecules that can control these cell-cell interactions. The 
overall aim in this thesis was to identify novel molecules that can control the 
interactions between T cells and DCs. This will further our understanding of 
disease processes and highlight new potential therapeutic targets for human 
disease. 
7.1 Summary of Key Findings 
The first aim of this study was to select candidate molecules that could be 
important in the interactions between T cells and DCs. To achieve this, I analysed 
transcriptomic data generated from previous experiments using a murine model 
of RA. I identified genes upregulated in immune cells that did not migrate from 
the joints to LNs, in comparison with migratory immune cells. I hypothesised that 
molecules encoded by these genes could be important for T cell-DC interactions 
that occur in the inflamed joint and influence T cell activation and/or 
differentiation6. From this list, the expression of genes related to leukocyte 
migration were analysed in a gene bank for the identification of the most 
promising candidates based on its expression in T cells and DCs: CEACAM1, CX3CR1 
and F11R. I started to test my second aim of evaluating if disruption of pathways 
involving molecules encoded by these genes could change CD4+ T cells outcomes 
by studying CEACAM1. CEACAM1 was found to be expressed on DCs and BMDCs and 
in low levels on CD4+ T cells. Treatment with anti-CEACAM1 mAb CC1 in vitro did 
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not affect the profile of T cell secreted cytokines, which contradicted the 
literature that showed increased IFN-γ under CEACAM1 blockade during priming291. 
As I couldn’t replicate these results, I employed gene knockdown aiming 
downregulation of CEACAM1 surface expression on BMDCs for further use of these 
cells on functional assays. Small interfering RNA targeting CEACAM1 gene was only 
able to minimally decrease CEACAM1 protein expression. I then moved to another 
candidate from out list: F11R. 
JAM-A, a protein encoded by the F11R gene, was expressed on cDCs and BMDCs 
but only in small levels on CD4+ T cells. I showed that JAM-A was present in the 
site of interaction between DCs and CD4+ T cells. Treatment with anti-JAM-A mAb 
BV11 during priming in vitro affected cell cluster formation, attenuated CD4+ T 
cell activation and proliferation and impacted on CD4+ T cell differentiation and 
cytokine secretion. In support, this treatment was found to decrease CD4+ T cell 
proliferation in vivo, in comparison to cells from isotype-treated animals, 
addressing the second aim of the thesis to identify the potential of the chosen 
molecule to disrupt CD4+ T cell-DC interactions in vivo. The last aim of this thesis 
was to investigate the impact of disrupting JAM-A function on the progress of 
inflammation in a breach of self-tolerance murine model of arthritis. Analysis of 
JAM-A protein expression in this model showed that JAM-A was upregulated on the 
surface of non-migratory immune cells in comparison with those that migrated 
from the joints to the pLNs, supporting the findings from the transcriptomic data. 
I then tested the impact of JAM-A blockade on disease progression in this murine 
model of early arthritis. No changes were found in clinical disease, activation of 
peripheral blood CD4+ T cells or in levels of autoantibodies of mice treated with 
anti-JAM-A in comparison to isotype-treated animals. I then decided to extend the 
model to a late model of arthritis to allow possible late effects on autoimmunity 
to be seen. The analysis of the results from this late model will further our 
understanding on the effects of JAM-A blockade during the induction phase of RA. 
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7.2 Detection of Molecules with Potential for 
Controlling T cell-DC Interactions 
The primary aim in Chapter 3 was to identify molecules with potential for 
controlling T cell-DC interactions. For that, I consulted unpublished data from 
experiments previously performed in our laboratory. Former members Drs Robert 
A. Benson and Catriona Prendergast have identified genes related to leukocyte 
migration that were upregulated in leukocytes arrested in inflamed joints after 
induction of a breach of self-tolerance murine model of arthritis, in comparison 
with migratory leukocytes. Presumably, these gene upregulation may reflect an 
upregulation on protein expression on the surface of DCs and/or CD4+ T cells and 
these upregulated molecules could be relevant for the crosstalk between these 
cells’ types during antigen presentation. I hypothesized that blockade of some of 
these molecules during CD4+ T cell priming could modulate T cell outcomes, such 
as activation, proliferation, differentiation and profile of cytokine secretion. After 
analysing the expression profile of these genes in immune cells from a genetic 
database and in addition to the commercial availability of antagonistic or agonistic 
reagents, I identified 3 genes that encode molecules with potential to test my 
hypothesis: CEACAM1, the first chosen to be studied, CX3CR1 and F11R. 
I showed that CEACAM1 protein is expressed on DCs, BMDCs and in low levels on 
CD4+ T cells. I used anti-CEACAM1 mAb CC1, an antibody reported to be effective 
in functional assays, in in vitro to test its potential to modulate CD4+ T cell-DC 
interactions and therefore T cell outcomes. Treatment with this mAb during 
priming did not change T cell outcomes, this differs from a report in the literature 
where a different mAb was employed in a similar assay and modulated the profile 
of secreted cytokines291. CC1 mAb also did not have any effects in both in vitro 
and in vivo experiments performed by other members of our research group. Later, 
the CC1 mAb was found to not block CEACAM1-CEACAM1 ligation317. I then 
attempted collaboration with another research group who have reagents proven 
to be useful for functional assays, however, logistical problems prevented us from 
obtaining sufficient reagent, in a time for this thesis. In addition, I also attempted 
to downregulate CEACAM1 surface expression on BMDCs by siRNA gene knockdown 
for use of these cells in prospective assays however this was not found to be 
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satisfactory. Although it was not possible to study CEACAM1 role on CD4+ T cells 
priming, studies from the literature suggest that CEACAM1 ligation may play a role 
T cell activation, proliferation260,294 and cytokine secretion291. However, its 
definition as stimulatory or inhibitory co-signalling molecule seems to be more 
complex as it may depend on the predominance of CEACAM1 isoforms 
expressed261,279–283. Therefore, more studies are required to investigate CEACAM1 
role as a T cell co-signalling molecule and highlight its potential targeting for 
inflammatory diseases. For the purposes of the studies in this thesis, I moved to 
another candidate: F11R. 
7.3 JAM-A Role on CD4+ T Cell Priming 
The F11R gene was identified in a list of genes related to leukocyte migration as 
described in section 7.2. As the majority of the non-migratory leukocytes sent for 
sequencing were neutrophils, I reanalysed the expression profile of the candidate 
genes in a genetic database. F11R was the only candidate that was highly 
regulated in splenic and/or LN cDCs but not in neutrophils from the synovial fluid 
from the arthritic joints of mice. Before considering performing experiments to 
analyse if the gene expression correlated with surface protein expression, I have 
evaluated the functions of the protein encoded by this gene in vitro and in vivo. 
The F11R gene encodes JAM-A, a protein that I showed to be expressed by cDCs 
and BMDCs and in lower levels by pDCs and CD4+ T cells. By utilising confocal 
microscopy, I demonstrated that JAM-A is physically present within the site of 
immunological synapse between CD4+ T cells and DCs. Treatment with anti-JAM-
A mAb BV11 in vitro attenuated CD4+ T cell activation and proliferation in 
comparison with both isotype-treated and untreated cells. Based on literature 
reports, a positive impact on T cell activation/proliferation could have been 
expected under JAM-A blockade in vivo. JAM-A-deficient DCs showed increased 
migration from a skin inflamed site to draining LNs in comparison with DCs 
expressing normal levels of JAM-A326. In addition, higher transmigration of JAM-A-
expressing BMDCs through layers of JAM-A-deficient lung endothelial cells in 
comparison with endothelial cells from JAM-A-/- mice reconstituted with full-
length JAM-A complementary DNA (cDNA) was reported347. These studies indicate 
a complex participation of JAM-A in DC migration, dependent on the cell in which 
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it is expressed. While expression of JAM-A may participate in DC trafficking 
through the lymphatics, endothelial JAM-A may play an important role in DC arrest 
and migration functions through the vascular endothelium. As such, systemic 
blockade of JAM-A intercellular ligation could simultaneously impact different 
pathways that are responsible for distinct migration functions. Nevertheless, in 
vivo blockade of JAM-A pathways with anti-JAM-A mAb in my adoptive transfer 
model attenuated CD4+ T cell proliferation in comparison to isotype-treated 
animals, although no differences were found in the proportion of naïve, memory 
and recently primed CD4+ T cells. This finding in addition to my in vitro data 
suggest that JAM-A may play a role in the interactions between CD4+ T cells and 
DCs that lead to T cell proliferation. However, the disruption of JAM-A pathways 
may also influence other functions, such as DC migration, as schematised in Figure 
7-1; or the secretion of IL-2 by other cells present in the system, an essential 
cytokine for T cell division382.  
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Figure 7-1. Proposed model for effects of JAM-A blockade in CD4+ T cell priming 
Schematic representation of the potential effects of JAM-A blockade in CD4+ T cell priming. 
Treatment with anti-JAM-A mAb in vivo may affect CD4+ T cell priming in distinct manners. (A) 
JAM-A blockade may affect the migration of DCs from the affected tissue to the draining LN. This 
potential altered kinetics may affect the time that these cells populate the LN and consequently 
the time or quality of their crosstalk with CD4+ T cells. (B) JAM-A may work as a co-signalling 
molecule or as an adhesion receptor that stabilise T cell–DC contacts. As such, JAM-A blockade 
may potentially disrupt these interactions, leading to changes in post-priming CD4+ T cell 
outcomes, such as (C) a decrease in clonal expansion of activated T cells. 
Following the assessment of JAM-A blockade on T cell outcomes, I investigated 
the effects of anti-JAM-A mAb BV11 treatment during T cell priming on T cell 
differentiation and cytokine secretion. In vitro, JAM-A blockade did not affect 
IL10 and IFN-γ secretion 72 hours after initiation of priming, supporting results 
from the literature that found no differences in IFN-γ secretion in 5-day co-
cultures in a similar CD4+ T cell-DC assay347. In the meantime, I demonstrated that 
JAM-A blockade in vitro increased the secretion of IL-17. A study from the 
literature demonstrated that cells from the colonic lamina propria of JAM-A KO 
mice stimulated in vitro with PMA/ionomycin had significantly higher absolute 
numbers of CD4+ IL17+ T cells in comparison with WT mice, with no differences 
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in IFN-γ-expressing CD4+ T cells numbers reported371. To investigate if disruption 
of JAM-A pathways during antigen presentation could lead to enhanced Th17 
differentiation, I performed a T cell-DC in vitro assay and investigated 
intracellular expression of RORγt, the major Th17 transcription factor. JAM-A 
blockade during priming in vitro increased the proportion of RORγt+ T cells in 
comparison to isotype-treated cells. Additionally, JAM-A blockade decreased the 
proportion of T-bet+ T cells, as induction of differentiation into specific subsets 
can inhibit the differentiation to other subsets76. Under suboptimal concentrations 
of antigen, anti-JAM-A treatment during priming in vitro also increased the 
proportion of FoxP3-expressing T cells when compared to cells treated with its 
isotype control. Findings in the literature describe an increase in the absolute 
numbers of CD4+ FoxP3+ T cells from the colonic mucosa of JAM-A-deficient mice 
in comparison with WT mice371. Altogether, these data suggest that JAM-A ligation 
may influence pathways that can promote Th1 differentiation. As I showed that 
anti-JAM-A treatment during antigen stimulation in vitro produced normal levels 
of IFN-γ but decreased proportions of T-bet+ T cells, I evaluated the capacity of 
anti-JAM-A-treated cells to produce IFN-γ. Although no differences on the 
proportion of IFN-γ+ T cells on cells re-stimulated with PMA/ionomycin were found, 
the populations of IFN-γ producers had increased capacity to produce IFN-γ, 
supporting my previous findings of normal levels of IFN-γ secretion but lower 
proportions of T-bet+ T cells under JAM-A blockade during priming. In vivo, 
however, different components could impact T cell differentiation, such as a 
disruption in DC migration patterns that could indirectly influence the time or 
quality of cell-cell crosstalk and different inflammatory mediators that could be 
present under LPS stimulus, such as IL-6 that are secreted by some TLR4-
expressing endothelial cells381. In addition, endogenous DCs comprise a 
heterogenous population with different profile of surface ligands/receptors that 
also differ from the ones found on BMDCs that were used in my in vitro assays47,54. 
As such, antigen presentation from endogenous DCs or BMDCs to CD4+ T cells 
involve different quality and/or quantity of signals. In this adoptive transfer model, 
no differences were found in the expression of key transcription factors of Th1, 
Th17 and Treg cells. 
To understand the mechanisms where the adhesion molecule JAM-A could be 
involved in interactions between T cells and DCs, I first studied the ability of cells 
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treated with anti-JAM-A mAb BV11 to form clusters. Treatment with anti-JAM-A 
under suboptimal and optimal antigen concentrations disrupted DC-T cell cluster 
formation when cells were analysed 48 hours after priming. Anti-JAM-A treatment 
decreased the number of clusters in both conditions in comparison to isotype-
treated cells. The analysis of clusters from suboptimal conditions showed that the 
treatment also decreased the total area occupied by them. Under optimal 
conditions, however, anti-JAM-A treatment did not affect the total area of 
clusters, which I attributed to an increase in the mean area of individual clusters. 
As clusters were analysed 48 hours after initiation of priming, these results don’t 
reflect only cell interaction, but also take into account T cells proliferation, as 
these cells have already started to divide at this point. To analyse cell interaction 
only, I analysed clusters 24 hours after the initiation of antigen presentation. 
Analyses of T cell-DC colocalization with fluorescent dyed-cells utilising widefield 
microscopy showed that anti-JAM-A treatment did not affect interactions between 
these two cell types. However, even if cells are not touching each other, 
colocalization indexes based on widefield images might still count them as 
contacting cells. Follow-up experiments using confocal microscopy that would 
allow a more specific definition of membrane interaction will help our 
understanding on the mechanisms in which JAM-A blockade during priming affects 
CD4+ T cell outcomes. 
7.4 JAM-A-Targeted Therapy in Rheumatoid Arthritis 
The higher expression of F11R mRNA found in the experiment previously 
performed by our research group as described in Chapter 3 (section 3.1) suggests 
that JAM-A protein expression could be upregulated on non-migratory leukocytes 
arrested in inflamed joints in comparison with migratory immune cells. To test 
that, I performed the breach of self-tolerance model of arthritis in Kaede mice. 
By tracking the non-migratory and migratory Kaede red cells, I confirmed that 
JAM-A is upregulated on the surface of immune cells arrested in the joints. When 
analysing the expression of JAM-A in APCs from these two populations, I reported 
a higher proportion of JAM-A-expressing cells on non-migratory cDCs and B cells 
compared to migratory cells. However, a significantly higher proportion of 
migratory pDCs expressed JAM-A compared with non-migratory and pLN-resident 
pDCs. The population of JAM-A-expressing pDCs also expressed high levels of MHCII, 
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suggesting that JAM-A+ pDCs may play a role on carrying joint antigen and possibly 
presenting it to CD4+ T cells in the pLNs during RA. 
To evaluate JAM-A-targeted therapy in RA, the breach of self-tolerance model of 
arthritis was performed in WT mice. While studies in antigen-independent models 
of inflammatory diseases suggest that JAM-A blockade may ameliorate clinical 
disease by a possible decrease in accumulation of leukocytes in inflamed tissues, 
studies using antigen-dependent models suggest that disruption of JAM-A 
pathways could promote a worsen in clinical disease, possibly by increasing 
activation of T cells. In spite of that, no effects were found in clinical disease up 
to 7 days after post-challenge in my RA model. This was evidenced by similar mean 
clinical scores and paw thickness in groups that received antigen footpad 
injections. In addition, no differences were found in the concentration of serum 
anti-OVA and anti-CII antibodies, suggesting that the treatment did not impact T 
cell-dependent B cell activation  or humoral immune responses to CII. Furthermore, 
the treatment did not change the proportion of peripheral blood activated CD4+ 
T cells in comparison to cells from isotype-treated mice. Considering the costs of 
the blocking antibody, I did not perform experiments to investigate if the antibody 
was reaching the inflammation site, such as with the use of kit to conjugate it to 
a fluorophore and track it in vivo. As such, it was not possible to affirm that the 
antibody was blocking JAM-A pathways locally. Although no impact in the breach 
of self-tolerance was reported up to 7 days post-challenge, I hypothesised that 
JAM-A blockade during the phase of RA induction could have an impact in late 
stages. As such, I decided to postpone the experiment closure to allow an analysis 
of the effects of prophylactic JAM-A blockade in late time points. The future 
analysis of this late model of RA , as well as experiments aiming JAM-A 
manipulation during the phase of induction or after disease onset in other models 
of inflammatory diseases will further our knowledge of the participation of this 
molecule in the context of inflammation. 
Antagonistic JAM-A targeting in preclinical models of inflammatory diseases show 
promising results for controlling inflammation caused by leukocyte or platelet 
accumulation. Disruption of JAM-A intercellular ligation may decrease the 
accumulation of leukocytes in these inflamed tissues and affect T cell outcomes 
that promote/enhance pathology. However, the possible disruption in multiple 
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pathways (endothelial cell-endothelial cell, leukocyte-endothelial cell, leukocyte-
leukocyte) caused by JAM-A targeting suggests precaution in the interpretation of 
results from preclinical model studies. Disruption of JAM-A pathways may affect 
epithelial barrier integrity that may ultimately increase susceptibility to infections 
caused by facilitated infiltration of pathogens to affected tissues. In support, 
drugs targeting some T cell co-stimulation molecules such as LFA-1, a JAM-A ligand, 
resulted in its withdrawn from the market due to fatal brain infections 408. As such, 
studies with cell-selective JAM-A disruption that aim to distinguish pathway-
specific effects in different pathological conditions are essential for furthering our 
understanding of JAM-A role in inflammatory diseases. These studies may point to 
pathway-specific therapies with a high therapeutic potential but diminished 
adverse effects. 
7.5 Final Conclusions 
The data provided in this thesis has identified JAM-A as a novel molecule 
controlling CD4+ T cell-DC interactions. JAM-A provides support to CD4+ T cell 
activation, proliferation, differentiation and profile of secreted cytokines. JAM-A 
manipulation with an antagonistic mAb in an adoptive transfer model attenuated 
CD4+ T cell proliferation in comparison to cells from isotype-treated animals. 
These findings highlight the relevance of JAM-A in regulating immune responses in 
the context of inflammation. However, disruption of JAM-A pathways by 
prophylactic treatment with anti-JAM-A mAb did not affect arthritis in a breach 
of self-tolerance murine model of arthritis. Further work will investigate possible 
therapeutic effects of JAM-A manipulation in late models of RA, as well as in other 
inflammatory disease animal models, which may ultimately highlight JAM-A as a 
potential therapeutic target for human diseases. 
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